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ABSTRACT 
 
 
FUNCTIONAL PLASTICITY OF HIPPOCAMPAL 
GLUTAMATERGIC SYNAPSES IN DEVELOPMENT AND 
DISEASE 
Xiaoyu Peng 
Rita J. Balice-Gordon, Ph.D. 
  
 The establishment and maintenance of synaptic connections are critical for the 
normal function of the central nervous system. The function of mature neural circuits 
depends critically on the appropriate apposition of pre- and postsynaptic specializations 
and on the spatial organization of synapses along axon arbors and postsynaptic dendrites.  
In neurological disease, the integrity of these processes may be compromised or lost, 
resulting in profound cognitive and behavioral deficits.  In my thesis work, I have 
investigated the spatial distribution of functional properties of presynaptic terminals 
along axon arbor, and the determinants of these properties across different spatial scales.  
My results suggest that, for a single axonal arbor, presynaptic strength over short 
distances is determined by variations in total vesicle pool size, whereas over longer 
distances presynaptic strength is determined by the spatial modulation of release fraction.  
Thus the mechanisms that determine synaptic strength differ depending on spatial scale.  
 iii
I have also examined the structural and functional consequences of loss of postsynaptic 
components, NMDA and AMPA type glutamate receptors, that occur in two forms of 
human autoimmune encephalitis in which these proteins are specifically targeted, and that 
result in dramatic deficits in cognition and behavior.  My results suggest that patient 
antibodies against these two types of glutamate receptors selectively result in the 
internalization of receptor from the neuron surface, decreasing synaptic localization, 
currents and thus influencing synaptic function.  My work extends our understanding of 
the repertoire of pre- and postsynaptic mechanisms that are required to establish and 
maintain functional neural circuits during development and in diseases that compromise 
nervous system function. 
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Introduction 
 
Part 1:  Mechanisms specifying presynaptic strengths in the central nervous system 
 In the central nervous system (CNS), synapses between pre- and postsynaptic 
neurons are the essential functional units where information is relayed, integrated and 
stored.  In contrast to peripheral synapses, central synapses, especially the presynaptic 
terminals, are highly “unreliable” in responding to individual stimuli.  Conversely, these 
“unreliable” synapses are observed to be able to “reliably” respond to diverse and 
complex spikes among neurons in normal behavior.   Mechanisms determining pre- and 
postsynaptic functional properties in synaptic development and activity-dependent 
changes have been under investigation for the last century.  However, the graphic 
pictures with spatial information are still missing.  While thousands of presynaptic 
terminals innervate hundreds of different postsynaptic neurons, at every pre-and 
postsynaptic contact site in every connection, presynaptic strength is regulated to match 
with the postsynaptic specialization.  Recent studies have begun to investigate 
mechanisms determining presynaptic strengths at different spatial locations along axons 
and dendrites, yet much remains unknown.   
 
Presynaptic functional properties are heterogeneous  
 The heterogeneity of functional properties of central presynaptic terminals has 
long been appreciated.  Several studies documented that the initial release probability (Pr) 
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of central presynaptic terminals is highly heterogeneous even between just one pair of 
pre- and postsynaptic neurons, ranging from less than 0.05 to close to 1, with the majority 
of them less than 0.2 (Hessler et al., 1993; Rosenmund et al., 1993; Huang and Stevens, 
1997; Murthy et al., 1997).  The heterogeneous presynaptic release probabilities also 
feature broad and/or skewed distributions with large coefficients of variation (Murthy et 
al., 1997). This means that most central presynaptic terminals are not reliable and will 
only release less than two times out of ten separate stimuli.  In addition to heterogeneity 
in initial release probabilities, heterogeneity has also been reported for other functional 
properties.  The facilitation ratio of vesicle release during a pair of high frequency stimuli 
is very different from terminal to terminal (Dobrunz and Stevens, 1997),  as is the 
depletion rate of vesicle release during a train of high frequency stimuli (Dobrunz and 
Stevens, 1997).  These functional properties are related to the initial release probability: 
the higher Pr terminals have lower facilitation rates and faster depletion rates than the 
lower Pr terminals.  The heterogeneity of presynaptic properties in terminals is critical 
and is thought to underlie reliable neurotransmission in the presence of highly variable 
stimuli in normal, behaving animals (Dobrunz and Stevens, 1999). These results together 
suggest that individual presynaptic terminals, even distinct terminals in the same 
connection between a pair of pre- and postsynaptic neurons, have their own set of defined 
properties and are heterogeneous.  
 
Possible presynaptic determinants of vesicle release to specify functional properties 
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 Determinants of presynaptic vesicle release have been studied extensively.  
Presynaptic terminals in the central nervous system contain a few hundreds of 
neurotransmitter-filled vesicles and a specialized membrane region for release called the 
active zone.  The cycle of the release of a presynaptic vesicle consists of multiple steps 
(Sudhof, 2004):  1) a small cluster of vesicles are docked at the active zone and primed 
for release; 2) an action potential reaches the terminal, causing Ca2+ channels to open in 
response to the ensuing depolarization; 3) Ca2+  influx and bind to the calcium sensor; 4) 
the calcium sensor on vesicles mediates the fusion between the plasma membrane and the 
vesicular membrane; 5) vesicles are endocytosed and recycled for further rounds of 
release.  Every step can be modulated by the current status of the terminal, the history of 
activity of the terminal, the developmental history of the terminal, postsynaptic signals, 
etc.  Together, these factors specify heterogeneous presynaptic properties from terminal 
to terminal.   
 Ca2+ channels and Ca2+ influx     The spatiotemporal dynamics of Ca2+ influx into 
presynaptic terminals can be regulated to change presynaptic functional properties. In 
many regions of the nervous system, a developmentally regulated switch of presynaptic 
Ca2+ channel types from N-type channels in immature synapses to P/Q- type channel in 
mature synapses has been observed in vitro and in vivo, (Iwasaki and Takahashi, 1998; 
Rosato Siri and Uchitel, 1999; Iwasaki et al., 2000), including cultured hippocampal 
neurons (Scholz and Miller, 1995).  Since the N-type Ca2+ channels are more distant from 
releasing sites than the P/Q- type (Wu et al., 1999), this developmental switch gives rise 
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to more synchronous transmitter release (Chuhma and Ohmori, 1998) and thus higher 
release probability.  Other studies using calyx of Held synapses as a model suggest that 
developmental tightening of the spatial coupling between Ca2+ channels and vesicle 
release, instead of increasing intrinsic Ca2+ sensitivity of vesicles, enhances presynaptic 
release probability during synaptic maturation (Fedchyshyn and Wang, 2005; Wang et 
al., 2008; Kochubey et al., 2009).  These results together suggest that modulating the 
Ca2+ channels and Ca2+ influx can be a common strategy to specify presynaptic functional 
properties during maturation or, possibly during activity dependent processes. 
 Mechanisms regulating active zone components      Changing the quantity of 
active zone components could change presynaptic functional properties.  Presynaptic 
terminals have heterogeneous amounts of active zone components and vesicle associated 
proteins mediating vesicle docking and fusion.  Assembly of new presynaptic terminals 
from trafficking packets to functional terminals needs a few hours (Ahmari et al., 2000), 
followed by maturation, which may take a few days in vitro (Mozhayeva et al., 2002).  
During synaptic assembly, two discrete packets containing either synaptic vesicle 
precursors (Ahmari et al., 2000; Krueger et al., 2003) or active zone components such as 
Bassoon and Piccolo (Zhai et al., 2001; Shapira et al., 2003) have been shown to be 
transported along axons.  These presynaptic components may pause at sites along an axon 
(Sabo et al., 2006) or be recruited to pre-clustered postsynaptic specializations (Gerrow et 
al., 2006).  Even after a terminal has been established and reached a static status, its 
active zone components, and vesicles with associated proteins, are not strictly enclosed 
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by its own territory.  Instead,  the neighboring terminals are constantly exchanging 
vesicles and active zone components (Ahmari et al., 2000; Friedman et al., 2000; Shapira 
et al., 2003; Bresler et al., 2004; Darcy et al., 2006; Tsuriel et al., 2006; Tsuriel et al., 
2009).  While mature presynaptic terminals, on average, have a scaling relationship 
among active zone areas, number of docked vesicles, and total number of vesicles, these 
components are subject to dynamic changes in development and maturation.  The 
temporal and spatial dynamics of active zones, vesicles, and their associated proteins in 
presynaptic terminals suggest that these determinants are being regulated constantly to 
specify functional properties at individual sites.    
 In addition, adding, eliminating, and/or switching critical molecules associated 
with active zones and vesicles have been suggested to be another way to modulate 
presynaptic function.  During maturation of the calyx of Held synapse, deletion of the 
filamentous protein Septin 5 gives rise to features of mature synapses including synaptic 
vesicles tightly localized to active zones, and increased vesicle fusion coupling with Ca2+ 
influx, leading to increased release probability (Yang et al., 2010).  Studies examining the 
expression profile of synaptotagmin (Syt), the Ca2+ sensor of vesicles, during maturation 
suggests that there is a regulated change of the Syt-isoform expression profile in a single 
neuron type (Xiao et al., 2010).  These data together suggest that some critical molecules 
participating in vesicle docking and fusion at active zones are regulated during 
maturation to specify presynaptic functional properties.  
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  Organization of vesicle pools    Vesicles clustered in presynaptic terminals 
participate in different pools according to their physiological properties; thus, changing 
the participation of vesicles in different pools can change presynaptic functional 
properties.  The readily releasable pool (RRP) usually contains between 4 and 8 vesicles, 
corresponding to the docked vesicles from EM studies (Schikorski and Stevens, 2001), 
and these are the ones that can be depleted by high frequency stimuli or hypertonic 
sucrose (Rosenmund and Stevens, 1996).  The reserved pool (RP) usually contains 17-20 
vesicles (Murthy et al., 1997), which require prolonged stimuli for release. RRP and RP                    
vesicles participate in evoked presynaptic release.  The rest of the vesicles, around 170 in 
number, are in the resting pool.  The functions of these vesicles are less clear, but they 
may participate in spontaneous release (Fredj and Burrone, 2009).  Studies suggest that 
the initial release probability is determined by the number of readily releasable pool 
vesicles and their average release probability (Dobrunz and Stevens, 1997; Dobrunz, 
2002) and sustained release during prolonged stimulation is determined by all recycling 
vesicles (Dobrunz and Stevens, 1997; Sudhof, 2004).  These data together suggest that 
changing the number of vesicles in each pool can influence different aspect of 
presynaptic function.  For example, a recent study suggests that the fraction of the vesicle 
pool participating in release can be modulated in chronic inactivity by homeostatic 
scaling, via CDK5 dependent mechanisms (Kim and Ryan, 2010).  In addition, studies 
examining vesicle pool maturation over time in cultured hippocampal neurons suggest 
that RRPs are preferentially filled during early synapse maturation, followed by reserved 
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pools (Mozhayeva et al., 2002).  Thus, immature terminals may not have the same 
number or ratio of RRP and RP veicles as mature terminals.  These results together 
suggest that changing the participation of vesicles in different pools in presynaptic 
terminals during maturation or activity-dependent plasticity can change presynaptic 
functional properties.   
 Endocytosis machinery      Endocytosis is essential to maintain presynaptic vesicle 
release during prolonged stimulation. Since vesicle release ( < 2 ms between action 
potential arrival at presynaptic terminals and postsynaptic currents being recorded) is far 
more rapid than recycling ( > 3 seconds (Zhu et al., 2009)),  efficient endocytosis is 
critical in maintaining the defined presynaptic properties over longer terms.  However, 
the dynamics as well as the molecular mechanisms of synaptic vesicles endocytosis are 
still under debate and investigation.  The most recent studies using single vesicle imaging 
techniques suggest that there is a fast endocytosis pathway ( 3 s) as well as a slower 
endocytosis pathway (>10 s) (Gandhi and Stevens, 2003; Granseth et al., 2006; Balaji 
and Ryan, 2007; Zhu et al., 2009) through clathrin. As stimulation frequency and Ca2+ 
influx increase, the slow endocytosis is accelerated and becomes the predominant 
pathway (Zhu et al., 2009).  Studies showed that presynaptic Ca2+ influx during 
stimulation is heterogeneous from terminal to terminal (Brenowitz and Regehr, 2007).  
Thus it is possible that the endocytosis rates at different presynaptic terminals are set 
differently via fast or slow pathways according to differences in Ca2+ influx, giving rise 
to another mechanism to specify presynaptic functional properties in different terminals.   
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Retrograde mechanisms modulating presynaptic functional properties 
 Previous work has suggested that postsynaptic targets retrogradely influence 
presynaptic release probability (Reyes et al., 1998; Koester and Johnston, 2005; Branco 
et al., 2008; Branco and Staras, 2009).  In rat neocortex, presynaptic terminals contacting 
different postsynaptic neurons have heterogeneous release probability (Reyes et al., 1998; 
Koester and Johnston, 2005).  In cultured rat hippocampal neurons, presynaptic terminals 
contacting different dendrites of the same postsynaptic neuron also have heterogeneous 
release probability (Branco et al., 2008).  These suggest that there are spatially defined 
postsynaptic signals from individual neurons/dendrites to specify presynaptic properties.   
Several different postsynaptic retrograde mechanisms have been suggested to 
influence presynaptic functional properties (Tao and Poo, 2001; De Paola et al., 2003; 
Pratt et al., 2003; Ziv and Garner, 2004; Dalva et al., 2007; Williams et al., 2010).  These 
include cell adhesion molecules such as the neuroligin-neurexin complex (Chih et al., 
2005; Levinson et al., 2005; Futai et al., 2007), SynCAM (Biederer et al., 2002), EphBs 
and ephrin-Bs (Dalva et al., 2000; Kayser et al., 2006), and cadherins (Benson and 
Tanaka, 1998; Takeichi, 2007; Arikkath and Reichardt, 2008), among others, as well as 
secreted factors such as neurotrophins (Du and Poo, 2004), FGF22, FGF 7 (Terauchi et 
al., 2010) and Sema3F (Tran et al., 2009), among others.   
 However, two important aspects are missing.  Not much is known about the 
spatial arrangement of these postsynaptic mechanisms, especially at subcellular levels.  In 
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addition, most studies looking at postsynaptic retrograde signals do not differentiate from 
mechanisms of being synaptogenic, thus secondarily influencing functional properties, or 
modulating functional properties directly. The details of functional properties and how 
different postsynaptic mechanisms interact with different presynaptic functional 
determinants to specify functional properties are not clear.  Recent studies using RNAi 
knockdown or overexpression of postsynaptic PSD-95-NLG-1 complex suggested that 
presynaptic release probabilities and facilitation can be altered by changing postsynaptic 
NLG mediated signals (Futai et al., 2007).  However, functional and spatial details are 
still missing for most studies examining postsynaptic molecular mechanisms. Thus, 
which of these cell-cell signaling mechanisms contribute to the modulation of presynaptic 
release properties on different spatial scales across an axon arbor remains to be 
determined. 
 
Activity-dependent changes of presynaptic functional properties 
 Presynaptic functional properties are constantly adjusted during neuronal network 
activities.  Presynaptic terminals can undergo Hebbian plasticity, which implies the 
strengthening or weakening of connections upon coordinated activity, such as long-term 
potentiation (LTP) and long-term depression (LTD).  Presynaptic LTP, where release 
probability increases after potentiation, has been observed in several central synapses, 
including cerebellar parallel fiber (PF) synapses, hippocampal mossy fiber synapses, and 
corticothalamic synapses (Zalutsky and Nicoll, 1990; Castro-Alamancos and 
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Calcagnotto, 1999; Rancillac and Crépel, 2004).  Presynaptic activity-dependent 
plasticity would probably be a more widespread phenomenon if detection technique of 
presynaptic functions were more sensitive and less dependent on postsynaptic current 
recording (Becker et al., 2008).   The molecular mechanisms of presynaptic plasticity 
have been investigated.  The induction of presynaptic LTP at these synapses is 
independent of postsynaptic NMDA receptor activation but dependent on presynaptic 
Ca2+ rise during synaptic transmission (Zalutsky and Nicoll, 1990; Castro-Alamancos and 
Calcagnotto, 1999; Rancillac and Crépel, 2004).  Studies suggest that release machinery 
proteins such as RIM1α and Rab3a are modified (Castillo et al., 1997; Castillo et al., 
2002; Lonart et al., 2003) so that the coupling between Ca2+ and release is enhanced 
(Lonart et al., 2003).  These results suggest that at least some of the pre- and postsynaptic 
mechanisms that specify presynaptic functional properties are activity-dependent and 
follow Hebbian rules. 
 Presynaptic terminals can also undergo homeostatic plasticity, which is another 
important activity-dependent change in which the synaptic strengths change in the 
opposite direction to compensate for the loss or increase of network activity, and to 
maintain gain control.  Classic studies with network activity blockade suggested that in 
addition to upscaling of postsynaptic AMPA receptor function, presynaptic terminal size, 
active zone area, and readily releasable and total vesicle pool sizes increased, along with 
increased presynaptic release probabilities (Murthy et al., 2001).  A recent study 
suggested that the fraction of the vesicle pool participating in release can be modulated 
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by chronic inactivity via homeostatic scaling, by CDK5 dependent mechanisms (Kim and 
Ryan, 2010).  Furthermore, recent studies suggest that homeostatic rules also allow 
individual synapses to maintain their activity level, at least on postsynaptic sites (Béïque 
et al., 2010).  Thus, it is possible that an individual presynaptic terminal’s functional 
properties are subjected to Hebbian plasticity as well as homeostatic plasticity to reach an 
optimum strength.    
 
Spatial distribution 
 Previous studies mainly focused on assessing presynaptic functional properties 
and mechanisms modulating these properties without much spatial information. With 
recent advancement of optical physiology techniques, it is more appreciated that the 
functional properties of spatially distributed synapses can be regulated differently, and 
that there is rich information to be explored (Markram et al., 1998; Reyes et al., 1998; 
Koester and Johnston, 2005; Pelkey and McBain, 2007; Branco et al., 2008).  The 
distribution of synapses along dendrites have been investigated, probably partially due to 
easier tracking of dendrites (a couple of hundreds microns in length) of individual 
neurons in vitro and in vivo, comparing to axons (up to thousands of microns or even 
longer).  A study using serial-section electron microscopy to reconstruct individual apical 
synapses of CA1 pyramidal neurons suggested that synaptic strengths are scaled along 
dendritic branches in the direction to enhance the contribution of each dendritic branch to 
neuronal output (Katz et al., 2009). Studies using a genetic synaptic labeling method that 
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relies on expression of a presynaptic marker, synaptophysin-GFP (Syp-GFP) in 
individual neurons in vivo observed the distribution of structural properties of presynaptic 
terminals along cerebellar granule cells’ axons (Li et al., 2010).  Another study employed 
a presynaptic channelrhodopsin-2 (ChR2)-assisted method to map the spatial distribution 
of presynaptic inputs within the dendritic arborizations of postsynaptic neurons and 
revealed high specificity in the subcellular organization of excitatory synapses(Petreanu 
et al., 2009).  Together, these studies show that examining the spatial distribution of 
functional presynaptic terminals along individual axon arbors and dendritic branches, the 
rules setting synaptic strengths, and how pre- and postsynaptic mechanisms specify these 
properties, will provide a fundamental understanding of how functional circuits of the 
nervous system are established and maintained.  
 
Conclusions and future directions 
 The studies described above have begun to investigate mechanisms specifying 
presynaptic functional properties in the central nervous system.   Investigations into the 
spatial arrangement of the functional properties of presynaptic terminals and the 
mechanisms that specify them represent important directions for future research.  
Examining how functional synaptic connections are established and maintained spatially 
in the central nervous system will greatly contribute to the understanding and potential 
treatment of neurological disorders such as epilepsy, autism and mental retardation, in 
which synapse function is aberrant or reduced. 
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Thesis rationale and goals 
 The spatial arrangement of functional presynaptic terminals along axon arbors and 
the mechanisms specifying functional properties spatially are largely unknown.  
Understanding this spatial arrangement is critical for investigating the mechanisms of the 
establishment and maintenance of synaptic connections of the central nervous system. 
 Using Synaptophysin-pHluorin as an optical physiology tool to measure 
presynaptic functional properties, I examined the spatial distribution of functional 
presynaptic terminals across axon arbors and plausible pre-and postsynaptic mechanisms 
in individual glutamatergic neurons in vitro (Chapter 2). Using optical physiology, 
immunochemistry, and live imaging techniques, I tested the hypothesis that Determinants 
of presynaptic strength vary across an axon arbor. 
 My work demonstrated that over short axon segments, synaptic strength is 
determined by total vesicle pool size and is related to the density of postsynaptic 
components such as NMDA receptors and PSD-95.  Over the entire axon arbor, synaptic 
strength is determined by proximal to distal changes in release fraction, independent of 
total vesicle pool size, that can be accounted for by changes in individual vesicle release 
probability and/or readily releasable pool size.  Our results thus suggest that the 
mechanisms that establish synaptic strength vary over different spatial scales. 
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Part 2: Mechanisms underlying autoimmune synaptic encephalitis 
 Ionotropic receptors are the most critical postsynaptic components in synaptic 
transmission and activity dependent plasticity in normal circuits.  Disruption of 
Glutamatergic or/and GABAergic receptors functional can leads to severe neurological 
disease such as epilepsy, schizophrenia and autisms.  Recently, several novel, potentially 
lethal, and treatment-responsive syndromes that affect hippocampal and cortical function 
have been shown to be associated with auto-antibodies against synaptic antigens, notably 
glutamate or GABA-B receptors (Rudnicki and Dalmau, 2000; Phillips, 2003; 
Tormoehlen and Pascuzzi, 2008; Meriggioli and Sanders, 2009).  Patients with these 
autoantibodies, sometimes associated with teratomas and other neoplasms, present with 
psychiatric symptoms, seizures, memory deficits, and decreased level of consciousness.  
These symptoms often improve dramatically after immunotherapy or tumor resection 
(Rudnicki and Dalmau, 2000; Phillips, 2003; Tormoehlen and Pascuzzi, 2008; Meriggioli 
and Sanders, 2009).  However, the cellular and synaptic mechanisms underlying these 
autoimmune encephalitides  remained to be addressed.  The importance of these disorders 
is that they offer human models of brain-immune interactions in which the target antigens 
have critical roles in neuronal synaptic transmission and plasticity. Therefore, studying 
these mechanisms will improve our understanding of the effects of the antibodies at the 
cellular, synaptic and circuit levels, eventually impacting the clinical management of the 
patients. 
 
  
15 
Autoimmune synaptic encephalitis  
 Many encephalitides once considered idiopathic are now thought to be immune 
mediated. One of these disorders predominantly affects structures of the limbic system, 
including medial temporal lobes, amygdala, hippocampus and orbitofrontal cortex 
(Gultekin et al., 2000; Posner and Dalmau, 2000; Graus and Dalmau, 2007).  As a result, 
patients develop short-term memory deficits, emotional and behavioral disturbances such 
as confusion, irritability, depression, and sleep disturbances, as well as seizures and 
sometimes dementia (Gultekin et al., 2000; Tüzün and Dalmau, 2007).  
 Recently, a novel group of disorders associates with autoantigens that are on the 
cell or synaptic surface has been reported, with or without tumor association and are 
likely antibody-mediated (Table 1) (Rudnicki and Dalmau, 2000; Phillips, 2003; 
Tormoehlen and Pascuzzi, 2008; Meriggioli and Sanders, 2009).  However in 
autoimmune synaptic encephalitis the autoantigen is located behind the blood-brain-
barrier (BBB) requiring that the antibodies or cells producing antibodies cross this barrier 
in order to cause neurological dysfunction.  In some disorders the patients’ cerebrospinal 
fluid (CSF) show lymphocytic pleocytosis and intrathecal synthesis of antibodies 
suggesting that after initial systemic immune activation by a tumor or unknown causes, 
there is an expansion of the immune response within the nervous system (Dalmau and 
Rosenfeld, 2008).  The role of the immune response in the neurological symptoms is 
further supported by the correlation between antibody titers and symptoms, and the 
frequent response of the disorders to immunotherapies, including plasmapheresis, IVIg, 
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corticosteroids, cyclophosphamide, or rituximab, a B-cell depleting monoclonal antibody.  
These novel autoimmune mediated synaptic encephalitides  include:  
 Anti-NMDA receptor encephalitis   A new, severe, potentially lethal, and 
treatment-responsive disorder, anti-NMDA receptor encephalitis was reported within the 
last several years by Dalmau and colleagues (Dalmau et al., 2007; Sansing et al., 2007).  
Patients are usually young women, but also include men, without a past medical history 
of interest, who, often after prodromic symptoms of mild hyperthermia, headache, or a 
viral-like process, develop sudden behavioral and personality changes for which they are 
often seen by psychiatrists (Dalmau et al., 2007; Sansing et al., 2007). This clinical 
presentation is usually followed by seizures, decreased level of consciousness, abnormal 
movements (orofacial and limb dyskinesias, dystonia, choreoathetosis), autonomic 
instability (fluctuating blood pressure, cardiac rhythms, and temperature), and sometimes 
hypoventilation. MRI is frequently normal, but in about 40% of the patients’ findings 
suggesting inflammation are transiently identified in hippocampus, cerebral or cerebellar 
cortex, and subcortical regions (Dalmau et al., 2008).   
 Patients have serum and CSF antibodies that react with brain antigens 
predominantly expressed in the hippocampus (Dalmau et al., 2008).  In two large cohorts 
comprising 180 patients, including young adults and children, neurologic improvement 
was correlated with a decrease in antibody titer (Dalmau et al., 2008). Overall, about 75% 
of the patients had dramatic or substantial recoveries despite the severity or long duration 
of symptoms; 19% had partial or limited improvement, and 6% died. Analyses of brain 
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biopsies in 14 cases and autopsy of three patients showed microgliosis, occasional 
inflammatory B-cell and plasma cell infiltrates, and very rare T-cell infiltrates, in contrast 
to other paraneoplastic syndromes in which cytotoxic T-cell infiltrates are prominent 
(Stein-Wexler et al., 2005).  
 When patient antibodies are used to stain rodent brain sections, immunoreactivity 
is observed in the neuropil of the hippocampus, with less staining in cortex, striatum and 
cerebellum (Dalmau et al., 2008). When used to stain live cultured hippocampal neurons, 
patient antibodies react with surface antigens localized to synapses.  Additional studies, 
including immunoprecipitation followed by mass spectroscopy, led to the identification 
of the NR1 subunit of NMDA receptor as the target autoantigen. NMDA receptors are 
usually formed from heteromers of two NR1 and two NR2 subunits (Kendrick et al., 
1996; Laube and Kiderlen, 1997).  There are four NR2 subunits (NR2A-D), which have 
50-70% sequence identity in the extracellular domain; NR1 is ubiquitously distributed in 
the brain (Monyer et al., 1994; Standaert et al., 1994; Waxman and Lynch, 2005).  
Domain swapping and other experiments showed that the epitope was located at the N-
terminal extracellular domain of NR1 (Dalmau et al., 2008; Gleichman et al., 2009).  
Since NR1 is ubiquitously expressed in brain as an obligate subunit of functional NMDA 
receptors (Monyer et al., 1994; Standaert et al., 1994; Waxman and Lynch, 2005), it 
remains unclear why patient NR1 antibodies preferentially label hippocampus rather than 
all brain regions. This binding pattern may reflect the relative high density of NMDA 
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receptors in the hippocampus or a differential posttranslational modification of NR1 in 
different brain regions (Gleichman et al., 2009).   
 The underlying cellular and synaptic mechanisms of how patients’ autoantibodies 
change the structure and function of synapses, neurons and circuits are not well known.  
It has been recently shown that patients’ antibodies cause a selective but reversible 
decrease of NMDA receptor surface density, synaptic localization in vitro (Dalmau et al., 
2008).  Thus whether this change of NMDA receptor localization from postsynaptic 
specialization underlies the functional changes of synapses and the spectrum of patients 
syndromes need to be addressed.   
 Other autoimmune synaptic encephalitides   Currently, ~90% of patients studied 
by us with limbic encephalitis of non-viral etiology have well-defined immune responses 
against neuronal antigens (Bataller and Dalmau, 2004; Bataller et al., 2007; Graus et al., 
2008).  The importance of antibodies to cell surface or synaptic proteins was shown in a 
recent study in which these antibodies were found to be more prevalent than antibodies to 
intracellular antigens described in paraneoplastic disorders (54% versus 24%; (Graus et 
al., 2008)). A study of 1570 patients with diffuse encephalitis by the California 
Encephalitis Project showed that in only 30% could a final diagnosis be established 
(viral, bacterial, prion, parasitic, fungal) (Glaser et al., 2006).  A pilot study examining a 
group of cases selected by subphenotype (“encephalitis, psychosis, and dyskinesias”) 
showed that 50% had NMDA receptor antibodies (Gable et al., 2009).  This suggests that 
other antibodies to currently unknown antigens may occur in the remaining cases. 
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In the last 2 years, a second form of immune mediated encephalitis in which patients’ 
serum and CSF antibodies are directed against AMPA receptors was identified by 
immunoprecipitation followed by mass spectrometry (Lai et al., 2009).  Most patients 
develop a clinical picture of limbic encephalitis including confusion, agitation, seizures, 
and severe short-term memory deficits. Sometimes patients present with a rapidly 
progressive abnormal behavior resembling acute psychosis. Patients are usually women 
older than 50 years, and 70% had an underlying tumor, usually lung or breast cancer or 
tumors of the thymus that express AMPA receptors. Immunotherapy and treatment of the 
tumor, if detected, usually results in neurological recovery. The neurological disorder has 
a tendency to relapse, and for these patients the outcome depends of how well each 
relapse is controlled.    
 AMPA receptors mediate most of the fast excitatory synaptic transmission in the 
brain (Shepherd and Huganir, 2007) and the majority are heterotetramers composed of 
GluR1, 2, 3 or 4 subunits that are expressed in a region-specific manner (Palmer et al., 
2005).  GluR1/2 and GluR2/3 levels are high in hippocampus and other limbic regions 
(Sprengel, 2006), similar to the distribution of immunostaining with patients’ antibodies. 
Preliminary analyses suggest that the location of the epitope is the N-terminal 
extracellular domain of GluR1 or/and GluR2 AMPA receptor subunits (Gleichman et al., 
2009).  None of these patients’ antibodies reacted with GluR3, a subunit identified as an 
autoantigen in some patients with Rasmussen’s encephalitis (Rogers et al., 1994).   
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 The cellular mechanisms underlying anti-AMAPR encephalitis is not clear.  
Studies suggest that the treatment of rat hippocampal neurons with patients’ antibodies 
resulted in a significant decrease in the synaptic localization of AMPA receptor clusters, 
without a decrease in overall synaptic density or NMDA receptor clusters (Lai et al., 
2009).  Moreover, these effects were reversible: after 3 days of treatment with patients’ 
CSF containing GluR1/GluR2 antibodies, followed by 4 days of treatment with control 
CSF, AMPA receptor cluster density and synaptic localization recovered to levels seen in 
control cultures (Lai et al., 2009).  However,  what are the functional consequences of the 
loss of synaptic localization of AMPA receptors and how these give rise to the severe 
neurological presentation in patients are to be investigated.   
 A third subtype of autoimmune encephalitis associated with antibodies against the 
γ-amino-butyric acid-B (GABAB) receptor was also recently identified (Lancaster et al., 
2009). The median age of a cohort of 15 patients was 62 years (24-75); 8 were men. All 
presented with early and prominent seizures; other symptoms, as well as MRI and EEG 
findings, were consistent with predominant limbic dysfunction.  Forty-seven percent of 
patients had small cell lung cancer (SCLC), and 40% showed propensity to 
autoimmunity. Cancer screening and demographic data indicate the disorder also occurs 
in patients without cancer. Neurological improvement occurred in 60% of the patients 
and was correlated with prompt immunotherapy and tumor control. Staining of live 
neurons showed that all patients’ serum and CSF had antibodies against a cell surface 
antigen. Immunoprecipitation and mass spectroscopy demonstrated that the autoantigen 
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was the B1 subunit of the GABAB receptor, a metabotropic receptor that when disrupted 
causes seizures and memory dysfunction (Prosser et al., 2001; Schuler et al., 2001).  
Preliminary studies show that patients’ antibodies do not affect the levels of GABAB 
receptor, but block the effects of baclofen, a selective B1 subunit agonist (Lancaster et al. 
Neurology 2010 abstract, in press).   This result suggests that not all anti-synaptic 
encephalitis have similar underlying cellular mechanisms so that individual diseases need 
to be investigated.  Comparing different mechanisms and syndromes among different 
type of antoimmune encephalitides may help understanding critical synaptic proteins’ 
function and dynamics.    
 While in vitro approaches have been useful to establish the effects of antibodies to 
NMDA, AMPA, and GABAB1 receptors on neurons and in particular on synapses, in vivo 
models will be needed to establish the relationship between the effects of each antibody 
on synapse and circuit function, and the changes in behavior, memory and cognition that 
are hallmarks of these disorders.  
 
Mechanisms underlying antibody pathogenic effects on the target receptors 
 Several mechanisms may account for the pathogenicity of autoantibodies in these 
disorders.   
 The first possibility is that patient anti-receptor antibodies agonize or antagonize 
the receptor. NR2 antibodies from patients with SLE cause neuronal death when injected 
into mouse brain; this effect is attenuated by treatment with the NMDA receptor blocker, 
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MK-801, suggesting the antibodies mediate cell death by enhancing channel activation 
(DeGiorgio et al., 2001).  Conversely, application of nicotonic acetylcholine receptor 
(nAChRs) antibodies from myasthenia gravis patients to outside-out patches of mouse 
myotubes caused an acute block of AChR currents that became irreversible with time 
(Jahn et al., 2000).  The epitope for both NMDA receptor and AMPA receptor antibodies 
is in the N-terminus raises the possibility that autoantibodies could have direct functional 
effects. The ligand binding domain for both channels is also in the N-terminus, and 
conformational changes are thought to couple ligand binding to channel opening 
(Armstrong and Gouaux, 2000; Sobolevsky et al., 2009). Therefore, patient antibodies 
could initially sterically hinder ligand binding or enhance its effects.  In addition, N-
terminal binding sites for channel modulators such as zinc and polyamines may be 
obscured by patients’ antibodies (Rassendren et al., 1990; Herin and Aizenman, 2004; 
Paoletti and Neyton, 2007). Whole cell recording experiments during acute application of 
antibodies will allow this issue to be resolved. 
 The second possibility is that patient anti-receptor antibodies cause receptor 
internalization and degradation, resulting in diminished receptor function. AChR 
antibodies from patients with myasthenia gravis cause a loss of surface AChRs by cross-
linking and internalization (Drachman et al., 1978). Cross-linking and internalization of 
voltage gated calcium channels by autoantibodies has also been shown to occur in 
patients with Lambert-Eaton syndrome (Nagel et al., 1988b; Peers et al., 1993).  
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Experiments comparing whole patients’ antibody IgG with Fab fragments will help to 
address this possibility.   
 The third possibility is that patient anti-receptor antibodies cause complement-
mediated neuronal damage or death. Muscle biopsies from patients with myasthenia 
gravis have revealed extensive deposits of components of the complement cascade (Engel 
et al., 1977; Sahashi et al., 1980).  Autopsy and in vitro studies have also linked 
complement activation with Rasmussen’s encephalitis and neuromyelitis optica, the later 
characterized by antibodies to aquaporin-4 (Whitney et al., 1999; Lucchinetti et al., 2002; 
Waters et al., 2008).  IgG1 and IgG3, subclasses of IgG capable of activating 
complement, are the main IgG types of NMDA and AMPA receptor antibodies. In anti-
NMDA receptor encephalitis, we previous have not found evidence of deposits of 
complement in autopsies of patients. In light of the substantial recoveries made by many 
of these patients, extensive neuronal damage due to complement activation seems 
unlikely.  Furthermore, it is unclear whether the elements of the complement cascade that 
are present in the central nervous system are sufficient to induce complement-mediated 
lysis. This is in contrast with neuromyelitis optica where the autoantigen, aquaporin-4, is 
expressed by astrocyte foot processes adjacent to the cerebral microvasculature. Further 
studies are needed to determine the degree of involvement of complement mediated 
mechanisms in the brain and tumor of patients with synaptic autoimmune encephalitis.   
 
Pathways that postsynaptic receptors are trafficked and recycled  
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 NMDA receptors and AMPA receptors are trafficked into and out of postsynaptic 
sites during physiological processes.  Surface NMDA receptors are normally internalized 
during synapse maturation, in long-term depression (LTD), and in response to ligand-
binding (Roche et al., 2001; Vissel et al., 2001; Barria and Malinow, 2002; Montgomery 
and Madison, 2002; Snyder et al., 2005b). Internalization of NMDA receptors has been 
shown to be mediated by clathrin via endocytotic signal on C-terminal of NR2A or NR2B 
subunits (Roche et al., 2001; Lavezzari et al., 2004).  NMDA receptors sort into different 
intracellular pathways after endocytosis, with NR2B containing receptors preferentially 
trafficking through recycling endosomes and NR2A through late endosomes (Lavezzari 
et al., 2004).  Under physiological conditions, such as during LTD, it has been suggested 
that AMPA receptors are first moved to extrasynaptic sites followed by endocytosis 
through clathrin dependent pathways ((Ehlers, 2000; Shi et al., 2001; Park et al., 2004)).   
The endocytosis of AMPA receptors have at least one GluR2 dependent pathway that 
requires GluR2 C-terminals interaction with clathrin (Lüthi et al., 1999; Lee et al., 2002) 
and GluR2 independent pathways (Jia et al., 1996; Meng et al., 2003), which may involve 
AMPA receptor activity-dependent ubiquitination of GluR1 and subsequent 
internalization and their trafficking to the lysosome (Ehlers, 2000; Schwarz et al., 2010). 
Whether the internalization of the patients’ antibodies in different types of encephalitis is 
mediated by a pathway that would otherwise be used in normal processes, or by a 
pathway specific for pathogenic conditions, is a question to be addressed.   
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Homeostatic compensatory changes in response to antibody-mediated decrease of 
receptor levels 
 Compensatory mechanisms at the cellular and synaptic level have been shown to 
occur in autoimmune disorders of the nervous system in humans and in experimental 
model systems.  Studies from mouse models of myasthenia gravis and patients’ tissue 
have shown an enhanced rate of synthesis of AChRs and increased expression levels of 
the α, β, δ, and ε subunits of the AChR, as well as increased acetylcholine release upon 
stimulation (Wilson et al., 1983; Guyon et al., 1994; Plomp et al., 1995; Guyon et al., 
1998).  Purkinje cells treated with IgG from patients with Lambert-Eaton syndrome show 
a loss of P/Q-type VGCC currents and a concomitant increase in R-type calcium channel 
currents (Pinto et al., 1998).  Deletion of the α-1a subunit of the P/Q-type channel in 
mice causes age related ataxia and muscle weakness and results in enhanced L- and N-
type calcium channel currents in Purkinje cells (Jun et al., 1999). 
 These observations raise the possibility that homeostatic mechanisms occur in 
anti-NMDA receptor and anti-AMPA receptor encephalitis, though this remains to be 
clearly demonstrated.  Support for this idea comes from synaptic changes following 
pharmacological blockade of glutamate receptors.  NMDA receptor or AMPA receptor 
blockade for 48 hours enhanced mEPSC amplitude (Turrigiano et al., 1998) (Sutton et al., 
2006).  
   
Relating the effects of synaptic receptor antibodies to neurological symptoms 
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 Glutamate binding to NMDA receptor and AMPA receptor is crucial for synaptic 
transmission and plasticity.  Pharmacological blockade or genetic reduction of NMDA 
receptor or AMPA receptors has been shown to alter measures of learning and memory 
and other behaviors in animal models (Nishikawa et al., 1991; Mohn et al., 1999b; Kapur 
and Seeman, 2002; Krystal et al., 2002b; Nabeshima et al., 2006; Large, 2007; Schmitt et 
al., 2007; Labrie et al., 2008).   
 It’s interesting to consider why patients with anti-NMDA receptor antibodies 
develop a complex syndrome that includes psychosis, learning and memory dysfunction, 
abnormal movements, autonomic instability and frequent hypoventilation, while those 
with AMPA receptor antibodies preferentially develop psychiatric and amnestic 
symptoms.  Studies using genetic deletion of NMDA receptor or AMPA receptor 
subunits in mouse models provide some insight into this issue.  While NR1 knockout 
mice die shortly after birth of hypoventilation (Li et al., 1994), CA1-specific NR1 
knockouts mice have impaired spatial and temporal memory and a loss of CA1 LTP 
(Tsien et al., 1996). Mice with an inducible, reversible knockout of NR1 in forebrain 
show impairment in the maintenance of long-term memory (Cui et al., 2004).  In addition 
to memory deficits, targeted manipulation of NR1 expression can result in schizophrenia-
like symptoms: hypomorphic expression of NR1 leads to increased stereotypic behavior 
and decreased sociability, while early postnatal loss of NR1 in a subset of cortical and 
hippocampal interneurons results in decreased pre-pulse inhibition and increased social 
isolation-induced anxiety (Mohn et al., 1999a; Belforte et al., 2010).  Moreover, 
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subanesthetic doses of NMDA receptor blockers such as phencyclidine and ketamine are 
psychotomimetic, and they recapitulate many of the positive and negative signs of 
schizophrenia in both humans and rodents as well as repetitive orofacial movements, 
autonomic instability and seizures.  (Luby et al., 1962; Krystal et al., 1994a; Lahti, 2001; 
Krystal et al., 2002a).  These results together suggest that the hypothetical NMDA 
receptor hypofunction underlies patients’ syndromes in anti-NMDAR encephalitis as in 
schizophrenia (Belforte et al., 2010). 
 The consequences of loss of AMPA receptor expression have also been studied in 
mouse models.  Spatial learning and memory are largely unaffected in GluR1 knockout 
mice (Zamanillo et al., 1999) and only working memory is diminished (Reisel et al., 
2002; Sanderson et al., 2007).  GluR2 knockout mice show reduced exploration and 
impaired motor coordination.  While AMPA receptor subunit knockout mice have not 
provided a satisfying explanation for the role of AMPA receptors in synaptic plasticity 
related to learning and memory, the fact that patients with AMPA receptor antibodies 
have short-term learning and memory deficits argues that further studies at the circuit and 
behavioral levels are warranted. 
 
Conclusions and future directions 
 We have begun to obtain a better cellular- and synaptic-level understanding of a 
new and remarkable group of immune-mediated behavioral and memory disorders.  On 
the clinical side, it is important to know the spectrum of the syndromes, especially on 
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young children and adults. It is also critical to know optimal type of immunotherapy at 
different stages of the disease, the duration of treatment as well as whether or how these 
treatments modify the effects of antibodies on synapses. On the basic neuroscience side, 
the first important question is to ask how the patients’ antibodies from different 
encephalitides alter structure and function of synapses and circuits.  The ultimate goal 
will be to develop and test rodent models in a battery of behavioral tests designed to 
assay hippocampal, amygdala, cortical and cerebellar function in each disorder.  In this 
way, we can begin to relate the cellular, synaptic, and circuit effects of patients’ 
antibodies to behavioral deficits in learning, memory, and other cognitive and motor 
manifestations.  
   
Thesis rationale and goals 
 While the pathogenesis of autoimmune disorders of the peripheral nervous system 
has been well defined, the mechanisms underlying the newly identified disorders, anti-
NMDAR encephalitis and anti-AMPAR encephalitis, remain poorly understood. Whether 
this CNS autoimmune disorder utilizes similar mechanisms as in the PNS to cause its 
characteristic cognitive and behavioral deficits is unknown. Previous work from our lab 
has suggested that autoantibodies against the NR1 subunit of the NMDA receptor for 
NMDAR encephalitis, and autoantibodies against the GluR1/GluR2 subunit of the 
AMPA receptor for AMPAR encephalitis present in the CSF of patients with the disorder 
may mediate the deficits of this disorder (Dalmau et al., 2008; Lai et al., 2009). Based on 
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these observations, I examined the effects of autoantibodies in patients with anti-
NMDAR encephalitis on NMDA receptors in vitro and in vivo (Chapters 3, 4), and the 
effects of autoantibodies in patients with anti-AMPAR encephalitis (Chapters 5). Using 
biochemical, electrophysiology and imaging techniques, I tested the hypothesis that 
autoantibodies present in patients with anti-NMDAR encephalitis/anti-AMPAR 
encephalitis underlie the cellular mechanism of this disorder of cognition and behavior. 
My results suggest that patient antibodies against these two types of glutamate 
receptors selectively result in the internalization of receptor from the neuron surface, 
decreasing synaptic localization, currents and thus influencing synaptic function.  
Moreover, this work has extended our understanding of the cellular mechanisms 
underlying anti-NMDAR encephalitis, anti-AMPAR encephalitis and, in the future, may 
facilitate a better understanding of the role of glutamate receptors in learning, memory 
and behavior. 
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Abstract 
               We used Synaptophysin-pHluorin expressed in hippocampal neurons to ask how 
functional properties of terminals vary spatially across individual axon arbors.  Over 
short arbor distances (ca. 100 microns), evoked release and total vesicle pool size were 
spatially heterogeneous when an axon contacted different dendrites.  In contrast, evoked 
release and total vesicle pool size were spatially homogeneous when an axon made 
contacts along a single dendrite.  Regardless of the postsynaptic configuration, the 
magnitude of evoked release and total vesicle pool size spatially co-varied, suggesting 
that the fraction of synaptic vesicles available for release was similar over short distances.  
Evoked release and total vesicle pool size were highly correlated with the amount of 
NMDA receptors and PSD-95.   However, when individual axons were followed over 
longer distances (several hundred microns), we found greater heterogeneity in the 
presynaptic strength of terminals in distal rather than proximal segments, as well as a 
significant increase in evoked release in distal segments.  Within proximal or distal axon 
segments, evoked release was correlated with total vesicle pool size, but release fraction 
was higher in terminals in distal segments.  The increase in distal release fraction was 
accounted for by changes in individual vesicle probability and or readily releasable pool 
size.  Our results suggest that, for a single axonal arbor, presynaptic strength over short 
distances is determined by variations in total vesicle pool size, whereas over longer 
distances presynaptic strength is determined by the spatial modulation of release fraction.  
Thus the mechanisms that determine synaptic strength differ depending on spatial scale. 
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Introduction 
The ability of hippocampal neurons to differentially regulate presynaptic strength 
at terminals located along the same axonal branch is thought to underlie reliable 
neurotransmission in the presence of highly variable stimuli.  Several studies documented 
the heterogeneous functional properties among presynaptic terminals of initial release 
probability (Hessler et al., 1993; Rosenmund et al., 1993; Huang and Stevens, 1997; 
Murthy et al., 1997), short term plasticity (Dobrunz and Stevens, 1997) and 
heterogeneous cellular determinants such as the active zone area, numbers of docked 
vesicles and total vesicles (Schikorski and Stevens, 1997).  Heterogeneity is indicated by 
broad and/or skewed distributions with large coefficients of variation (Murthy et al., 
1997), or large normalized differences in these properties, between any pair of 
presynaptic terminals (Branco et al., 2008).  However, previous studies mainly focused 
on assessing the functional properties of a small number of terminals without much 
spatial information, or those in short axon segments (Hessler et al., 1993; Rosenmund et 
al., 1993; Huang and Stevens, 1997; Murthy et al., 1997; Koester and Johnston, 2005).  
Recent studies suggest that postsynaptic neurons (Markram et al., 1998; Reyes et al., 
1998; Koester and Johnston, 2005; Pelkey and McBain, 2007), or different dendrites of 
the same neuron (Branco et al., 2008) can specify different presynaptic functional 
properties.  While CNS axons are usually up to thousands of microns long and making 
synapses on many targets, how functional properties are distributed along individual long 
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axon arbors, and how these are associated with postsynaptic specializations, remain 
unclear.   
Here we address three specific questions:  what is the spatial distribution of 
presynaptic functional properties along an axon arbor, specifically the amount of evoked 
release, total vesicle pool size, and release fraction, as assayed by changes in 
Synaptophysin-pHluorin fluorescence?  How do presynaptic functional properties vary 
across different postsynaptic neurons and/or dendrites?  What is the relationship among 
presynaptic functional properties and the composition of postsynaptic specializations?  
The work we report here shows that the answers to these questions are different 
depending on spatial scale.  Over short axon segments, synaptic strength is determined by 
total vesicle pool size and is related to the density of postsynaptic components such as 
NMDA receptors and PSD-95.  Over the entire axon arbor, synaptic strength is 
determined by proximal to distal changes in release fraction, independent of total vesicle 
pool size, that can be accounted for by changes in individual vesicle release probability 
and/or readily releasable pool size.  Our results thus suggest that the mechanisms that 
establish synaptic strength vary over different spatial scales.  
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Results 
Evoked release and total vesicle pool size are heterogeneous in short axon segments 
Previous studies have shown that presynaptic terminals of cultured hippocampal 
neurons have heterogeneous release properties (Hessler et al., 1993; Rosenmund et al., 
1993; Dobrunz and Stevens, 1997; Murthy et al., 1997).  However, the spatial 
arrangement of presynaptic functional properties across long individual axons is poorly 
understood.  To address this question, the strength of presynaptic terminals in ~ 100 µm 
axon segments of individual glutamatergic hippocampal neurons transfected with 
Synaptophysin-pHluorin were first assessed by measuring the fluorescence changes (∆F) 
evoked by extracellular electrical stimulation, then multiple segments along the entire 
axon arbor were assessed to map the overall distribution of presynaptic strength.   
Axon segments with Synaptophysin-pHluorin labeled presynaptic terminals were 
selected for imaging based on their presumptive apposition to postsynaptic dendrites, 
confirmed via post-hoc immunostaining for the dendritic marker MAP2 (Fig. 1A, top).  
Stimulation at 20 Hz for 3.5 seconds with saturating current (Methods) resulted in an 
increase in integrated ∆F (∆F per pixel x area) at discrete sites along a ~ 50 – 100 µm 
length of axon (Fig. 1A, B).  Stimulation evoked ∆F was visible over time at most 
terminals along an axon segment (Fig. 1A, middle, terminal 1, 2 and 3).  As previously 
reported, ∆F increased montonically for the duration of the stimulus, and then returned to 
baseline with a slower time course (Fig. 1B), as pHluorin was internalized and reacidified 
(Sankaranarayanan and Ryan, 2000; Atluri and Ryan, 2006; Burrone et al., 2006).  
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Evoked release varied among terminals by more than 10 fold (Fig. 1).  The local 
differences in evoked release among terminals along an axon segment did not follow any 
obvious spatial gradient.   
To quantify the extent of presynaptic functional heterogeneity along ~100 µm 
segments, the random pair ratios of the evoked release between each possible pair of 
terminals in the field of view along the axon segment were calculated (to reduce random 
error, the higher value was always divided by a lower value).  The higher the ratio, the 
greater the discrepancy or heterogeneity was between two terminals’ release properties.  
This measurement enabled us to evaluate a relatively small number of terminals and 
define a reference value for “homogeneity” using the ratio of evoked release from two 
consecutive stimulations of the same terminal (at least 5 minutes apart).  The average 
control ratio was significantly less than the average ratio of evoked release between 
random pairs of presynaptic terminals (Fig. 1C).  Thus although ∆F of a given terminal 
does vary somewhat with repeated stimulation, this source of variation alone does not 
account for the differences in ∆F between different terminals along short axon segments.  
This result is consistent with previous reports that presynaptic terminals along an axon 
segment are functionally heterogeneous.  For subsequent analyses, a pair ratio between 
1.4 to 2.6 (95% confidence interval of the average of the two repeats ratio) was regarded 
as indicative of functionally homogenous release properties.   
To further explore the functional heterogeneity among terminals along an axon 
segment, neurons were perfused with an NH4Cl-containing extracellular solution (Fig. 
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1A, bottom).  This deacidifies synaptic vesicles, yielding a maximum ∆F that reflects the 
total pool of vesicles clustered at each presynaptic terminal (Sankaranarayanan et al., 
2000; Burrone et al., 2006).  Like the evoked ∆F, the NH4Cl induced ∆F was also 
heterogeneous among the presynaptic terminals along an axon segment.  The average 
ratio of total vesicle pool size between random pairs of terminals was significantly higher 
than the average control ratio calculated from two consecutive stimulations of the same 
terminal (Fig. 1D).  As above, homogeneity in total vesicle pool size was defined by the 
95% confidence interval of two repeated measurements, which was between 1.3 to 2.3.   
To substantiate this measure of total vesicle pool size, we determined whether the 
surface fraction of pHluorin contributed significantly to the measured total fluorescence 
signal (Wienisch and Klingauf, 2006).  The pHluorin surface fraction was on average 
13.7 ± 1.0 % (51 terminals, 4 neurons) and was stable over the time course of 
experiments.  Furthermore, immunostaining showed that pHluorin fluorescence was 
linearly correlated with immunostaining fluorescence of the endogenous synaptic vesicle 
markers SV2 and vGlut at each terminal (data not shown).  Thus the local heterogeneity 
in ∆F after NH4Cl perfusion is consistent with heterogeneity in total vesicle pool size 
among presynaptic terminals.  Taken together, these results show that evoked release as 
well as vesicle pool size are locally heterogeneous among presynaptic terminals along a ~ 
100 µm axon segment. 
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Heterogeneity in total vesicle pool size correlates with heterogeneity in evoked release 
in short axon segments, independent of stimulation frequency 
 Previous work assessed heterogeneity in exocytosis of presynaptic terminals using 
low frequency pulse stimulation at 1 Hz or lower (Hessler et al., 1993; Rosenmund et al., 
1993; Huang and Stevens, 1997; Murthy et al., 1997; Branco et al., 2008).  Because 
hippocampal neurons firing rates range from < 2Hz to  > 100 Hz in awake rodents or 
during slow wave sleep (Ranck, 1973), we assessed the functional properties of 
presynaptic terminals across simulation frequency.  Terminals were stimulated with 70 
action potentials delivered at 4 frequencies between 1 and 100 Hz.  A 5 minute interval 
between the different stimulation trains allowed the internalization and reacidification of 
surface Synaptophysin-pHluorin.  Evoked release decreased as stimulation frequency 
increased (Fig. 2A, B) when the total number of pulses was held at 70, probably due to an 
increased number of release failures.  Previous work showed that total vesicle pool size 
correlates with evoked release (Moulder et al., 2007).  By plotting the evoked ∆F against 
∆F from NH4Cl, a linear correlation between evoked ∆F and total vesicle pool size was 
observed at each stimulation frequency (Fig. 2A).  Notably, terminals with larger total 
vesicle pool size showed larger evoked release than smaller terminals across a wide range 
of stimulation frequency.  However, the amount of evoked release from a given total 
vesicle pool size depended on stimulation frequency.  Thus for terminals within short 
axon segments, the fraction of the total vesicle pool released, i.e. the release fraction, is 
similar for a particular stimulus frequency. 
  
39 
We next assessed whether heterogeneity is influenced by stimulus frequency.  The 
heterogeneity in evoked release was similar with different stimulation frequencies, as 
suggested by the evoked ∆F pair ratios for each stimulation frequency (Fig. 2C).  This 
suggests that, in short segments of axons, the underlying numerical distribution of 
presynaptic strengths is not influenced by stimulus frequency over a range of 1 to 100 Hz, 
and likely arises from a heterogeneity in total vesicle pool size.   
 
Functional properties among presynaptic terminals contacting different dendrites of 
the same or different postsynaptic neurons are heterogeneous 
 Previous studies suggest that different postsynaptic targets – either different 
neurons or different dendrites of the same neuron - specify presynaptic strengths (Koester 
and Johnston, 2005; Branco et al., 2008).  To verify that the local heterogeneity in evoked 
release and total vesicle pool size depend on the synaptic configuration of terminals and 
postsynaptic neurons and/or dendrites, pairs of presynaptic terminals in the same axon 
segment were classified as contacting the same dendrite (Fig. 3A, terminal 1 and 2), 
different dendrites from the same postsynaptic neuron (Fig. 3A, terminal 1 and 3, 2 and 
3), or different dendrites from different postsynaptic neurons (Fig. 3B, terminal 1 and 2).  
As predicted, heterogeneity of evoked release and total vesicle pool size from various 
synaptic configurations were different.  The pair ratios of terminals innervating two 
different dendrites of the same neuron were significantly higher than the control ratios 
calculated from two consecutive stimulations (Fig. 3A, C).  The same was true for 
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terminals innervating dendrites from two different postsynaptic neurons (Fig. 3B, C).  
However, evoked release from terminals contacting the same dendrite was homogeneous, 
because the pair ratios were not significantly different from the control ratios (Fig. 3A, C; 
7 neurons, 33 terminal pairs; Mann-Whitney U test, p = 0.15).  A similar dependence on 
synaptic configuration also was observed for the heterogeneity in total vesicle pool size, 
except that no significant difference was observed for terminals innervating two different 
dendrites of the same neuron (Fig. 3D).  Interestingly, the heterogeneity in evoked release 
and total vesicle pool size among terminals other than those contacting the same dendrite 
was not significantly different from the heterogeneity of random pairs of terminals in 
short axon segments (black bars in Fig. 3C, D). 
These results show that the strength of presynaptic terminals contacting different 
dendrites, whether of the same neuron or different neurons, is heterogeneous.  In contrast, 
the strength of presynaptic terminals innervating the same dendrite is homogeneous.  
Taken together, these results suggest that synaptic strength is determined by local 
interactions between presynaptic terminals and postsynaptic target neurons.  
 
Presynaptic heterogeneity across different synaptic configurations is correlated with 
the amount of postsynaptic NMDA receptors and PSD-95 
In order to understand how postsynaptic targets may influence presynaptic 
strength, we asked which of several postsynaptic constituents correlated with presynaptic 
strength.  Post-hoc immunostaining was used to measure the amount several postsynaptic 
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proteins, including the NMDA receptor subunit NR1, the AMPA receptor subunit GluR1, 
PSD-95 (colocalized pixel area x fluorescence intensity).  MAP2 served as a negative 
control.  Presynaptic terminals that were not colocalized with a postsynaptic dendrite as 
identified by MAP2 immunostaining, or a postsynaptic protein cluster, were excluded 
from this analysis.   
 Presynaptic terminals with higher evoked release (Fig. 4A, left) and larger total 
vesicle pool size (Fig. 4A, left middle) were colocalized with larger NMDA receptor 
clusters (Fig. 4A, right middle and right).  In the example shown in Fig. 4A, a significant 
linear relationship was observed between presynaptic evoked release (Fig. 4B) and total 
vesicle pool size (Fig. 4C), and in most segments (Fig. 4D, E).  A similar significant 
correlation was observed between presynaptic evoked release or total vesicle pool size 
and the amount of PSD-95 (Fig. 4D, E).  In contrast, the amount of GluR1 was not 
correlated with either evoked release or total vesicle pool size (Fig. 4D, E).  As expected, 
evoked release and total vesicle pool size were not significantly correlated with the 
amount of postsynaptic MAP2 in the vast majority of axon segments measured.  These 
data show that presynaptic evoked release and total vesicle pool size are correlated with 
the amount of some, but not all, postsynaptic components. 
To determine whether the local heterogeneity observed in presynaptic functional 
properties varied with the amount of a postsynaptic protein, regardless of whether these 
were in the same dendrite, or in multiple dendrites from one or multiple postsynaptic 
neurons, we used MAP2 staining to separate postsynaptic targets.  Because it is very 
  
42 
difficult to find an ideal configuration during live imaging without labeling multiple 
postsynaptic neurons, in this experiment, we estimated presynaptic strength by measuring 
total pHluorin fluorescence after fixation, as this mainly reflects total vesicle pool size.  
As described above, the total vesicle pool size of presynaptic terminals on different 
dendrites is heterogeneous (Fig. 4F, arrowheads).  We found that total vesicle pool size 
was correlated with the amount of NMDA receptors.  On different dendrites from the 
same postsynaptic neuron, a larger terminal was colocalized with more NMDA receptors 
(Fig. 4F, G; compare large terminal 5 and small terminal 3).  In 7 of 8 axon segments, 
each with > 5 terminals contacting different dendrites, total vesicle pool size was 
correlated with the amount of NMDA receptors (as in the examples shown in Fig. 4F, G).  
Thus, on different dendrites from the same postsynaptic neuron, heterogeneity in the 
amount of postsynaptic NMDA receptors co-varies with the total vesicle pool size of the 
apposed presynaptic terminal. 
To compare the amount of NMDA receptors beneath presynaptic terminals 
contacting different postsynaptic neurons, we assessed whether the average total vesicle 
pool size of two groups of terminals on two adjacent postsynaptic neurons correlated with 
average NMDA receptor cluster intensity.  In the example shown in Fig. 4H, the 6 
terminals of one axon on one postsynaptic neuron have, on average, a smaller total 
vesicle pool size and amount of NMDA receptors (red squares) than the 7 terminals of 
the same axon on a second nearby neuron (black squares).  Four of 6 axon segments 
showed a similar correlation (Fig. 4I).  In the other 2 segments, the terminals contacting 
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two different neurons had overlapping total vesicle pool size, with similar average 
amount of NMDA receptors.  Notably, the NMDA receptor clusters on individual 
dendrites of the same or different neurons were heterogeneous with respect to cluster 
size.  Taken together, these data suggest that the correlation between presynaptic total 
vesicle pool size and the amount of postsynaptic NMDA receptors is specific to a 
particular pre- and postsynaptic neuron pair, but is not determined by a postsynaptic 
neuron- or dendrite- autonomous mechanism; if this were the case, all presynaptic 
terminals on the same postsynaptic dendrite/neuron would have similar functional 
properties. 
While these data suggest that the amount of postsynaptic NMDA receptors and 
PSD-95 may reflect presynaptic strength, neither protein is required for a presynaptic 
terminal to be functional.  We found that 44 ± 9% of functional presynaptic terminals 
were not colocalized with NMDA receptors, and 36 ± 7% were not co-localized with 
PSD-95; 24% were not even colocalized with postsynaptic dendrites.  This is consistent 
with previous work that showed that orphan presynaptic terminals without an apposed 
postsynaptic specialization were functional (Krueger et al., 2003).  Nonetheless, over 7-
10 days of maturation in vitro, total vesicle pool size did not increase in the population of 
presynaptic terminals that were not co-localized with NMDA receptors or PSD-95; after 
14 days in vitro, these terminals have significantly smaller total vesicle pool size than 
terminals co-localized with NMDA receptors or PSD-95 (data not shown).  Taken 
together, these results suggest that NMDA receptor and PSD-95 are dispensable for the 
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initial functionality of a presynaptic terminal, consistent with work in mice null for these 
proteins (Elias et al., 2006; Ultanir et al., 2007).  However, these proteins accumulate 
postsynaptically as presynaptic terminals mature, in proportion to evoked release and 
total vesicle pool size. 
 
Distal terminals are functionally more heterogeneous than proximal terminals 
We then examined how presynaptic functional properties varied across individual 
axon arbors by co-transfecting neurons with mCherry to trace axon arbors for > 1000 µm 
(Fig. 5A) and sampling several 50 – 100 µm segments of axon over as much of the axon 
arbor as possible, always for more than several hundred microns.  The distribution and 
mean of presynaptic properties was determined in different segments along an axon 
arbor.  The distribution was determined using the heterogeneity pair ratio measurement 
and the coefficient of variation of individual values, and the mean was determined by 
averaging the values of a particular functional property across axon segments.   
Within an axon segment, there is a wide range of and thus heterogeneity in 
evoked release (Fig. 5B).  For example, the pair ratios of evoked release for 5 axon 
segments from the neuron shown in Fig. 5A were significantly higher compared to the 
control ratios calculated from two consecutive stimulations (Fig. 5C).  Evoked release 
was heterogeneous by this criterion in the majority (92%) of segments from each of 6 
neurons assessed in this way.  
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Total vesicle pool size was similarly heterogeneous (Fig. 5D).  Within each axon 
segment, the pair ratios of total vesicle pool size were significantly higher than the 
control ratios calculated from two consecutive measurements (Fig. 5E).  Total vesicle 
pool size was heterogeneous by this criterion in the majority (75%) of segments from 
each of 6 neurons assessed in this way.   
Previous studies suggest that heterogeneity in presynaptic release probability in 
short axon segments is not significantly different than the heterogeneity measured among 
all presynaptic terminals sampled in the same neuron (Branco et al., 2008).  Consistent 
with this, we found that the pair ratios of evoked release of terminals across ca. 1000 µm 
of an axon arbor were not significantly different from the pair ratios of evoked release for 
terminals within a short, ~ 50-100 µm axon segment (e.g., Fig. 5C, compare white bar 
with colored bars for 1 neuron; for all neurons, average of terminals in all short axon 
segments, 3.4 ± 0.2; average of all terminals in entire arbor, 3.4 ± 0.2; Mann-Whitney U 
test, p = 0.41).  Comparison of the pair ratios of total vesicle pool size were not 
significantly different for terminals in short axon segments compared to the entire axon 
arbor (e.g., Fig. 5E, compare white bar with colored bars for 1 neuron; for all neurons, 
average of terminals in all short axon segments, 3.2 ± 0.2; average of all terminals in 
entire arbor, 3.6 ± 0.3; Mann-Whitney U test, p = 0.24). 
 However, comparing all possible terminal pairs across an entire axon arbor would 
average out any proximal to distal differences.  Thus we also compared the average pair 
ratio for evoked release (Fig. 5F) and total vesicle pool size (Fig. 5G) in the most distal 
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segments with those in the most proximal segments.  Surprisingly, distal segments had a 
higher average pair ratio of evoked release (Fig. 5F) and total vesicle pool size (Fig. 5G).  
These data suggest that presynaptic terminals in distal axon segments are more 
heterogeneous in evoked release and total vesicle pool size compared to proximal 
segments.   
To further investigate how the heterogeneity in total vesicle pool size was related 
to the heterogeneity in evoked release proximally and distally, we used the coefficient of 
variation (CV) which is a size independent measure of heterogeneity.  A significant linear 
correlation was observed between the CV of total vesicle pool size and the CV of evoked 
release (Fig. 5H).  This result suggests that while the distribution of evoked release and 
total vesicle pool size is similar, the heterogeneity in total vesicle pool size drives the 
heterogeneity in evoked release, regardless of release fraction.  Together, these data 
suggest that the evoked release of distal terminals is more heterogeneous than proximal 
terminals, correlated with greater heterogeneity in total vesicle pool size distally 
compared to proximally, independent of the average total vesicle pool size, because distal 
terminals did not have larger total vesicle pool size than proximal terminals.   
 
Evoked release and release fraction are higher in distal segments of individual axon 
arbors  
We next determined the average value of evoked release and total vesicle pool 
size in short axon segments, and compared these to values from the most proximal and 
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most distal axon segments.  We found that distal axon segments had a significantly 
higher evoked release than proximal segments (Fig. 6A; 1.5 fold difference).  However, 
total vesicle pool size was not significantly different (Fig. 6B).  Thus, distal axon 
segments had a significant, 2.1 fold  higher release fraction than proximal segments (Fig. 
6C).   
Since evoked release correlates with total vesicle pool size in short axon segments 
such that release fraction is constant, how can this observation be reconciled with the 
observation that terminals in distal axon segments have a higher release fraction?  By 
plotting evoked release against total vesicle pool size, a strong linear relationship was 
observed between these two properties in most short axon segments, regardless of their 
location in the axon arbor (Fig. 6D, color coded axon segments shown in Fig. 5A).  A 
similar relationship was observed in the majority of short segments (71%; 17 / 24 
segments, 6 neurons; Pearson correlation test, p < 0.05).  However, within a neuron, 
some segments have a similar regression slope, indicative of similar release fraction (Fig. 
6D; e.g., segments I and II, III and IV), while release fraction is significantly different 
among other segments (Fig. 6D; e.g., segments I and V, II and V))).  These data suggest 
that release fraction was not constant across an entire axon arbor.  When terminals from 
the most proximal or distal segments from 13 neurons were pooled, and evoked release 
plotted against total vesicle pool size, a significant correlation between these two 
parameters was observed for proximal as well as distal terminals (Fig. 6E), regardless of 
whether total vesicle pool size was large or small (over a > 10 fold difference).  This 
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observation suggests that the release fraction in proximal segments is small and constant, 
and that between-neuron differences are smaller than within neuron proximal-to-distal 
differences.  Moreover, distal terminals have a significantly higher release fraction (Fig. 
6E).  Because terminals in distal axon segments had a wide range of total vesicle pool 
size, the higher release fraction was not due to a small total vesicle pool size (Fig. 6E).   
While most terminals measured were apposed to postsynaptic dendrites, the 
release fraction of terminals not apposed to dendrites was not significantly different from 
those that were (5 of 6 neurons; Student’s t-test, p > 0.05; data not shown).  This is 
consistent with the observation that local release fraction is relatively constant regardless 
of the spatial configuration of postsynaptic targets.  These data further support the 
conclusion that release fraction is unlikely to be retrogradely modulated by postsynaptic 
targets.   
Thus, in contrast to the correlation between evoked release and total vesicle pool 
size in short axon segments, evoked release and thus terminal release probability is 
modulated differently across the entire axon arbor.  This is because release fraction, but 
not total vesicle pool size, accounts for higher evoked release distally compared to 
proximally.  
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Discussion 
Here we report the distribution of the functional properties of presynaptic 
terminals and their relationship with postsynaptic specializations across two spatial 
scales.  Over short distances (ca. 100 microns), evoked released was spatially 
heterogeneous for axons contacting dendrites on different postsynaptic neurons and for 
axons contacting different dendrites on the same neuron.  The magnitude of evoked 
release and total vesicle pool size spatially co-varied, regardless of the spatial 
configuration of the postsynaptic target(s).  This suggests that the fraction of synaptic 
vesicles released and the average release probability of individual vesicles are similar 
among neighboring terminals over short axon distances.  Interestingly, evoked release 
and total vesicle pool size were spatially homogeneous when an axon made terminals 
only along a single dendrite.  Evoked release and total vesicle pool size were highly 
correlated with the amount of two postsynaptic proteins, NMDA receptors and PSD-95, 
regardless of the spatial configuration of postsynaptic targets.  Our results suggest that 
local presynaptic strength is determined mainly by local interactions with postsynaptic 
targets, through modulation of total vesicle pool size, associated with the amount of 
postsynaptic NMDA receptors and PSD-95.   
We report for the first time that over long distances (ca. 1000 µm) across the 
arbor of single axons, a proximal to distal difference exists in the heterogeneity of both 
evoked release and total vesicle pool size.  In contrast to short axon segments, distal 
terminals have higher evoked release, but not total vesicle pool size, than proximal 
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terminals.  Thus release fraction is increased in distal terminals, likely due to greater  
release probability of individual vesicles and/or readily releasable pool size distally 
compared to proximally.  Our results suggest that, across the arbor of a single axon the 
mechanisms that determine synaptic strength are different depending on spatial scale. 
 
Retrograde cellular and molecular determinants of heterogeneous presynaptic release 
properties in short axon segments 
 Previous work has suggested that postsynaptic targets retrogradely influence 
presynaptic release probability (Reyes et al., 1998; Koester and Johnston, 2005; Branco 
et al., 2008; Branco and Staras, 2009).  In rat neocortex, presynaptic terminals contacting 
different postsynaptic neurons have heterogeneous release probability (Reyes et al., 1998; 
Koester and Johnston, 2005).  In cultured rat hippocampal neurons, presynaptic terminals 
contacting different dendrites of the same postsynaptic neuron also have heterogeneous 
release probability (Branco et al., 2008).  Our results suggest that the heterogeneity 
among terminals contacting the same neuron, but on different dendrites, are as 
heterogeneous as the terminals contacting different postsynaptic neurons, extending 
previous studies by comparing the different spatial configurations in individual axons.  
Our results suggest that regardless of different postsynaptic configurations, and possibly 
different postsynaptic retrograde signals, the dynamic range of presynaptic strength of 
terminals in short axon segments is similar across different spatial configurations of 
postsynaptic targets.  This may be due to local, dynamic sharing of presynaptic vesicles 
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and active zone components among many terminals (Ahmari et al., 2000; Friedman et al., 
2000; Shapira et al., 2003; Bresler et al., 2004; Darcy et al., 2006; Tsuriel et al., 2006; 
Tsuriel et al., 2009).   
 Several different postsynaptic retrograde mechanisms have been suggested to 
influence presynaptic functional properties (Tao and Poo, 2001; De Paola et al., 2003; 
Pratt et al., 2003; Ziv and Garner, 2004; Dalva et al., 2007; Williams et al., 2010).  These 
include cell adhesion molecules such as the neuroligin-neurexin complex (Chih et al., 
2005; Levinson et al., 2005; Futai et al., 2007), SynCAM (Biederer et al., 2002), EphBs 
and ephrin-Bs (Dalva et al., 2000; Kayser et al., 2006) and cadherins (Benson and 
Tanaka, 1998; Takeichi, 2007; Arikkath and Reichardt, 2008), among others;  as well as 
secreted factors such as neurotrophins (Du and Poo, 2004), FGF22, FGF7 (Terauchi et 
al., 2010) and Sema3F (Tran et al., 2009), among others.  Which of these cell-cell 
signaling mechanisms contribute to the modulation of presynaptic release properties on 
different spatial scales across an axon arbor remains to be determined. 
Here we show that the amount of synaptic NMDA receptors and PSD-95 is highly 
correlated with presynaptic strength, regardless of the postsynaptic neuron target(s).  
However, it is unlikely that NMDA receptors or PSD-95 directly specify presynaptic 
strength.  Synapse formation and function are largely normal in the absence of PSD-95, 
probably due to functional redundancy (Elias et al., 2006).  However, neuroligins which 
bind to the PDZ domain of PSD-95 has been shown to retrogradely modulate presynaptic 
release probability (Futai et al., 2007; Wittenmayer et al., 2009).  This suggests that PSD-
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95 correlates with presynaptic strength indirectly, possibly via neuroligin-1 signaling. 
While blocking NMDA receptor currents doesn’t change the distribution of other pre- 
and postsynaptic molecules, except for a homeostatic increase in NMDA receptors (Rao 
and Craig, 1997), deletion of NMDA receptors in cortical pyramidal neurons resulted in 
fewer but larger spines and presynaptic terminals (Ultanir et al., 2007).  The correlation 
between NMDA receptors and presynaptic strength we observed may be because NMDA 
receptors bind the first PDZ domain of PSD-95 (Irie et al., 1997), which through its 
interactions with neuroligins retrogradely modulates release probability, resulting in a 
correlation between the amount of PSD-95 and presynaptic strength.  Other adhesion and 
signaling molecules associated with NMDA receptors or PSD-95, such as EphBs (Dalva 
et al., 2000; Kayser et al., 2006), may also retrogradely modulate synaptic strength .  The 
observation that the amount of GluR1 doesn’t correlate with presynaptic strength, while 
the amount of NMDA receptors and PSD-95 does, suggests that not all postsynaptic 
proteins are affected by retrograde signaling that matches pre- and postsynaptic 
properties.  Recent studies showed that the amount of AMPA receptors doesn’t correlate 
with presynaptic strength with baseline activity (Tokuoka and Goda, 2008) and AMPA 
receptor subunits retrogradely stabilize presynaptic terminals when neuroligin-1 is 
present (Ripley et al., 2010).  Our work suggests that the amount of two postsynaptic 
proteins, NMDA receptors and PSD95, is an indirect indicator of presynaptic strength, 
regardless of the spatial configuration or the identity of postsynaptic neuron targets. 
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Spatial distribution of heterogeneous presynaptic terminals across axon arbors  
 Different spatial patterns of presynaptic strength have been documented for axons 
and terminals in several different model systems.  Heterogeneity in the strength of 
presynaptic evoked release has been observed along CNS axons segments and within 
individual mouse motor nerve terminals, while proximal-to-distal gradients of exocytosis 
have been observed in motor nerve terminals of fly, toad and crayfish (Atwood, 1967; 
Bennett et al., 1986; Guerrero et al., 2005).  Whether large scale spatial patterns of 
presynaptic strength also exist across the arbor of CNS axons has not been well studied 
prior to the work we present here.    
Consistent with previous work, we found that in short axon segments, presynaptic 
terminals were heterogeneous with respect to evoked release and total vesicle pool size, 
over a ca. 3 fold range of values (Hessler et al., 1993; Rosenmund et al., 1993; Murthy et 
al., 1997; Moulder et al., 2007; Branco et al., 2008).  In short axon segments, evoked 
release was correlated with total vesicle pool size, similar to other studies using pHluorin 
(Moulder et al., 2007) and electron microscopy studies that showed that large presynaptic 
terminals contain more vesicles (Rosenmund and Stevens, 1996; Dobrunz and Stevens, 
1997; Schikorski and Stevens, 2001).  The magnitude of evoked release can be predicted 
by a simple model that takes into account the size of the readily releasable pool size, the 
release probability of individual vesicles and number of times the terminal is stimulated 
(Fig. 7A).  For short axon segments, this model also mimics the dependence of the 
heterogeneity in evoked release on total vesicle pool size, if the readily releasable pool 
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size is constrained to scale in proportion to the total vesicle pool size (Fig. 7B; note linear 
relationship for either proximal or distal segments).  Thus in short axon segments, the 
heterogeneity in evoked release is determined by the heterogeneity in total vesicle pool 
size, independent of stimulation frequency, and this may be important for maintaining the 
relative strength of terminals across a range of action potential firing rates similar to those 
present in vivo.   
We report here for the first time that evoked release was significantly higher, by 
1.5 fold, in terminals located in proximal compared to distal axon segments.  In contrast 
to the heterogeneity in short axon segments, in which terminals with larger total vesicle 
pool size have higher evoked release, the proximal low / distal high evoked release was 
not correlated with total vesicle pool size, because the distal segments which had higher 
evoked release had the same, or smaller, average total vesicle pool size.  The distal 
increase in evoked release and release fraction is also predicted by the simple model, 
given either an increase in individual vesicle release probability and or an increase in 
readily releasable pool size, if the readily releasable pool is increased independent of total 
vesicle pool size (Fig. 7B; compare change in slope of linear relationship for proximal 
versus distal segments).  The postulated presynaptic loci for the distal increase in release 
properties is consistent with our observation that these differences are not correlated with 
the spatial configuration of postsynaptic targets or the amount of postsynaptic 
components.  A previously reported mechanism that could be attributed to increasing 
distal release by increasing individual vesicle release probability is found in Drosophila 
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motor nerve terminals, where higher distal release is coupled to higher Ca2+ influx 
(Guerrero et al., 2005).  Conversely, in crayfish, higher distal release is correlated with 
boutons that have denser T-bars within active zones (Atwood, 1967), suggestive of a 
larger readily releasable pool.  Future studies employing ultrastructural studies of the 
number of docked vesicles in distal compared to proximal terminals, and measurements 
of Ca2+ influx in individual presynaptic terminals to assay the sensitivity of the release 
fraction to external Ca2+, would provide further insights into the prominent proximal to 
distal difference in evoked release across an individual axon arbor.   
Evoked release and total vesicle pool size were observed to be significantly more 
heterogeneous in distal compared to proximal axon segments, evidenced by a higher 
coefficient of variance and assessment of random pair ratios of these values.  This 
heterogeneity is independent of the mean values of evoked release or total vesicle pool 
size distally, and instead is determined by the distribution of these values, which is 
greater distally than proximally.  What might drive the proximal to distal difference in the 
heterogeneity of these presynaptic properties?  One possibility is a difference in 
spontaneous action potential activity, which may be lower in distal segments due to 
branch point failures along an axon arbor.  However, activity blockade results in a shift to 
higher readily releasable pool size, but the coefficient of variation in the distribution of 
these values is not different (Murthy et al., 2001), suggesting that activity-dependent, 
homeostatic scaling doesn’t change the heterogeneity of release probabilities.   During 
development, proximal segments were once distal segments, and could be less 
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heterogeneous than later added, distal segments if the heterogeneity in the functional 
properties of terminals decreases over time.  Studies employing pHluorin and imaging 
over time as axons grow in vitro and in vivo will be useful to address the spatial 
dynamism in the functional properties of presynaptic terminals as circuits are established.  
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Materials and Methods 
Cell Culture 
 Primary neurons co-cultured with astrocytes were prepared as described 
previously (Elmariah et al., 2005), with minor modifications. Briefly, hippocampi were 
dissected from embryonic day (E) 18 rats, dissociated in Hanks’ Balanced Salt Solution 
(Invitrogen, Grand Island, NY;  with MgCl2 and HEPES) containing 1% papain for 20 
min, triturated in Basal Medium Eagle (Invitrogen), and plated at 75000 cells/ml on a 
poly-L-lysine (Sigma, at a concentration of 1mg/ml) coated coverslips with grids (Bellco 
Biotechnology)  in 24-well plates. Cells were grown at 37°C, 5% CO2, 95% humidity in 
Neurobasal medium (Invitrogen) plus B27 (Invitrogen) and Fetal Bovine Serum 
(Hyclone, to sustain astrocytes in the first week) that was changed weekly.  Neurons co-
cultured with astrocytes instead of those treated with astrocyte conditioned medium were 
used, because contact with astrocytes has been shown to increase the number of 
functional presynaptic terminals in vitro (Elmariah et al., 2004; Hama et al., 2004).  
 
Constructs and transfection 
 The Synaptophysin-pHluorin construct, in which 1 copy of the pHluorin sequence 
was inserted into the lumenal loop of the mouse Synaptophysin sequence, was obtained 
from Dr. Y. Zhu  (Zhu et al., 2009).  Primary hippocampus neuron cultures were 
transfected with this construct (0.03 / 0.06 µg DNA) using Lipofectamine 2000TM (0.06 / 
0.12 µg per coverslip Invitrogen) at 7 DIV at very low efficiency (< 5-10 Synaptophysin-
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pHluorin+ neurons per coverslip) and were imaged 7-10 days after transfection.  In some 
experiments, neurons were co-transfected with mCherry (obtained from Dr. R.Y. Tsien), 
to identify axons from individual neurons.  Synaptophysin-pHluorin was localized 
primarily to axons, accumulated at presynaptic terminals. Immunostaining showed that 
total pHluorin fluorescence was linearly correlated with immunostaining fluorescence of 
the endogenous synaptic vesicle markers SV2 and vGlut at each terminal (data not 
shown).   
 
Live imaging and extracellular stimulation 
At 14-17 DIV, coverslips were mounted in a customized imaging chamber 
(modified RC26 chamber, Warner Instruments).  Coverslips were constantly perfused 
with physiological saline solution containing (in mM) 119 NaCl, 2.5 KCl, 2 CaCl2, 1.3 
MgCl2, 25 HEPES (pH = 7.4) and 30 glucose.  NH4Cl saline solution (pH = 7.4) was 
prepared by substituting 50 mM NaCl in normal saline with NH4Cl.  In experiments to 
measure evoked release during 1 Hz 70 seconds stimulation, Bafilomycin A1 to block the 
re-acidification (Calbiochem, 0.25 uM) was included in the bath.  An in-line heater 
(Warner Instruments) was used to maintain the solution in the chamber at ca. 35 °C.  The 
chamber was mounted onto an inverted microscope (Leica DMI3000B) and neurons were 
imaged with a 63x, 1.2 numerical aperture objective using a Hamamatsu cooled CCD 
camera (C9100), appropriate fluorescence excitation and emission filters (fN2.1 filter 
cube for mCherry, GFP filter cube for pHluorin; Leica), and the incident light was 
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attenuated so that photobleaching was minimal or absent during the imaging session. 
Only glutamatergic neurons that had complex dendritic arbors, short dendritic segment 
lengths and relatively more round cell bodies under DIC illumination (c.f. (Benson et al., 
1994)) were imaged.  Axon segments with Synaptophysin-pHluorin labeled presynaptic 
terminals were selected for imaging based on their presumptive apposition to 
postsynaptic dendrites, confirmed via post-hoc immunostaining for the dendritic marker 
MAP2 (Fig. 1A).  Axon segments were stimulated with a glass pipette (0.5 – 0.9 MΩ) 
placed near an axon of interest at 20 Hz using 1 ms, 400 – 800 µA square pulses in trains 
of 3.5 sec. duration if not stated otherwise.  Pulses were delivered through Iso-Flex  
isolator controlled by a Master-8 (AMPI, Inc.).   
 Stimulation parameters were chosen to maximize the presynaptic response and 
also to saturate the image field.  Over a range of stimulation amplitudes, from 50 µA to 
1200 µA, we found that presynaptic responses began to saturate at about 600 µA (data 
not shown).  When the stimulation exceeded 1000 µA, damage to axons was noted (i.e., 
fluorescence did not return to baseline after 5 min.).  Thus 400 - 800 µA was used for 
experiments.  To determine whether a presynaptic terminal’s response varied 
significantly with electrode location, the electrode was placed at two positions within a 
field and terminal responses compared in two trials at least 5 min. apart.  The ratio of 
evoked release between trials 1 and 2 was ~ 1 with a correlation coefficient r = 0.9.  
These data suggest that presynaptic responses are replicable and are independent of 
electrode placement.   
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 When multiple segments of axon arbors were measured, segments were at least 
300 µm away from each other.  The most proximal axons segments were those closest to 
the cell body with Synaptophysin-pHluorin clusters.  Axon arbors were sampled and 
measured until reaching the growth cone or a point where ambiguously tracking an axon 
was no longer possible.  The stimulation was either moving from proximal to distal or 
vice versa in different neurons.   
  Coverslips were perfused with NH4Cl saline to deacidify synaptic vesicles, 
allowing measurement of maximum ∆F that reflects the total pool of vesicles clustered at 
each presynaptic terminal (Sankaranarayanan et al., 2000; Burrone et al., 2006).  This 
was followed by acidic saline to quench surface fluorescence.  The surface fluorescence 
fraction was measured as surface fluorescence / total fluorescence (Wienisch and 
Kingauf, 2006). 
Time lapse images were acquired using Metamorph (Molecular Devices, Inc.) 
controlling a Lambda SC Smart shutter (Sutter Inst.) at 2Hz for evoked release, and at 0.5 
Hz for NH4Cl saline perfusion, to visualize all Synaptophysin-pHluorin+ clusters and 
total vesicle pool size.  At the end of the experiment, a bright field image was taken to 
document the field of interest, and coverslips fixed and processed for subsequent 
immunostaining.   
    
Immunostaining  
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 Coverslips were fixed in 4% paraformaldehyde and 4% sucrose at room 
temperature for 15 minutes and rinsed in PBS with 0.25% Triton X-100.  For anti-NR1 
immunostaining, coverslips were fixed in 4% paraformaldehyde and 4% sucrose at room 
temperature for 1 minute, followed by MeOH at -20 °C for 4 minutes. Coverslips were 
rinsed in PBS and blocked in PBS containing 5% normal goat serum.  Coverslips were 
then incubated in one or more of the following primary antibodies: anti-PSD-95 (mouse 
monoclonal; Affinity BioReagents, CO), anti-MAP2 (mouse polyclonal; gift from Dr. V. 
Lee), anti-NR1 (rabbit polyclonal; Sigma, MO), anti-GluR1 (rabbit polyclonal; 
Chemicon, MO), anti-vGlut (guinea pig polyclonal, Chemicon, MO), anti-SV2 (mouse 
monoclonal, Dev. Studies Hybridoma Bank, IA). Antibodies were visualized after 
staining with the appropriate FITC-, TRITC- or Cy5-conjugated secondary antibodies 
(Jackson ImmunoResearch, PA).  After immunostaining, the region of interest was 
located and imaged using a confocal microscope (Leica TCS 4D).  Field size and pixel 
resolution were adjusted so that confocal images were in register with live images pixel 
by pixel.  In each image, laser light levels and detector gain and offset were adjusted so 
that no pixel values were saturated in the regions analyzed.  
 
Analysis 
An averaged image was made from all time lapse images obtained in NH4Cl, in 
which all Synaptophysin-pHluorin+ clusters were visualized (Fig. 1).  This process 
averaged out small, mobile Synaptophysin-pHluorin+ clusters within axons, while 
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retaining stable clusters that were likely to be bona fide presynaptic terminals.  Regions 
of interest (ROIs) were then made from the averaged image, using a customized 
algorithm in ImageJ software (adapted from (Bergsman et al., 2006)).  The major 
advantage of this algorithm is that a wide range of presynaptic terminal area, from 0.3 to 
8 µm2, was more accurately identified compared to simple thresholding.  ROI were 
defined using the cluster size range and a thresholded intensity, determined by measuring 
presynaptic terminals defined by eye in 3 representative images from the same set of 
images. These parameters were then used in all subsequent analyses.   
Evoked release was measured by subtracting the total fluorescence in ROIs 
averaged from 3 consecutive frames right before the stimulation from the total 
fluorescence in ROIs in the 1 frame right after the stimulation was stopped.  The total 
fluorescence in each ROI was determined by summing pixel intensity in each ROI.  
Among all ROIs, the fluorescence intensity of ROIs was plotted versus time, some 
fluorescence traces increased linearly during stimulation, while others were flat (Fig. 1).  
The R2 of the regression slope was calculated for each trace of fluorescence changes 
during stimulation for each ROI.  The R2 was also calculated for baseline fluorescence 
over 3.5 sec. prior to stimulation, assuming that during this period of time, there is no 
evoked fluorescence change and any R2 value is due to random fluorescence fluctuation.  
The distribution of R2 ( n = 1387 terminals) values in the absence of stimulation was 
compared to the distribution of R2 values during stimulation.  As expected, during 
stimulation, the frequency of large R2 values increases.  To keep the rate of false 
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positives low (≤ 5%), 0.72 was used as a threshold value.  Thus a fluorescence trace with 
a positive slope during stimulation and with an R2 value > 0.72 was characterized as a 
releasing terminal.  Those with an R2 value < 0.72 were regarded as non-releasing 
terminals.  If not stated otherwise, only presynaptic terminals that were characterized as 
releasing during 20 Hz stimulation were used in subsequent analyses.   
Total vesicle pool size was estimated by subtracting the baseline fluorescence 
from the total fluorescence in NH4Cl.  Thus total vesicle pool size was measured as the 
maximum change of fluorescence in NH4Cl, as if all the vesicles clustered within a 
terminal were exocytosed.  The release fraction of individual terminals was determined as 
∆F / total vesicle pool size and reflected the percentage of vesicles exocytosed upon 
stimulation.  
  Co-localization between pHluorin+ terminals and a pre- or postsynaptic marker 
after post-hoc immunostaining was evaluated in time lapse or immunostaining images 
taken at the same pixel resolution.  The orientation of images after immunostaining was 
adjusted using free rotation in Metamorph, and the ROIs defined from time lapse images 
were superimposed.  The ROIs were moved together to align them with pHluorin+ 
terminals. Individual ROIs were then moved by a few pixels for final alignment.  If there 
was no pHluorin+ terminal within 5 pixels of an ROI defined from time lapse imaging, 
the ROI was not analyzed further. Different fluorescence channels were separated and 
segmented with the ImageJ algorithm as described in segmenting pHluorin+ live images.  
An overlap mask of Synaptophysin-pHluorin and an immunostained marker was made, 
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ROIs superimposed, and any pair of clusters with more than 1 pixel overlap within the 
ROI was defined as co-localized.   
The Komolgorov-Smirnoff test was used to determine whether values were 
parametrically distributed.  Student’s t test was used for parametrically distributed values; 
the Mann-Whitney U test or Wilcoxon matched-pairs test was used for non-
parametrically distributed values; the Pearson correlation test was used to compare 
correlated values; and the F test was used to compare linear regressions (GraphPad 
Prism).   
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Figure and Legends  
 
Figure 1.  Evoked release and total vesicle pool size are heterogeneous in short axon 
segments. 
A.  Top:  Representative images of Synaptophysin-pHluorin+ synaptic vesicle 
clusters (green) along an local axon segment from a 14 DIV neuron after live imaging 
followed by fixation and immunostaining for MAP2 (red).  All of the terminals analyzed 
in this segment were apposed to neuronal dendrites from multiple postsynaptic neurons.  
Arrows and arrowheads indicate all presynaptic terminals in this axon segment (defined 
using criteria described in Materials and Methods).  Arrows indicate releasing terminals, 
arrowheads indicate non-releasing terminals.  The numbers 1-4 indicate the releasing or 
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non-releasing presynaptic terminals shown in the middle pseudo-colored time lapse 
image series. The cluster labeled with an asterisk was trafficked to that location in the 
interval between when the NH4Cl image was taken and fixation and was excluded in the 
analysis.  Scale bar = 10 µm.  
Middle:  Pseudo-colored time lapse images of presynaptic terminals 1-4 taken 
before, during (black line, 3.5 sec. duration) and after electrical stimulation.  The ∆F of 
evoked vesicle exocytosis (evoked release) at terminals 1-4 are measured as fluorescence 
by the end of stimulation – baseline fluorescence (also refer to Methods and Materials).  
The color scale is in arbitrary fluorescence units (AFU).   
Bottom:  The maximal ∆F of Synaptophysin-pHluorin+ synaptic vesicle cultures 
is assessed in NH4Cl saline at the end of stimulation.  The total vesicle pool size of 
presynaptic terminals 1-4 is estimated by measuring maximal ∆F within each terminal.  
B.  Total fluorescence of individual presynaptic terminals plotted against time to 
show changes in fluorescence (∆F) during stimulation.  The stimulation duration is 
indicated with the black line below the x axis from 3.5 to 7 sec.  The ∆Fs of presynaptic 
terminals 1-4 are heterogeneous, varying over a more than 10 fold range; e.g., the ∆F for 
terminal 2 was 30.9 x 104 AFU, whereas ∆F for terminal 3 was 3.4 x 104 AFU.  
Fluorescence returned to baseline within 1-2 minutes after stimulation ceased, as 
Synaptophysin-pHluorin+ vesicles were endocytosed and reacidified (τ = 16.1 ± 0.3 sec., 
11 presynaptic terminals, comparable to (Sankaranarayanan and Ryan, 2000)). 
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C.  The average pair ratio of evoked release between two consecutive trials of 
stimulation at the same terminals was significantly less than the average pair ratio of two 
random presynaptic terminals in a short axon segment (49  terminals, 6 neurons;  Mann-
Whitney U test, p = 0.004).  Error bars indicate SEM. 
D.  The average pair ratios of ∆F in NH4Cl, reflecting total vesicle pool size, 
between two consecutive trials of the same terminals was significantly lower than the 
average pair ratio between two random presynaptic terminals in a short axon segment (49 
terminals, 6 neurons; Mann-Whitney U test, p = 0.004).  Error bars indicate SEM. 
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Figure 2.  Heterogeneity in total vesicle pool size correlates with heterogeneity in 
evoked release in short axon segments, independent of stimulation frequency. 
 Local axon segments are stimulated with 70 pulses delivered at 1 Hz, 5 Hz, 20 
Hz, 100 Hz for 70 sec., 12 sec., 3.5 sec., and 0.7 sec., respectively.  Baflomycin was 
added for the 1 Hz measurement (see Methods).  Evoked release was measured at each 
stimulation frequency; at the end of the experiment, total vesicle pool size was measured.   
A.  Plots of scaling between total vesicle pool sizes and evoked release of the 
same set terminals across different simulation frequencies (correlation coefficient for 1, 
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5, 20, 100 Hz: r = 0.92, 0.95, 0.84, 0.83, respectively; Pearson correlation test, p = 0.001, 
<0.001, 0.008, 0.01, respectively; similar for 4 of 4 neurons).  Each symbol indicates 
individual terminal across different stimulation frequencies. 
B.  Plot of average evoked release of the representative terminals as 70 pulses 
delivered at different frequencies.  The average is fitted by a one exponential decay (R2 = 
0.99; one exponential decay regression analysis, p = 0.0004).  
 C.  Random pair ratios of evoked release of terminals within short axon segments 
at different stimulation frequencies were similarly heterogeneous (28 terminals, 4 
neurons; one-way ANOVA, p = 0.13). 
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Figure 3.  Functional properties among presynaptic terminals contacting different 
dendrites of the same or different postsynaptic neurons are heterogeneous. 
 Local axon segments are stimulated with 70 pulses delivered at 20 Hz to measure 
evoked release, followed by NH4Cl saline perfusion to measure total vesicle pool size.  
Posthoc immunostaining was performed with anti-MAP2 to reveal postsynaptic 
dendrites/neurons.   
A.  Representative presynaptic terminals’ evoked release and total vesicle pool 
sizes.  On the left image panel, the top image is posthoc immunostaining with MAP2 
showing that terminal 1 and 2 overlap with the same dendrite, terminal 3 overlaps with a 
different dendrite from the same neuron.  The middle image is a pseudocolor image 
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showing evoked ∆F by the end of the 20 Hz stimulation train.  The bottom image is a 
pseudocolor image showing ∆F in NH4Cl.  The right panel traces are showing evoked ∆F 
over time of terminals 1, 2, 3.  Scale bar = 10 µm.  
B.  On the left image panel, the top image shows terminal 1 and 2 overlap with 
different dendrites from different neuron.  The middle image is a pseudocolor image 
showing evoked ∆F at the end of the 20 Hz stimulation train.  The bottom image is a 
pseudocolor image showing ∆F in NH4Cl.  Right panel, evoked ∆F over time of terminal 
1, 2.  Scale bar = 10 µm. 
C.  The random pair ratios of evoked release were significantly higher than the 
two repeats control ratios for terminals innervating two different dendrites of the same 
neuron (8 neurons, 40 terminal pairs; Mann-Whitney U test, p = 0.04), for terminals 
innervating dendrites from two different postsynaptic neurons (5 neurons, 29 terminal 
pairs; p = 0.002), and for random pairs of terminals (8 neurons, 40 terminal pairs; p = 
0.001), but not for terminals innervating the same dendrite (7 neurons, 33 terminal pairs; 
p = 0.15).  
D.  The random pair ratios of total vesicle pool size were significantly higher than 
the two repeats control ratios for terminals innervating dendrites from two different 
neurons (p = 0.02) and for random pairs of terminals (p = 0.004), but not for terminals 
innervating the same dendrite (p = 0.14) or two different dendrites of the same neuron (p 
= 0.25).   
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Figure 4.  Presynaptic heterogeneity across different synaptic configurations is 
correlated with the amount of postsynaptic NMDA receptors and PSD-95. 
 Local axon segments were stimulated with 70 pulses delivered at 20 Hz to 
measure evoked release, followed by NH4Cl saline perfusion to measure total vesicle 
pool sizes.  Posthoc immunostaining was performed with anti-PSD95, NR1, GluR1 or 
MAP2 antibodies to reveal postsynaptic specializations or dendrites.   
 A.  Representative images of evoked ∆F (left), total vesicle pool size (left 
middle), posthoc immunostaining of NR1 clusters (right middle, green channel is 
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pHluorin, red channel is NR1), and colocalized pixels between NR1 and Synaptophysin-
pHluorin (right).  Arrowhead indicates the terminals plotted in B and C.  Scale bar = 5 
µm.  
B.  Correlation plot of NR1 intensity and evoked ∆F of terminals in Fig. 4A 
(correlation coefficient r = 0.99, Pearson correlation test, p = 0.006).   
C.  Correlation plot of NR1 intensity and total vesicle pool size of terminals in 
Fig. 4A (correlation coefficient r = 0.97, Pearson correlation test, p = 0.03). 
D.  The average correlation coefficient between evoked release and NR1 (9 
segments; r = 0.8 ± 0.04) or PSD-95 (11 segments; r = 0.80 ± 0.04) was significantly 
different from the MAP2 correlation coefficient (asterisk; Mann-Whitney U test, NR1 p = 
0.003, PSD-95, p = 0.003), but not that of GluR1 (r = 0.6 ± 0.1; p = 0.27).  Evoked 
release was not significantly correlated with the amount of MAP2 for terminals in 7 / 8 
axon segments measured (r = 0.4 ± 0.1). 
E.  The average correlation coefficient between total vesicle pool size and NR1 (r 
= 0.8 ± 0.03) or PSD-95 (r = 0.80 ± 0.04) were significantly different from the MAP2 
correlation coefficient (asterisk; Mann-Whitney U test, NR1 p = 0.008, PSD95 p = 0.01), 
but not that of GluR1 (r = 0.7 ± 0.1; p= 0.17).  Total vesicle pool size was not 
significantly correlated with the amount of MAP2 for terminals in 6 / 8 segments 
measured (r = 0.5 ± 0.1). 
F.  Left:  Posthoc immunostaining images of MAP2 (blue) and NR1 (red) of 
several terminals from a segment of axon contacting different dendrites of one single 
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postsynaptic neuron.  Arrow heads indicate presynaptic terminals that are overlapping 
with MAP2.  Middle:  Higher magnification images of numbered presynaptic terminals 
1-5.  Right:  Masks of Synaptophysin-pHluorin (green) and NR1 (red) and their 
overlapped pixels (yellow).  Scale bar = 10 µm.  
G.  Linear correlation between total vesicle pool size and amount of NR1 for 
terminals 1-5 shown in 4F (correlation coefficient r = 0.83; Pearson correlation test, p = 
0.08).   
H.  Correlation between total vesicle pool size and amount of NR1 among 
terminals from an axon contacting two different postsynaptic neurons (red squares, black 
squares; (correlation coefficient r = 0.75; Pearson correlation test, p = 0.003).   
I.  Average values ± SEM of total vesicle pool size and amount of NR1 from 6 
axons contacting two different neurons (red and black symbols represent two 
postsynaptic neurons contacted by the same axon).  Some axons only made one or two 
terminals on a  postsynaptic neuron, thus there are no error bars.  The squares represent 
the average values of  the terminals shown in Fig. 4H. 
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Figure 5.  Distal terminals are functionally more heterogeneous than proximal 
terminals. 
  A.  Neurolucida tracing of a neuron transfected with Synaptophysin-pHluorin and 
mCherry (not shown) to enable long distance axon tracking.  Colors indicate axon 
segments that were stimulated and imaged.  Images taken after stimulation show the 
distribution of releasing presynaptic terminals (arrows).  Scale bar = 100 µm.   
B.  Evoked release of individual presynaptic terminals, color coded by segment.   
C.  The average random pair ratios of evoked release for terminals in color coded 
axon segments in A (range 2.9 ± 0.5 to 4.4 ± 0.5; average of all 5 segments from this 
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neuron, white bar), as well as 22 / 24 axon segments from 6 neurons (average of 
terminals in all segments, 3.4 ± 0.2), is significantly higher than the two repeats control 
(indicated by dashed line, 1.9 ± 0.2; Mann-Whitney U test, p < 0.05).  The random pair 
ratios of evoked release for terminals in color coded segments and all segments from all 
axons are not significantly different (one-way ANOVA, p = 0.66).   
D.  Total vesicle pool size of individual presynaptic terminals, color coded by 
segment.   
E.  The average random pair ratios of total vesicle pool size for terminals in short 
axon segments in A (range 3.3 ± 0.6 to 5.0 ± 0.9; average of all 5 segments from this 
neuron, white bar), as well as 18 / 24 axon segments from 6 neurons (average of 
terminals in all segments, 3.2 ± 0.2), is significantly higher than the two repeats control 
(indicated by dashed line, 1.9 ± 0.1; Mann-Whitney U test, p < 0.05).  The random pair 
ratios of total vesicle pool size for terminals terminals in color coded segments and all 
segments from all axons are not significantly different (one-way ANOVA, p = 0.92).   
F.  Heterogeneity in evoked release, assessed by random pair ratios, was 
significantly greater distally compared to proximally (distal, 3.7± 0.5; proximal, 2.6 ± 
0.3; 6 neurons; paired Student’s t-test, p = 0.04). 
G.  Heterogeneity in total vesicle pool size, assessed by random pair rations, was 
significantly greater distally compared to proximally (distal, 3.7± 0.5; proximal, 2.5 ± 
0.2; paired Student’s t-test, p = 0.02).   
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H.  Relationship between coefficient of variance (CV) of evoked release and total 
vesicle pool size of presynaptic terminals from the most proximal (white circles; 
correlation coefficient, r = 0.65, Pearson correlation test, p < 0.05) and the most distal 
(black circles; correlation coefficient, r = 0.82; Pearson correlation test, p < 0.05) 
segments from 13 neurons (slope = 0.96 ± 0.05; Pearson correlation test, p < 0.0001).   
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Figure 6.  Evoked release and release fraction are higher in distal segments of 
individual axon arbors.  
A.  Average evoked release in proximal axon segments (black dots; 1.3 ± 0.2 x 
104 AFU) is slightly but significantly smaller than distal segments (1.9 ± 0.3 x 104 AFU; 
16 neurons; Wilcoxon matched-pairs test, p < 0.001).  The average evoked release in 
proximal compared to distal segments is indicated by red dots.   
B.  Average total vesicle pool size in proximal axon segments (black dots; 15.2 ± 
3.9 x 104 AFU) of individual neurons  is not significantly different from that in distal 
segments (10.1 ± 2.0 x 104 AFU; 16 neurons; Wilcoxon matched-pairs test, p = 0.17).  
The average of total vesicle pool size in proximal compared to distal segments is 
indicated by red dots.   
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C.  Average release fraction in proximal axon segments (black dots; 0.15 ± 0.02) 
is significantly smaller than in distal segments (0.30 ± 0.04; 16 neurons; Wilcoxon 
matched-pairs test, p = 0.003).  The average release fraction of proximal compared to 
distal segments is indicated by red dots. 
D.  Relationship between evoked release and total vesicle pool size of presynaptic 
terminals from axon segments 1-5 from the representative neuron shown in Fig. 5A, color 
coded as in 5A, C, E.   For each segment, correlation coefficient and Pearson correlation 
test: Segment I, r = 0.67, p = 0.15; II, r = 0.86, p = 0.006; III, r = 0.81, p = 0.002; IV, 
N/A; V, r = 0.88, p = 0.004).   In this example, as for all axons measured (24 segments, 6 
neurons), some segments have a similar regression slope, indicative of similar release 
fraction (segments I and II, segments III and IV), while release fraction is significantly 
different among other segments (one way ANOVA, p = 0.007).   
E. Relationship between evoked release and total vesicle pool size of all terminals 
in the most proximal segments (gray) and the most distal (black) segments from 13 
neurons (evoked release, correlation coefficient r = 0.90, Spearman correlation test p < 
0.0001; total vesicle pool size, correlation coefficient r = 0.85; Spearman correlation test 
p < 0.0001).  The linear regression lines are significantly different (average proximal 
slope = 0.05 ± 0.005, distal slope = 0.14 ± 0.009; F test, p < 0.001), indicating that distal 
terminals have a significantly higher release fraction compared to proximal terminals. 
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Figure 7.  Model of release property heterogeneity in distal versus proximal axon 
segments.   
A simple model of vesicle exocytosis in hippocampal nerve terminals was capable 
of recapitulating the experimental data and provides some insight in the possible 
mechanisms underlying spatial differences in release properties.   
A.  The number of vesicles releasing neurotransmitter (ER, evoked release) was 
given by the number of vesicles in the readily releasable pool (RRP), the release 
probability of individual vesicles (Pv) and the number of times the axon was stimulated 
(N).  The size of the RRP was proportional to total vesicle pool size (TVP), defined as the 
sum of the RRP, the reserve pool, and the resting pool.  The fraction of vesicles released 
(RF) was defined as the ratio of ER to TVP.  Thus, ER = RRP x Pv x N; RRP =  k x 
TVP; and RF = ER / TVP, where k = RRP / TVP.    Based on an anatomical model of 
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vesicle distribution in terminals (Sudhof, 2000), TVP was set at 200 vesicles and the RRP 
to 5 vesicles which yields an initial value of k of  0.025.  Following substitution and 
rearrangement, individual vesicle release probability is Pv = RF / (k x N); the measured 
value of RF, 0.15 for proximal segments, can be used to determine an initial value for Pv 
in the model.    
B.  TVP was systematically varied over a 10-fold range to generate heterogeneity 
in TVP and yield values of ER consistent with the experimental data from proximal 
segments (black line).   The measured increase in RF for distal segments from 0.15 to 
0.30 could be achieved in the model by either doubling the individual release probability 
(Pv, red line) or increasing the size of the RRP independent of the size of the TVP, i.e. 
doubling k (blue line).   This holds true for any combination of Pv and RRP such that Pv 
x k = RF / N.    These model findings are consistent with the notion that differences in ER 
within short axon segments (either proximal or distal) can be attributed to the changes in 
terminal size, or at least TVP size, whereas proximal / distal differences arise from either 
changes in RRP size and or Pv. 
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Abstract 
 We recently described a severe, potentially lethal, but treatment responsive 
encephalitis that associates with autoantibodies to the N-methyl-D-aspartate receptor 
(NMDAR) and results in behavioral symptoms similar to those obtained with models of 
genetic or pharmacologic attenuation of NMDAR function.  Here we demonstrate that 
patients’ NMDAR antibodies cause a selective and reversible decrease in NMDAR 
surface density and synaptic localization that correlates with patients’ antibody titers.  
The mechanism of this decrease is selective antibody mediated capping and 
internalization of surface NMDARs, as Fab fragments prepared from patients’ antibodies 
did not decrease surface receptor density, but subsequent crosslinking with anti-Fab 
antibodies recapitulated the decrease caused by intact patient NMDAR antibodies.  
Moreover, whole-cell patch clamp recordings of miniature excitatory postsynaptic 
currents in cultured rat hippocampal neurons showed that patients’ antibodies specifically 
decreased synaptic NMDAR-mediated currents, without affecting AMPA receptor-
mediated currents.  In contrast to these profound effects on NMDARs, patients’ 
antibodies did not alter the localization or expression of other glutamate receptors or 
synaptic proteins, number of synapses, dendritic spines, dendritic complexity, or cell 
survival.  In addition, NMDAR density was dramatically reduced in the hippocampus of 
female Lewis rats infused with patients’ antibodies, similar to the decrease observed in 
the hippocampus of autopsied patients.  These studies establish the cellular mechanisms 
through which antibodies of patients with anti-NMDAR encephalitis cause a specific, 
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titer-dependent, and reversible loss of NMDARs.   The loss of this subtype of glutamate 
receptors eliminates NMDAR-mediated synaptic function resulting in the learning, 
memory and other behavioral deficits observed in patients with anti-NMDAR 
encephalitis. 
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Introduction 
Synaptic plasticity is thought to underlie mechanisms of memory, learning, and 
cognition. Central to these neurological functions is the proper synaptic localization and 
trafficking of the excitatory glutamate NMDA and AMPA receptors(Lau and Zukin, 
2007; Shepherd and Huganir, 2007).  The roles of these receptors at the synaptic and 
cellular levels have been established through animal models in which the receptors have 
been genetically or pharmacologically altered(Jentsch and Roth, 1999; Mouri et al., 
2007).  In humans the role of these receptors in memory, learning, cognition and 
psychosis comes from more indirect approaches, such as pharmacological trials (e.g., 
NMDAR antagonists causing psychosis)(Gunduz-Bruce, 2009), and analysis of brain 
tissue from patients with Alzheimer’s disease or schizophrenia in which several 
molecular pathways causing a downstream alteration of glutamate receptors are 
affected(Snyder et al., 2005a; Hahn et al., 2006). We recently identified a disorder in 
which the extracellular domain of the NR1 subunit of the NMDAR is directly targeted by 
autoantibodies(Dalmau et al., 2007; Dalmau et al., 2008). Patients develop prominent 
psychiatric and behavioral symptoms, rapid memory loss, seizures, abnormal movements 
(dyskinesias), hypoventilation, and autonomic instability(Dalmau et al., 2007; Dalmau et 
al., 2008; Iizuka et al., 2008).  In two series comprising 181 cases(Dalmau et al., 2008; 
Florance, 2009), there was a strong female predominance (ratio 8.5:1.5) and the median 
age of the patients was 19 years (23 months-75 years; 40% children). In 55% of the 
adults (less frequently in children), the disorder appears to be triggered by the presence of 
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a tumor, mostly an ovarian teratoma that contains nervous system tissue and expresses 
NMDARs. Despite the severity of the symptoms, 75% of patients recover after receiving 
immunotherapy and, when appropriate, tumor removal, and 25% are left with memory, 
cognitive and motor deficits, or, rarely, die of the disorder. The autoantibodies are present 
in patients’ serum and cerebrospinal fluid (CSF), the latter usually showing intrathecal 
synthesis and high antibody concentration (Dalmau et al., 2008; Florance, 2009). All 
patients’ antibodies recognize the N-terminal extracellular domain of NR1 (amino-acid 
residues 25-380), suggesting an antibody-mediated pathogenesis (Dalmau et al., 2008).  
While patients’ antibodies can cause a decrease in NMDAR cluster density, the 
underlying mechanisms remain poorly understood (Dalmau et al., 2008).  Here we report 
in vitro and in vivo studies that indicate the cellular mechanisms by which patients’ 
antibodies lead to a reduction in surface and synaptic NMDAR density and function, 
likely underlying the learning, memory and other behavioral deficits observed in patients 
with anti-NMDAR encephalitis. 
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Results 
Patients’ antibodies reduce surface NMDA receptor clusters and protein in a titer 
dependent fashion 
 Hippocampal neurons were cultured for 1 day with CSF or purified IgG 
containing anti-NR1 antibodies from patients with anti-NMDAR encephalitis (see 
Supplemental Table 1), followed by immunohistochemical and Western blot analyses of 
surface and total NR1 protein. Patients’ antibodies significantly decreased NR1 or 
NMDAR surface and total cluster density in a titer dependent fashion, compared to CSF 
or IgG from control patients (Fig. 1a, c).  Similar findings were obtained after treating the 
neurons for 3 or 7 days with patients’ antibodies (Supplemental Fig. 3).  
A significant titer-dependent decrease in surface and total NR1 protein was also 
observed with Western blot analyses (Fig. 1b, d).  Moreover, Western blot analyses of the 
effect of patients’ antibodies on NR2 subunits (which assemble with NR1 to form 
NMDARs) showed that patients’ antibodies significantly decreased surface and total 
NR2A and NR2B proteins in a titer dependent fashion (Supplemental Fig. 4). 
To determine whether the effects of patients’ antibodies correlate with the change 
of titers during the course of the disease, hippocampal neurons were cultured with CSF 
samples obtained at two different time points of the disease of two patients. The initial 
CSF was obtained at the time of symptom presentation and the second sample during 
symptom improvement in one patient and during symptom worsening in the other. The 
CSF obtained at symptom presentation had a higher NR1 antibody titer than the CSF 
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obtained during symptom improvement of the first patient; in contrast, the CSF obtained 
during symptom worsening had a higher antibody titer than the CSF obtained at symptom 
presentation of the second patient. In both cases the CSF with higher NR1 antibody titer 
decreased NMDAR surface and total cluster density (or total NMDAR protein measured 
by Western blot) (Fig. 1e, f) to a greater extent than the CSF with the lower titer. 
Together, these results show that NR1 antibodies from patients with anti-NMDAR 
encephalitis decrease NMDAR surface cluster density and protein in a titer-dependent 
manner and that the effects of the antibodies vary with the change of titers during the 
course of the disease. 
 
Patients’ antibodies reversibly reduce synaptic NMDA receptor clusters without 
affecting the number of synapses and other synaptic components 
 Because patient antibodies decreased overall NMDAR surface cluster density and 
protein, we determined whether the antibodies also affected NMDAR synaptic 
localization, the number of synapses, and other synaptic components.  Hippocampal 
neurons were cultured with CSF or purified IgG for 3 or 7 days, followed by 
immunostaining or Western blot analysis of NR1 and synaptic components such as 
presynaptic VGlut, postsynaptic PSD-95, AMPA receptor subunits GluR1 and GluR2, 
and GABA receptors.   
While the overall structural integrity of excitatory neurons and synapses was not 
affected (see below), patients’ antibodies dramatically reduced the synaptic localization 
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of NMDAR clusters in a titer-dependent fashion compared to controls (Fig. 2a, c; see also 
Supplemental Fig. 5), consistent with the overall decrease in surface NMDAR cluster 
density (Fig. 1).  To determine whether the antibody-mediated decrease in NMDAR 
synaptic localization is reversible, patient antibodies were removed from the culture 
medium after 3 days of treatment and neurons were cultured for 4 additional days.  The 
density of synaptically localized NMDAR clusters returned to baseline levels 4 days after 
patient antibodies were removed (Fig. 2a, c).  These results show that patients’ antibodies 
cause a specific loss of NMDARs from excitatory synapses and that this loss is reversed 
after antibody removal. 
Patients’ antibodies did not affect the number of excitatory synapses compared to 
controls (Fig. 2a, b). Moreover, patients’ antibodies did not affect the density of 
postsynaptic PSD-95, GluR1, GluR2 receptor clusters, or the surface or total amount of 
these proteins or the amount of surface GABA receptor protein (Fig. 3), dendritic 
branching, dendritic spine density, or Bassoon cluster density (Fig. 4). In addition, 
patients’ antibodies did not affect cell survival (Fig. 4h,i). The effects of patients’ 
antibodies on NMDAR cluster density were not mediated by complement, because 
purified patient IgG from serum or heat-inactivated patient CSF decreased NMDAR 
cluster density and localization to a similar extent as non-heat inactivated patient CSF 
(Supplemental Fig. 1).   
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These results show that patients’ antibodies specifically affect NMDAR without 
any demonstrable effect on AMPA or GABA receptors, other synaptic proteins, the 
number of excitatory synapses, and neuronal morphology or viability. 
  
Patients’ antibodies selectively decrease synaptic NMDAR currents 
 We next assessed the effects of patient antibodies on NMDAR function using 
whole-cell patch recordings of miniature excitatory postsynaptic currents (mEPSCs), 
which consist of a fast AMPA receptor-mediated current and a slow NMDAR current.  
Neurons were treated for 1 day with patient or control CSF and spontaneous mEPSCs 
were recorded at -70 mV in a 0 Mg2+ extracellular solution to unmask the synaptic 
NMDAR-mediated component.  TTX was used to block action potentials, CNQX was 
used to block AMPA receptor mediated mEPSCs, APV was used to block NMDAR-
mediated mEPSCs, and picrotoxin was used to block GABA receptor-mediated miniature 
inhibitory postsynaptic currents (Fig. 5a). 
  In neurons treated for 1 day with CSF from control patients, CNQX blocked 
large, fast AMPA receptor-mediated currents, revealing small, slower NMDAR-mediated 
currents that were completely blocked by APV (Fig. 5a, left).  In contrast, in neurons 
treated for 1 day with patient CSF, CNQX blocked all mEPSCs, and no further reduction 
was observed after APV (Fig. 5a, right).  This result shows that patient antibody 
treatment decreases NMDAR-mediated current. 
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 To quantify the reduction in synaptic NMDAR-mediated currents, currents were 
examined before and after APV application.  In neurons treated for 1 day with CSF from 
control patients, APV reduced or abolished the late, slow NMDAR-mediated component 
of the mEPSC (Fig. 5b, left; 5c, left).  In contrast, in neurons treated for 1 day with 
patient CSF, APV application did not further reduce the NMDAR-mediated component 
of the mEPSC (Fig. 5b, middle; 5c, left).  The difference between the 0 Mg 2+ and the 0 
Mg 2+ + APV traces shows that neurons treated for 1 day with patient CSF have less 
NMDAR-mediated synaptic current than neurons treated with control CSF (Fig. 5b, right; 
5c, left).  No difference was observed in the peak AMPA receptor-mediated component 
of the mEPSC (Fig. 5c, right).   Patient antibody treatment did not affect mEPSC 
frequency or amplitude (Supplemental Fig. 6), suggesting that presynaptic release 
probability is unaltered.  These data are also consistent with structural analyses that 
showed that patients’ antibodies do not affect the number of excitatory synapses or the 
number of postsynaptic sites containing AMPA receptors.  These results show that 
patients’ antibodies specifically decrease synaptic NMDAR-mediated currents and do not 
affect AMPA receptor mediated currents, consistent with the specific loss of surface, 
synaptically localized NMDAR clusters.   
Patients’ antibodies crosslink and internalize NMDA receptors 
 We next determined the mechanism by which patients’ antibodies decrease 
surface NMDAR cluster density and protein.  The Fc IgG domain was enzymatically 
removed from patients’ antibodies to generate Fab fragments.  These Fab fragments, like 
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intact patient IgG, bound to surface NR1 clusters identified with commercial anti-NR1 
immunostaining (Supplemental Fig. 2).  Neurons treated for 1 day with patients’ Fab 
fragments had the same NMDAR cluster density and surface protein as neurons treated 
with control IgG (Fig. 6a, b).  In contrast, neurons treated for 1 day with patients’ Fab 
fragments and anti-Fab secondary antibodies (linking two Fab fragments in a 
conformation similar to unmodified patients’ antibodies) had significantly lower 
NMDAR cluster density and surface protein as compared to neurons treated with control 
IgG (Fig. 6a, b).  These results show that patients’ antibodies mediate the loss of surface 
NMDARs in part by binding to, capping and crosslinking NMDARs, resulting in their 
internalization (Fig. 6c).   
 
Patients’ antibodies decrease NMDA receptor cluster density and protein in rodent 
and human hippocampus in vivo  
 Our results show that, in vitro, patients’ anti-NR1 antibodies lead to a selective 
loss of surface NMDAR clusters and their function, without loss of other synaptic 
components or neuron viability. To determine the effects of patients’ antibodies in vivo, 
CSF from patients with  high titers of NR1 antibodies, or control CSF from individuals 
without NR1 antibodies, was infused directly into the hippocampus of adult rats for two 
weeks, followed by immunostaining for human IgG to examine the diffusion and 
deposition of patients’ antibodies, immunostaining and Western blot analysis of 
NMDARs and other synaptic components to assess the effects of patients antibodies, and 
  
94 
analysis of cell death using the TUNEL assay.  Patients’ antibodies colocalized with 
NMDAR clusters in vivo as in vitro (Supplemental Fig. 7 a).  Moreover, IgG from 
infused patient CSF, but not from control CSF, was found bound to rat hippocampus in a 
predictable pattern that was dependent on NMDAR density (e.g., high density in 
proximal dendrites of dentate gyrus, Supplemental Fig. 7 b).  This pattern was similar to 
the direct immunostaining of bound IgG reported in the autopsy of two patients with anti-
NMDAR encephalitis (Dalmau et al., 2007).  Moreover, in regions where human IgG was 
deposited, there was a significant decrease in NMDAR cluster density and intensity of 
NR1 immunostaining without affecting the number of synapses, the density of other 
synaptic components (Fig. 7a-e; Supplemental Fig. 7 b) or cell death (Supplemental Fig. 
7 c).  The magnitude of the effects of each patient’s CSF was significantly correlated with 
the titer of NR1 antibodies infused into rat brains (Fig. 7b), as in in vitro studies (Fig. 1).  
Furthermore, the total amount of NR1 protein was reduced in rodent hippocampus 
infused with patients’ CSF compared to the contralateral, uninfused hippocampus (Fig. 
7c).     
 To investigate whether NMDAR cluster density is reduced in the brains of 
patients with anti-NMDAR antibodies, paraffin-embedded sections of the hippocampus 
of two patients with anti-NMDAR encephalitis and the hippocampus of three age-
matched, anti-NR1 negative, neurologically normal individuals were immunostained with 
commercial anti-NR1 antibodies.  The intensity of NMDAR immunostaining was 
significantly decreased in patients’ hippocampus compared to controls (Fig. 7f-h). 
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Moreover, deposits of human IgG, but not complement, were identified in some of the 
regions with reduced NMDAR clusters (data not shown). These data show that patient 
anti-NMDAR antibodies reduce NMDAR clusters in rodent neurons in vitro and in vivo 
as well as in the brain of patients with the disorder. 
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Discussion 
 Anti-NMDAR encephalitis is a recently described disorder that is 
associated with antibodies against the NR1 subunit of the NMDAR and results in a well 
defined set of symptoms. Our previous studies noted that the resulting syndrome 
resembled the phenotype of animals in which the NMDAR function had been attenuated 
pharmacologically or genetically, suggesting that patients’ antibodies decreased NMDAR 
levels(Dalmau et al., 2008). We now demonstrate using in vitro and in vivo studies that 
patients’ antibodies decrease the surface density and synaptic localization of NMDAR 
clusters via antibody mediated capping and internalization, independent of the presence 
of complement, and without affecting other synaptic proteins, AMPA receptors or 
synapse density. The magnitude of these changes depends on antibody titer, and the 
effects are reversible when the antibody titer is reduced.  Moreover, patients’ NR1 
antibodies decrease NMDAR, but not AMPA receptor mediated synaptic currents.  Thus 
the selective loss of surface clusters abolishes NMDAR mediated synaptic currents.  
These findings indicate that NR1 antibodies from patients with anti-NMDAR encephalitis 
decrease glutamatergic synaptic function without a substantial loss of synapses. 
This reversible loss of NMDARs, and the resulting synaptic dysfunction, may 
underlie the deficits of memory, behavior and cognition that are hallmarks of anti-
NMDAR encephalitis(Sansing et al., 2007; Dalmau et al., 2008; Iizuka et al., 2008). 
Indeed, a remarkable feature of this disorder is the frequent reversibility of symptoms, 
even when these are severe and protracted (Iizuka et al., 2008; Ishiura et al., 2008). 
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Previous studies with 100 patients showed a correlation between clinical outcome and 
antibody titers, which are often higher in CSF than serum due to intrathecal antibody 
synthesis(Dalmau et al., 2008; Seki et al., 2008). The work we present here demonstrates 
that the effect of patients’ CSF on surface NMDARs correlates with the antibody titers 
and is coupled to changes in antibody titers and symptom severity during the course of 
the disease.  Analysis of the hippocampus of two patients who died of this disorder 
showed a substantial decrease of NMDAR levels compared with the hippocampus of 
three age-matched, neurologically normal individuals. This decrease of NMDARs was 
comparable to that observed in rats infused with patients’ antibodies. Moreover, we 
previously reported that patients’ hippocampus showed deposits of IgG and absence of 
complement(Dalmau et al., 2007), consistent with the complement-independent antibody 
effects demonstrated in in vitro studies.  
In the peripheral nervous system, immune-mediated disruption of synaptic 
structure and function results in well known disorders of neuromuscular transmission 
such as myasthenia gravis and the Lambert-Eaton syndrome(Sanders, 2002; Conti-Fine et 
al., 2006).  Anti-NMDAR encephalitis provides a new model of central nervous system 
synaptic autoimmunity, antigenically different but mechanistically similar to the 
Lambert-Eaton syndrome in which autoantibodies, but not monovalent Fab fragments, 
crosslink and internalize voltage-gated calcium channels, without complement 
activation(Nagel et al., 1988a). Both disorders may occur as paraneoplastic manifestation 
of a tumor that expresses neuronal proteins (e.g., small-cell lung cancer in Lambert-Eaton 
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syndrome)(Titulaer et al., 2008) or contains ectopic nervous tissue (e.g., teratoma in anti-
NMDAR encephalitis)(Dalmau et al., 2007). Moreover, in both disorders the 
immunological trigger of cases without tumor association is unknown, although a genetic 
predisposition to autoimmunity has been demonstrated or suggested(Wirtz et al., 2004; 
Wirtz et al., 2005; Florance, 2009). Although both disorders respond to immunotherapy 
and when appropriate tumor removal, the response of anti-NMDAR encephalitis is 
slower and less predictable, particularly in cases with delayed diagnosis or without a 
detectable tumor(Dalmau et al., 2008; Florance, 2009). These patients usually have 
persistently high CSF antibody titers, despite the effectiveness of plasma exchange or 
IVIg in reducing serum antibody titers. In these cases, symptoms frequently respond to 
cyclophosphamide, which crosses the blood-brain barrier, or rituximab, which depletes 
memory B-cells(Sansing et al., 2007; Dalmau et al., 2008; Ishiura et al., 2008; Florance, 
2009).  As postulated in other disorders, these cells are able to cross the blood-brain-
barrier, and are believed to undergo re-stimulation, antigen-driven affinity maturation, 
clonal expansion, and differentiation into antibody-secreting plasma cells(Hauser et al., 
2008).  
NMDAR dysfunction has been implicated in several other cognitive disorders, 
including schizophrenia (Olney and Farber, 1995; Gunduz-Bruce, 2009).  Studies 
investigating the effects of phencyclidine and ketamine (noncompetitive antagonists of 
NMDARs) in human subjects show these drugs induce behaviors similar to the positive 
and negative symptoms of schizophrenia, along with repetitive orofacial and limb 
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movements, autonomic instability, and seizures (Luby et al., 1959; Bailey, 1978; 
Castellani et al., 1982; Krystal et al., 1994b; Weiner et al., 2000).  In rodents, drugs that 
antagonize NMDAR function induce cataleptic freeze, and locomotor and stereotype 
behaviors, consistent with schizophrenia-like manifestations (Haggerty et al., 1984; 
Jentsch and Roth, 1999; Chartoff et al., 2005; Mouri et al., 2007).  Furthermore, mice 
with decreased expression of NR1 have similar behavioral deficits, while mice lacking 
NR1 develop breathing problems and die in the perinatal period (Mohn et al., 1999b).  
Interestingly, most patients with anti-NMDAR encephalitis present with acute 
schizophrenia-like symptoms and are admitted to psychiatric institutions before they 
develop catatonia, catalepsy, stereotyped movement disorders, and frequent autonomic 
instability and hypoventilation. The striking similarity between these phenotypes, the 
effect of patients’ antibodies resulting in a dramatic decrease of surface NMDAR clusters 
and function, and the reduced levels of NMDARs in autopsied patients, support an 
antibody-mediated pathogenesis of anti-NMDAR encephalitis.  The psychosis and 
cognitive and behavioral deficits in patients with anti-NMDAR encephalitis most likely 
result from NMDAR hypofunction, directly and indirectly affecting synapse and circuit 
structure and function in regions that bind NR1 autoantibodies.  Thus the findings we 
report here also support the hypothesis that NMDAR hypofunction underlies many 
manifestations of schizophrenia. Future studies will focus on the circuit-level dysfunction 
caused by patients’ antibodies in hippocampus and other brain regions in order to begin 
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to connect synaptic and circuit dysfunction with the behavioral abnormalities that are 
hallmarks of this disorder.   
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Materials and Methods 
Patients, NR1 antibodies, titers, and controls 
 Cerebrospinal fluid and serum were obtained from randomly selected patients 
with anti-NMDAR encephalitis (Supplemental Table 1) among a series of 320 cases. All 
patients had well characterized clinical manifestations of anti-NMDAR encephalitis, 
including at least 4 of the following features: prominent psychiatric symptoms, decreased 
level of consciousness, seizures, dyskinesias, autonomic instability, or hypoventilation. 
Antibodies to extracellular epitopes of the NR1 subunit of the NMDAR were 
demonstrated using three different assays, as reported(Dalmau et al., 2008): 
immunohistochemistry with rat and human brain, immunostaining of live, non-
permeabilized cultures of rat hippocampal neurons, and immunolabeling of HEK293 
cells transfected with NR1 or NR1 and NR2 (forming NR1/2 heteromers). We previously 
reported that patients’ NMDA receptor antibodies are IgG1 and IgG3, but not IgM(Tuzun 
et al., 2009); therefore we will refer to purified antibodies from patients’ serum as 
purified IgG.   CSF from patients with high antibody titer were diluted so that the final 
titer used in experiments was within the range of undiluted CSF of many patients with 
this disorder(Dalmau et al., 2008).   
 Control serum or CSF samples were obtained from normal individuals and 
patients undergoing CSF analysis for a variety of disorders not associated with antibodies 
to the NMDAR; samples were randomly selected from 1,500 cases negative for NR1 
antibodies applying similar test and criteria as above.     
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 Antibody titers from patients and controls were determined by ELISA(Dalmau et 
al., 2008). 
 
Preparation of patient and control CSF and IgG  
 Patient or control cerebrospinal fluid (CSF) and serum were collected, filtered, 
and kept frozen until use. CSF from individual patients with high NMDAR antibody titer 
was diluted 1:15-60 to treat neurons in vitro, and used undiluted for in vivo experiments. 
In some experiments, patient IgG antibodies were purified from serum with protein A/G 
sepharose columns and used to treat neurons.  To prepare patient and control IgG, 2 ml of 
serum were incubated with a 1 ml bio-spin chromatography column (Bio-Rad) of protein 
A/G sepharose beads (50:50) for 30 min. on an orbital shaker at 4 °C.  After 3 washes 
with phosphate buffered saline (PBS), eluted with 100 mM glycine, pH = 2.5 and 
neutralized with Tris-HCl, pH = 8.0,  dialyzed against PBS, concentrated in stock 
solutions of 20 mg/ml, and stored at -80 °C.  IgG concentration (~1mg / ml) and pH (7.4) 
was adjusted prior to use.  Each IgG preparation was tested for antibody reactivity by 
staining human or rat brain sections or HEK cells expressing NR1/NR2 heteromers of the 
NMDAR as previously described(Dalmau et al., 2007; Dalmau et al., 2008).  Both 
patients’ CSF and IgG decreased surface and total NMDARs to the same extent 
(Supplemental Fig. 1).   
 
Cell culture and patient antibody treatment  
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 Briefly, isolated rat hippocampi were placed in Ca2+ free HBSS (Hanks balanced 
salt solution, Life Technology) containing 1% papain for 20 min., triturated in Basal 
Media Eagle (BME; Invitrogen) supplemented with B-27 (Life Technology) and plated at 
100,000 or 400,000 (for biotinylation) cells per ml in Neural Basal (NB; Life 
Technologies) supplemented with 10% FBS (Hyclone), B-27, 1% Penicillin and 
Streptomycin (Life Technologies), and 1% L-Glutamine (Life Technologies) on poly-L-
lysine coated (Sigma) coverslips in 24-well plates.  Culture media was changed to NB 
supplemented with B27 at 4 div.  Cells were maintained at 37 °C, 5% CO2, 95% 
humidity; medium was changed weekly.  Neurons were treated with CSF or IgG from 
individual patients or controls for 1 day beginning at 14 days in vitro; in some 
experiments, neurons were treated for 3 or 7 days beginning at 14 days in vitro.  
  
Immunostaining for pre- and postsynaptic components, confocal imaging, and image 
analysis  
To stain surface NMDAR clusters, control or treated neurons were washed in 
Neurobasal plus B27 and incubated with patient CSF containing anti-NR1 antibodies for 
30 min., washed and incubated with fluorescently conjugated anti-human secondary 
antibodies for 30 min., and washed in PBS.  Neurons were then fixed in 4% 
paraformaldehyde, 4% sucrose in PBS, pH = 7.4 for 15 min., permeabilized with cold 
0.25% Triton X-100 for 5 min., and blocked in 5% normal goat serum (Invitrogen) for 1 
hour at RT.  Additional immunostaining was performed with various combinations of 
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primary antibodies:  to label glutamate receptors, anti-NR1 against the intracellular C-
terminus (1:1000; Chemicon), anti-GluR1 (1:10; CalBioChem) or anti-GluR2 (1:100; 
Chemicon); to label postsynaptic densities, PSD-95 (1:500; Bioaffinity Reagents); to 
label dendrites, mouse anti-MAP2 (1:1000; gift from Dr. V. Lee); to label presynaptic 
terminals, mouse anti-SV2 (1:200; DHSB), guinea pig anti-VGLUT 1 (1:1000; 
Chemicon), or mouse anti-Bassoon (1:400; Stressgen Bioreagents).  Antibodies were 
visualized after staining with the appropriate fluorescently conjugated secondary 
antibodies (1:200; Jackson ImmunoResearch). 
Images were obtained using a confocal microscope (Leica TCS SP2).  Images 
were thresholded automatically using iterative segmentation(Bergsman et al., 2006), and 
the number and area of individual immunostained pre- or postsynaptic clusters were 
determined using interactive software (custom-written ImageJ macros).  Clusters with 
pixel overlap of pre- and postsynaptic markers were considered colocalized and thus 
synaptic(Krivosheya et al., 2008).   
 
Biotinylation of surface proteins and analysis by Western blot   
Neurons were treated with 1 µg – 1 mg/ml IgG for 1 day, washed with PBS 
supplemented with 0.1 mM CaCl2 and 1 mM MgCl2 (rinsing buffer) and incubated for 30 
min. at 4 °C with 1 mg/ml Sulfo-NHS-Biotin (Thermo Scientific) in rinsing buffer.  
Neurons were then washed with rinsing buffer + 100 mM glycine (quenching buffer), 
incubated in quenching buffer for 30 minutes at 4°C to quench excess biotin, then lysed 
  
105 
in RIPA buffer (150 mM NaCl, 1 mM EDTA, 100 mM Tris HCl, 1% Triton X-100, 1% 
sodium deoxycholate, 0.1% SDS, pH 7.4, supplemented with 1:500 protease inhibitor 
cocktail III, Calbiochem) at 4 °C for 1 hour.  Lysates were cleared of debris by 
centrifugation at 12,400 x g for 20 min. An aliquot of the remaining supernatant was 
taken for the lysate fraction, and a second aliquot was incubated with avidin-linked 
agarose beads (Immobilized Monomeric Avidin, Thermo Scientific) overnight at 4 °C.  
After centrifugation, the supernatant was removed and the beads (surface fraction) were 
washed 1X RIPA buffer, 2X high-salt wash buffer (500 mM NaCl, 5 mM EDTA, 50 mM 
Tris, 0.1% Triton X-100, pH 7.5), and 1X no-salt wash buffer (50 mM Tris, pH 7.5). The 
surface fraction was eluted from the beads with 2X sample buffer and proteins separated 
on an 8% gel using SDS-PAGE.  Samples were transferred to nitrocellulose membranes 
and probed for antibodies against NR1 (1:1000, 556308, BD Pharmingen), NR2A 
(1:1000, AB1555, Millipore; 1:500, MAB5216, Millipore; 1:500, A6473, Invitrogen), 
NR2B (1:1000, AGC-003, Alomone; 1:500, 06-600, Upstate), GABAARα1 (1:1000, 06-
868, Upstate), GABAARα2 (1:500, AB5984, Chemicon), GluR 2/3 (1:1000, 07-598, 
Upstate), PSD-95 (1:1000, 610496, BD Pharmingen), and actin (1:2000, A2066, Sigma). 
Actin and GABAARs were used as loading controls for total and surface fractions, 
respectively. Blots were incubated with HRP-conjugated goat anti-mouse or goat anti-
rabbit secondary antibodies (1:3000, Cell Signaling), and signals were visualized using 
chemiluminescence (SuperSignal Chemiluminescent Substrate, Thermo Scientific).  All 
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quantified films were in the linear range of exposure, were digitally scanned and signals 
quantified using NIH ImageJ. 
 
Whole cell electrophysiological recordings of synaptic NMDA and AMPA receptor 
mediated currents 
Whole cell voltage clamp recordings were performed as previously 
described(Elmariah et al., 2004; Elmariah et al., 2005) from 14 – 21 div pyramidal 
neurons treated for 24 hours with patient CSF containing anti-NR1 antibodies, control 
CSF or left untreated.  Briefly, neurons were incubated in an extracellular physiological 
solution without Mg2+ (in mM:  119 NaCl, 5 KCl, 2 CaCl2, 30 Glucose, 10 HEPES, pH = 
7.4).  Voltage-clamp recordings were made at RT (22-25 °C) using glass microelectrodes 
(resistance 4-6 MΩ) filled with a Cesium substituted intracellular solution (in mM:  100 
Cesium gluconate, 0.2 EGTA, 5 MgCl2, 2 ATP, 0.3 GTP, 40 HEPES, pH = 7.2).  Pipette 
voltage offset was neutralized before the formation of a gigaohm seal. Membrane 
resistance, series resistance, and membrane capacitance were determined from current 
transients elicited by a 5 mV depolarizing step from a holding potential of -80 mV, using 
the whole cell application of PatchMaster software (HEKA Elektronik).  Criteria for cell 
inclusion in the data set included a series resistance ≤ 30 MΩ and stability throughout the 
recording period.  Currents were amplified, low-pass filtered at 2.5 kHz, and sampled at 5 
Hz using PatchMaster software.  Spontaneous miniature excitatory postsynaptic currents 
(mEPSCs) were recorded at -70mV in the presence of TTX (1 µM) and picrotoxin (10 
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µM).  APV (50 µM) and CNQX (10 µM) were bath applied to block NMDAR and 
AMPAR mediated currents respectively.   mEPSC events were detected and analyzed 
using MiniAnalysis (Synaptosoft, Leonia, NY), which employs a threshold-based event-
detection algorithm.  NMDAR and AMPAR components of mEPSCs were separated 
temporally by their distinct kinetics(Hestrin et al., 1990; Watt et al., 2000; Yang et al., 
2003). The amplitude of the NMDAR mediated current was determined in a window 
between 15 and 25 ms after the peak of the AMPAR mediated component, which has a 
fast, < 1 ms rise time.  All values are presented as mean ± s.e.m. 
 
Fab fragment preparation and treatment 
Fab fragments were prepared from serum IgG using a kit according to the 
manufacturer’s directions (Fab preparation kit, Pierce Protein Research Products, Thermo 
Scientific).  Briefly, serum IgG was digested for 2-4 hours at 37 °C with 1% (w/w) 
papain pH= 7.0 with 0.01 M cysteine, resulting in cleavage into Fab and Fc fragments.  
Fab fragments were isolated by chromatography and concentration determined by 
absorption at 280 nm, and then used to treat neurons at a concentration of 4 µg/ml.  
Control experiments showed that incubating neurons with patient Fab fragments for 30 
min. resulted in surface staining of NR1 clusters (Supplemental Fig. 2).  
 
Alzet mini-pump placement, IgG infusion, and analysis of effects on NMDA receptors 
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7-8 week old female Lewis rats were anesthetized and a cannula was placed into 
the left hippocampus using predetermined coordinates (-3.2 mm posterior to bregma, 2 
mm lateral, and 3 mm deep to the dura mater).  The cannula was secured to a head probe 
mounted to the skull, and attached with sterile tubing to an Alzet minipump (Alzet brain 
infusion kit #3, pump model 2002) implanted subcutaneously on the back. Patient or 
control CSF was then delivered at a rate of 0.5 µl / hr for 2 weeks. Rats were then 
euthanized, brain tissue harvested, immersion fixed in 4% paraformaldehyde in PBS, pH 
= 7.4 for 15 min., cryoprotected in 30% sucrose in PBS, pH = 7.4 overnight at 4 °C, and 
snap frozen in isopentane cooled in dry ice. Frozen 10 µm sections from infused 
hippocampus (where the track of the cannula was visible) and contralateral matched area 
of the non-infused hippocampus were immunostained in parallel to determine the 
presence of human IgG and the levels of NR1 using the primary and secondary antibodies 
described above.  The degree of cell death was assayed with TUNEL.  Sections were 
imaged and thresholded with the same parameters, and confocally imaged and analyzed 
as described above. 
Additionally, protein extracts from 20 µm sections of the infused and contralateral 
hippocampus were separated electrophoretically, transferred to nitrocellulose, incubated 
with anti-NR1 antibody (Chemicon), and the amount of NR1 protein quantified as 
described above, using Tubulin as a loading control. 
 
Immunostaining, imaging, and image analysis of human tissue 
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 Hippocampal sections of human tissue were immunostained in parallel as 
described above. Control and patients’ tissue sections were imaged with a Zeiss 
Axioskop 2 plus (software AxioVision 4.5) with identical optical settings and exposure 
times. For analysis of high magnification regions 7-10 images were collected from the 
CA1 region of the hippocampus. These images were inverted and a cumulative histogram 
of pixel intensity was calculated for each image. The average cumulative histogram of 
pixel intensity was generated for each sample and the cumulative probability of pixel 
intensity for each sample was determined, plotted and compared using a paired 
Komolgorov-Smirnov test (see below). 
 
Statistical analysis 
 Titer dependence was assessed with a linear regression analysis.  In experiments 
involving two conditions, the data was analyzed with a two-tailed unpaired Student’s t 
test.  In experiments involving three or more conditions, the normality of the data was 
analyzed with the D’Agostino and Pearson omnibus normality test, before using a one-
way ANOVA test followed by Bonferroni’s multiple comparison test.  Differences in 
distributions of NR1 intensity were assessed with a paired Komolgorov-Smirnov test.  
All values are presented as mean ± s.e.m. 
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Figures and Legends  
 
Figure 1:  Patients’ antibodies reduce surface NMDA receptor clusters and protein 
in a titer dependent fashion 
 (a) Hippocampal neurons immunostained for surface and total NMDAR clusters 
and presynaptic Bassoon. Surface NMDARs are defined as the colocalization between 
non-permeabilized patient CSF staining (extracellular NR1 epitope) and commercial 
NMDAR staining (intracellular epitope; left).  Patient CSF treatment for 1 day reduces 
surface and total NMDAR cluster density without affecting Bassoon cluster density.  
Scale bar = 10 µm. (b) Western blot analyses of surface biotinylated and total lysate 
NMDAR protein. Patient IgG treatment for 1 day reduces surface as well as total 
NMDAR protein; GABAAα1, actin are loading controls. Control NR1 levels have been 
overexposed in this image to visualize patient treated NR1 bands. (c) Surface (left) and 
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total (right) NMDAR cluster density after treatment with CSF from several patients with 
different antibody titer, showing a titer-dependent decrease in NMDA cluster density 
(linear regression analysis; surface R2 = 0.59, p < 0.001; total R2 = 0.44, p < 0.008).  All 
values are mean ± s.e.m. (n = 18 cells, 3 independent expts.; 12 patient, 2 control 
samples; see Supplemental Table 1). (d) Surface (left) and total (right) NMDAR protein 
after treatment with IgG from several patients with different antibody titer (n = 3-5 
Western blots; 10 patient, 2 control samples), showing a titer-dependent decrease in 
NMDA protein (linear regression analysis; surface R2 = 0.53, p < 0.0001; lysate R2 = 
0.30, p < 0.002).  (e) Surface (left) and total (right) NMDAR cluster density after 
treatment with CSF from the same patient at two timepoints with different antibody titer; 
a higher antibody titer decreases surface and total NMDAR clusters to a greater extent.  
(f) Surface (left) and total (right) NMDAR protein after treatment with IgG from two 
patients at two time points with different antibody titer; a higher antibody titer decreased 
surface and total NMDAR protein to a greater extent than IgG isolated from the same 
patient when a lower antibody titer was present. 
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Figure 2:  Patients’ antibodies reversibly reduce synaptic NMDA receptor clusters 
without affecting the number of synapses 
 (a) Hippocampal neurons immunostained for total NMDAR clusters, a 
presynaptic glutamatergic terminal protein, VGlut, and a postsynaptic protein localized to 
glutamatergic synapses, PSD-95.  Treatment with patient CSF for 3 days reduces the 
density of synaptic NMDAR clusters without affecting the number of excitatory 
synapses. After removal of patient CSF, the proportion of NMDAR clusters localized to 
synapses returns to baseline. Scale bar = 10 µm. (b) Colocalization of pre- and 
postsynaptic proteins at excitatory synapses (n = 36 cells, 3 independent experiments; 2 
patient, 1 control samples). (c) NMDAR cluster density at excitatory synapses (synaptic 
NR1).  Asterisk indicates significant difference (One-way ANOVA test followed by 
Bonferroni’s multiple comparison test, p < 0.001).   
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Figure 3: Patients’ CSF and IgG treatment does not affect other synaptic 
components 
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 (a) Hippocampal neurons immunostained for an excitatory postsynaptic protein, 
PSD-95, excitatory presynaptic protein, VGlut, and surface clusters of AMPA receptor 
subunits GluR1 or GluR2. Scale bar = 5 µm. (b) Quantification of excitatory synaptic 
protein density.  Treatment with patient CSF did not affect the density of these excitatory 
synaptic proteins.  All values are shown as mean ± s.e.m. (n = 18 cells, 3 independent 
expts.; 1 patient, 1 control sample; Student’s t test, p > 0.09).  (c) Western blots of 
excitatory postsynaptic proteins, AMPA receptor subunits GluR2/3, excitatory 
postsynaptic protein PSD-95 and GABAA receptors. Treatment with patient IgG did not 
affect surface or total neurotransmitter receptor or excitatory synapse protein levels.  
(d) Quantification of surface (left) and total (right) protein after treatment with IgG from 
several patients with different antibody titer.  Patient IgG resulted in a decrease in surface 
and total NMDAR NR1 protein but did not affect the levels of other synaptic proteins.  
All values are shown as mean ± s.e.m. (n = 3-5 Western blots; 10 patient, 2 control 
samples, One-way ANOVA test followed by Bonferroni’s multiple comparison test, p < 
0.001). 
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Figure 4: Patient CSF treatment does not affect dendritic branching, spines, 
Bassoon cluster density or cell survival 
 (a) Hippocampal neurons transfected with the fluorescent protein, Tomato-td, 
imaged before and after one day of treatment with control or patient CSF, and traced with 
NeuronJ. Control (top) or patient (bottom) CSF treatment did not affect dendritic 
  
116 
branching or complexity. Scale bar = 100 µm. (b) Quantification of primary dendrite 
number. (c) Quantification of primary dendrite length.  All values are shown as mean ± 
s.e.m. (n = 9 cells, 3 independent expts.; 1 patient, 1 control sample; Student’s t test, p > 
0.6). (d) Sholl analysis of dendrite complexity before (white) and after (black) one day of 
control (left) or patient CSF (middle) treatment. Comparison of the difference before and 
after control and patient CSF treatment (right).  (e) Hippocampal neurons transfected 
with fluorescent protein, Tomato-td, and treated for one day with control or patient CSF.  
Control (top) or patient (bottom) CSF treatment did not affect dendritic protrusion 
density. Scale bar = 5 µm. (f) Quantification of the density of dendritic protrusions 
(Student’s t test, p > 0.3).(g) Patient CSF treatment for 1 day does not affect Bassoon 
cluster density (linear regression analysis; R2 = 0.005, p = 0.79).  All values are mean ± 
s.e.m. (n = 18 cells, 3 independent expts.; 12 patient, 2 control samples; see Supplemental 
Table 1). (h) Quantification of the density of dissociated hippocampal cells in vitro after 
1 day treatment of control or patient CSF. (i) Quantification of the percent of TUNEL 
positive neurons in vitro (apoptotic cells).  These measures were not significantly 
different between control or patient CSF treatment (n = 30 fields (750 µm2), 4 
independent expts.; 1 patient, 1 control sample; Student’s t test, p > 0.6). 
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Figure 5:  Patients’ antibodies selectively decrease synaptic NMDA currents. 
 (a)  mEPSCs recorded in physiological saline with TTX, picrotoxin, and 0 Mg2+ 
to isolate synaptic NMDAR mediated currents (left upper trace). APV, an NMDAR 
antagonist, blocks the slow decay of mEPSCs leaving only AMPA receptor mediated 
currents which account for the fast rise of mEPSCs (left upper middle trace). CNQX, an 
AMPA receptor antagonist, blocks the fast rise of mEPSCs, allowing NMDAR mediated 
currents to be isolated (left lower middle trace). Both AMPA and NMDAR mediated 
synaptic currents are blocked by CNQX plus APV (left bottom trace). Note that, under 
the same recording conditions, treatment of hippocampal neurons with patient CSF for 1 
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day dramatically reduces synaptic NMDAR mediated currents (right traces).  (b) 
Representative average mEPSCs from neurons treated for 1 day with control CSF (left) 
or patient CSF (middle).  The difference between the 0 Mg 2+ and the 0 Mg 2+ + APV 
traces, plotted at right, shows the NMDAR current.  Neurons treated for 1 day with 
patient CSF have less NMDAR-mediated synaptic current than neurons treated with 
control CSF. (c) Effect of patient antibodies on NMDA (left) and AMPA (right) receptor 
mediated synaptic currents (n = 13 cells, 7 control CSF, 6 patient CSF, 4 independent 
expts.; 2 patient, 2 control samples).  Asterisk indicates significant difference (Student’s t 
test, p < 0.001).   
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Figure 6: Patients’ antibodies bind, crosslink and internalize NMDA receptors 
 (a) Hippocampal neurons immunostained for surface and total NMDAR clusters. 
Treatment with patient IgG decreases surface and total NMDAR cluster density (middle 
left).  Treatment with patient Fab fragments does not affect surface or total NMDAR 
cluster density (middle right), while treatment with divalent patient Fab fragments (Fab 
fragments + anti-Fab secondary antibodies) decreases surface and total NMDAR cluster 
density (right).  Scale bar = 10 µm. (b)  Effects of patient IgG, Fab fragments, and 
divalent Fab fragments on surface and total NMDAR cluster density. (n=30 cells, 4 
independent expts.; 2 patient, 2 control samples).  Asterisk indicates significant 
difference (One-way ANOVA test followed by Bonferroni’s multiple comparison test, p 
< 0.001).  (c)  Cartoon that outlines the effect of each treatment on surface receptor 
clusters. 
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Figure 7:  Patients’ antibodies decrease NMDA receptor cluster density and protein 
in rodent and human hippocampus in vivo  
  (a) Brain sections from rats infused with control CSF (top left) contain many 
NMDAR clusters in CA1, while brain sections from rats infused with patient CSF (top 
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right) contain significantly reduced NMDAR clusters.  Presynaptic synapsin 
immunostaining is similar between groups (bottom left, right).  Scale bar = 2 µm. (b) 
Effect of infusion of patient CSF with varying antibody titer on NMDAR cluster density 
in CA1.  Each point represents the mean NMDAR cluster density from 3-5 images from 
an infused rat.  Patient CSF with higher antibody titers reduce NMDAR cluster density to 
a greater extent than low titer samples. Infusion with patients’ CSF for 2 weeks results in 
a titer-dependent decrease in NMDA cluster density (linear regression analysis; R2 = 
0.32, p < 0.03).  All values are mean ± s.e.m. (n = 9 animals sacrificed after 14 days of 
infusion; 5 patient, 4 control samples).  (c) Western blot analyses of NR1 protein in 
patients’ CSF infused rat hippocampus (top); ipsilateral (I) and contralateral (C) to 
infusion; Tubulin protein is a loading control (below).  NR1 protein is reduced in 
ipsilateral patient CSF infused hippocampus compared to the contralateral, uninfused 
hippocampus.  F indicates NR1 protein in the frontal cortex ipsilateral to the 
hippocampus infused with patients’ CSF.  (d) Synapsin cluster density (Student’s t test, p 
> 0.6). (e) Excitatory synapse density (colocalization between synapsin and AMPAR 
clusters; Student’s t test, p > 0.5). (f) Hippocampal section from a control patient (left) 
and from a patient with anti-NMDAR encephalitis (right) immunostained with a 
commercial anti-NR1 antibody.  (g) Boxed areas in f shown at higher magnification. 
Scale bars = 1 mm (top); 25 µm (bottom).  (h)  Intensity of NR1 immunostaining is 
dramatically reduced in the hippocampi of anti-NMDAR encephalitis patients (n = 2) 
compared to hippocampi of control patients (n = 3).  The distribution of both patient 
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values for NR1 intensity is significantly different from the distribution of control values 
(paired Komolgorov-Smirnov test, p < 0.05).  
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Supplemental Table 1:  Summary of patients whose CSF or IgG were used in all 
studies 
 
Gender, 
age Tumor
a CSFb Brain MRI 
CSF NR1 
antibody 
titer (rfu)c 
Treatment Outcomed 
F, 35 Ovarian teratoma (M) 67 WBC Normal 3411488 
Tumor removal; 
C, IVIg 
Partial 
improvement 
F, 28 
Bilateral 
ovarian 
teratoma (M) 
60 WBC Normal 2963488 Tumor removal; RTX, CTX Full recovery 
F, 13 
Ovarian 
teratoma 
(Im) 
46 WBC Normal 1257440 Tumor removal; PLEX, IVIg Full recovery 
F, 22 Ovarian teratoma (M) 
20 WBC, 
OB Normal 532239 
Tumor removal; 
C, IVIg, PLEX 
Partial 
improvement 
F, 35 
Ovarian 
teratoma (M) 
(autopsy) 
189 WBC 
Increased FLAIR 
signal in medial 
temporal lobes 
376408 C, IVIg, PLEX, CTX Died
e 
F, 18 
Ovarian 
teratoma 
(Im) 
88 WBC, 
OB 
Mild transient 
leptomeningeal 
enhancement 
335792 Tumor removal;  PLEX, C Full recovery 
F, 24 No tumor 49 WBC, OB Normal 326550 IVIg 
Partial 
improvement 
F, 17 Ovarian teratoma (M) 480 WBC 
Increased FLAIR 
signal in medial 
temporal lobes 
285936 Tumor removal; C, IVIg, RTX 
Partial 
improvement 
F, 12 No tumor Normal Normal 103336 C, IVIg Partial improvement 
F, 25 
Ovarian 
teratoma 
(Im) 
14 WBC Normal 95207 Tumor removal; C, IVIg, PLEX Full recovery 
F, 38 Ovarian teratoma (M) Normal Normal 61744 
Tumor removal; 
PLEX Full recovery 
F, 18 
Bilateral 
ovarian 
teratoma (M) 
57 WBC Normal 26088 Tumor removal; C, PLEX Full recovery 
F, 24 
Ovarian 
teratoma (M) 
(autopsy) 
219, OB 
Increased FLAIR 
signal in parietal 
cortex; mild 
leptomeningeal 
enhancement 
1843616 Supportive care Diedf 
 
(a) All tumors contained nervous tissue; 5/5 tumors examined had expression of NMDARs 
(Dalmau et al., 2007). 
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(b) Normal: < 4/ microliter. 
(c) rfu: reference fluorescence units. Values in 100 randomly selected negative control CSF: 
<5000 rfu.  
(d) Full recovery: able to return to all activities; Partial recovery: patient living at home, 
independent for most daily activities, but unable to return to work at the time of this report. 
(e) Hippocampal sections from this patient were used for anti-NR1 immunostaining; see Fig. 5. 
(f) Hippocampal sections from this patient were used for anti-NRI immunostaining; see Fig. 5; the 
limited amount of CSF and/or IgG from this patient precluded their use in other experiments. 
 
CSF from the first 12 patients was used in the experiments in Fig. 1a, b.  IgG from 10 of these 
patients was used in the experiments in Fig. 1c, d and Supplemental Fig. 2.  Individual patient 
CSF and/or IgG were used for all other experiments. 
 
Abbreviations: M, mature; Im, immature; WBC, white blood cells; OB, oligoclonal bands; n.a., 
not available; C, corticosteroids; RTX, Rituximab; PLEX, plasma exchange; CTX, 
Cyclophosphamide; IVIg, intravenous immunoglobulin; FLAIR: fluid-attenuated inversion 
recovery. 
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Supplemental Figures 
 
Supplemental Figure 1: Patient IgG and CSF treatment have similar effects and 
these effects are not mediated via the complement pathway 
 (a) Quantification of hippocampal neurons immunostained for surface NMDAR 
clusters treated with Control IgG, CSF, patient IgG, CSF, and heat inactivated patient 
CSF. Treatment with patient IgG and CSF for one day decrease surface NMDARs to a 
similar extent. Heat inactivated patient CSF also decrease surface NMDARs to a similar 
extent as patient IgG and CSF, suggesting that these effects are not mediated by 
complement-mediated pathways (n = 18 cells, 3 independent expts.; 1 patient, 1 control 
sample; One-way ANOVA test followed by Bonferroni’s multiple comparison test, p < 
0.001). (b) Quantification of dissociated hippocampal neurons immunostained for total 
NMDARs treated with Control IgG, CSF, patient IgG, CSF, and heat inactivated patient 
CSF. 
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Supplemental Figure 2:  Patient antibody Fab fragments colocalize with NMDA 
receptor clusters 
 Hippocampal neurons immunostained for NMDAR clusters in neurons treated for 
1 day with control IgG (top row), patient IgG (middle top), patient IgG clustered with 
anti-IgG secondary antibodies (middle), patient Fab fragments (middle bottom), patient 
Fab fragments reclustered with anti-Fab secondary antibodies (bottom). Color overlays of 
NR1 (red) and human IgG (green) are shown at right.  While patient IgG and patient IgG 
+ anti-IgG stain neurons more intensely, patient Fab fragments and patient Fab fragments 
+ anti-Fab colocalize with NMDARs to a similar extent (n = 18 cells, 3 independent 
expts.; 1 patient, 1 control sample). Scale bar = 10 µm. Abbreviations:  anti-hIgG 2°, 
anti-human IgG secondary antibody; anti-hFab 2°, anti-human Fab secondary antibody. 
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Supplemental Figure 3: Treatment with Patient CSF for 1, 3, or 7 days decreases 
total NMDAR cluster density. 
 (a) Total NMDAR cluster density after treatment with CSF for 1, 3, or 7 days, 
each of which decreased NMDAR cluster density to a similar extent.  All values are mean 
± s.e.m. (n = 18 cells, 3 independent expts.; 1 patient, 1 control sample, One-way 
ANOVA test followed by Bonferroni’s multiple comparison test, p < 0.05). 
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Supplemental Figure 4: Patient IgG treatment decreases surface and protein of 
NMDA receptor NR2A/B subunits in a titer dependent fashion 
 (a) Western blots of surface and total NMDAR, NR2A and NR2B protein.  
Treatment with patient IgG reduced surface as well as total NMDAR, NR2A and NR2B 
protein. GABAAα1 and actin are loading controls for surface and total protein, 
respectively.  This blot was reprobed with antibodies against NR1 and displayed in Fig 
1b and is representative of the data set.  (b) Quantification of surface (left) and total 
(right) NMDAR NR2A protein after treatment with IgG from several patients with 
different antibody titer.  IgG from patients with higher titer resulted in a greater decrease 
in surface and total NMDAR NR2A protein than patients with a lower titer.  Thus 
treatment with patients’ CSF for 1 day results in a titer-dependent decrease in NR2A 
protein (linear regression analysis; surface R2 = 0.35, p < 0.005; lysate R2 = 0.33, p < 
0.002).  (c) Quantification of surface (left) and total (right) NMDAR NR2B protein after 
treatment with IgG from several patients with different antibody titer.  IgG from patients 
with higher titer resulted in a greater decrease in surface and total NMDAR NR2B 
protein than patients with a lower titer.  Thus treatment with patients’ CSF for 1 day 
results in a titer-dependent decrease in NR2B protein (linear regression analysis; surface 
R2 = 0.23, p < 0.02; lysate R2 = 0.29, p < 0.002).  All values are shown as mean ± s.e.m. 
(n = 3-5 Western blots, 10 patient, 2 control samples, from independent expts. with 
individual patients’ IgG (Supplemental Table 1)).   
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Supplemental Figure 5:  Patient IgG treatment decreases synaptic localization of 
NMDA receptors in a titer dependent fashion 
Synaptic NMDAR cluster density after treatment with CSF from several patients with 
different antibody titer for 1 day, showing a titer-dependent decrease in synaptic 
NMDAR cluster density Synaptic NMDARs are defined as the colocalization between 
commercial NMDAR staining (intracellular NR1 epitope) and presynaptic marker 
Bassoon (linear regression analysis; R2 = 0.43, p < 0.008).  This data was obtained from 
the data set displayed in Fig. 1.  See also Figure 2.  
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Supplemental Figure 6:  Patient CSF treatment does not affect mEPSC frequency or 
amplitude 
 (a) Quantification of mEPSC amplitude in neurons treated with control CSF, 
patient CSF, with and without APV.  The total mEPSC amplitude (which represents the 
amount of functional postsynaptic AMPA receptors) is not significantly different among 
control, patient CSF or APV conditions. All values are shown as mean ± s.e.m. (n = 13 
cells, 7 control CSF, 6 patient CSF, 4 independent expts.; 1 patient, 1 control sample; 
pairwise comparison, Student’s t test, p > 0.4).  (b) Quantification of mEPSC frequency 
in neurons treated with and without control, patient CSF, and APV. The frequency of 
mEPSCs (which represents the number of excitatory synapses) is not significantly 
different between control, patient CSF or APV though the trend of lower frequency of 
patient CSF and APV treated conditions could be the result of blockade of silent synapses 
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which have been shown to contribute to mEPSC frequency(Liao et al., 1995; Liao et al., 
2001).  All values are shown as mean ± s.e.m. (n = 6 cells, 4 independent expts.; 1 
patient, 1 control sample; pairwise comparison, Student’s t test, p > 0.2). 
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Supplemental Figure 7: Patient CSF recognizes NMDA receptor clusters in vivo 
and infusion into rat hippocampus results in deposition of human IgG without 
increasing cell death 
 (a) Rat brain sections immunostained with patient CSF (top left), NMDARs (top 
middle), and a postsynaptic protein, PSD-95 (top right).  Clusters immunostained with 
patient CSF are highly colocalized with NMDARs (yellow puncta, bottom left).  Clusters 
immunostained with patient CSF colocalize with PSD-95 to a similar extent as NMDARs 
(compare bottom middle to bottom right). (n = 9 images, 3 independent expts.; 1 patient, 
1 control sample).(b) Brain sections from rats infused with control (left) or patient CSF 
(right) into one hippocampus, and immunostained with human IgG, NR1, and TO-PRO 
to label nuclei. The deposition of human IgG was seen in the hippocampus of rats infused 
with patient CSF but not control CSF.  Below, higher magnification views of the CA1 
region of the hippocampus show that areas with human IgG deposits have reduced 
NMDAR clusters (see Fig. 5) and decreased overall staining intensity (n=6 animals; 3 
infused with patient CSF, 3 with control samples). (c) Brain sections from rats infused 
with control or patient CSF and immunostained with TO-PRO to label nuclei and 
TUNEL to label apoptotic cells. Infusion with control (left) or patient CSF (middle) did 
not cause significant cell death. While several apoptotic cells were found along the 
cannula tract (right), the total number and distribution did not differ between rats infused 
with control or patient CSF. 
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Abstract 
 Autoimmunity to NMDA receptor subunit 1 (NR1) is the cause of a severe but 
treatment responsive limbic encephalitis in which patients develop psychosis, seizures 
and profound deficits in memory, movement and other behaviors.  Previous studies 
showed that patients’ antibodies decreased the synaptic localization, and currents 
mediated by NMDA receptors, due to antibody mediated receptor cross-linking and 
internalization.  Here we show that patient antibodies rapidly increased the internalization 
rate of NMDA receptor clusters over the time course of a few hours.  The effects of 
patient antibodies are independent of the activity of NMDA receptors themselves.  
Furthermore, this internalization accounts for much if not all of the decrease in NMDA 
receptor mediated currents without an antibody mediated acute receptor blockade.  These 
suggest that patient antibodies decrease synaptic and circuit function due to the rapid, 
activity independent loss of NMDA receptors from the cell surface. 
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Introduction 
 The proper localization and trafficking of synaptic proteins is critical for 
neurological functions such as memory, learning and cognition.  There are several 
recently identified antoimmune disorders in which patients develop autoantibodies 
against cell surface and synaptic proteins, including NMDA receptors (Dalmau et al., 
2007; Dalmau et al., 2008) and AMPA receptors (Lai et al., 2009), among others 
(Moscato et al., 2010).  Patients with anti-NMDA receptor encephalitis develop 
prominent psychiatric and behavioral symptoms, including psychosis, short term memory 
loss, seizures and abnormal movements (dyskinesias), that if untreated can progress to 
catatonia, hypoventilation, and autonomic instability (Dalmau et al., 2007; Dalmau et al., 
2008).  However, patients can recover if antibody titer is reduced (Dalmau et al., 2007; 
Dalmau et al., 2008).  Using in vitro studies, we previously showed that patients’ 
antibodies selectively and reversibly cause a decrease in the surface density and synaptic 
localization of NMDA receptor clusters via antibody mediated capping and 
internalization (Dalmau et al., 2008; Hughes et al., 2010).  Moreover, patient antibodies 
decrease NMDA, but not AMPA, receptor mediated synaptic currents, consistent with a 
selective loss of surface NMDA receptor clusters (Hughes et al., 2010).  Using in vivo 
studies, we have also demonstrated that NMDA receptor cluster density is dramatically 
reduced in the hippocampus of rats infused with patients’ antibodies, as well as in the 
brain of autopsied patients with this disorder (Hughes et al., 2010). These studies 
established some of the cellular mechanisms by which patient anti-NMDA receptor 
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antibodies alter NMDA receptor density, localization and function, underlying the 
spectrum of neuropsychiatric and neurological dysfunction.  The onset of this disease is 
very rapid: there are only a few days to a couple of weeks from prodromal symptoms to 
prominent dysfunction requiring hospital admission and intensive care (Dalmau et al., 
2007; Dalmau and Rosenfeld, 2008).  Thus, it was of interest to investigate whether 
patient antibodies also have acute effects on NMDA receptors, including whether 
antibodies block NMDA receptor mediated currents prior to internalization.   When we 
examined the effects of patients’ antibodies on hippocampal neurons in vitro on a time 
scale of hours, we found that rapid, activity independent NMDA receptor internalization 
accounts for loss of receptor function.   
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Results  
Patients’ antibodies rapidly internalize surface NMDA receptors 
 Previous studies in rodent hippocampal neurons in vitro suggested that antibodies 
from patients with anti-NMDA receptor encephalitis decreased the density of surface and 
synaptic NMDA receptor clusters and decreased NMDA receptor mediated currents. We 
asked how rapid these effects were, and whether the loss of receptor mediated currents 
was due to internalization or acute receptor blockade, or both. 
 Neurons at 14 div were treated with either Fab fragments or whole IgG prepared 
from patient serum for 1 to 24 hours.  Since Fab fragments bind with NMDA receptors 
without leading to cross-linking and internalization (Hughes et al., 2010), Fab fragments 
serve as a control for steady state turnover of NMDA receptors.  After treatment, surface 
Fab or IgG bound NMDA receptors were labeled with FITC conjugated secondary 
antibodies in live, unpermeabilized neurons (Fig. 1A, B).  After fixation and 
permeabilization, internalized Fab or IgG bound NMDA receptor clusters, as well as 
remaining surface NMDA receptor clusters, were labeled with TRITC conjugated 
secondary antibodies (Fig. 1A, C).  Internalized NMDA receptors are red-only clusters 
without colocalization with green surface clusters.  After 1 hour of patient IgG treatment 
(Fig. 1A, C), internalized NMDA receptor clusters begin to accumulate.  By 2 hours, the 
density of internalized NMDA receptors clusters is significantly higher than at 15 
minutes and surface NMDA receptor cluster density is significantly decreased (Fig.. 1A-
C).  Over 24 hours, internalized NMDA receptor clusters continue to accumulate and the 
  
141 
surface clusters continue to decrease (Fig. 1A-C).  These data show that the loss of 
decreased surface NMDA receptor clusters is due to internalization of antibody bound 
clusters.  Neurons treated for 24 hours with Fab have a small number of internalized 
NMDA receptor clusters, without a significant decrease in the density of surface NMDA 
receptors, probably due to the rapid turnover and/or recycling of NMDA receptors to the 
cell surface.  However, by 24 hours, whole IgG treated neurons have a significantly 
higher density of internalized NMDA receptors, suggesting that the internalization rate of 
NMDA receptors is increased compared to constitutive NMDA receptor internalization.  
These results suggest that the rapid internalization of NMDA receptor account for the 
rapid decrease in NMDA receptor cluster density in the presence of anti-NMDA receptor 
antibodies from patients. 
 
Patient antibody induced internalization of NMDA receptor clusters is independent 
of receptor activity 
 To determine whether the rapid internalization of surface and synaptic NMDA 
receptors induced by patient antibodies is modulated by NMDA receptor activity, we 
used APV ((2R)-amino-5-phosphonovaleric acid) to block NMDA receptor activity 
during patient antibody treatment.  If NMDA receptor internalization were increased by 
inactivity, then APV would accentuate the effect of patient antibodies on the loss of 
surface and synaptic NMDA receptor clusters.  A wide range of patient antibody 
concentration was used to explore the effect of activity over a wide range of antibody 
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titer and thus NMDA receptor internalization (c.f. Hughes et al., 2010).   We found that 
APV treatment did not affect the extent of patient antibody induced loss of surface or 
synaptic NMDA receptors (Fig. 2A, B).  These data suggest that patient antibody induced 
receptor internalization is not activity dependent.   
 
Patient antibody mediated loss of NMDA receptor currents is due to internalization, 
not acute receptor blockade 
 Since the decrease in surface NMDA receptor cluster density is detectable 1-2 
hours after patient antibody treatment, we next asked whether patient antibodies acutely 
block receptor function and thus rapidly diminish NMDA receptor mediated synaptic 
currents.  Neurons were incubated with control or patient CSF for 10 minutes, followed 
by whole cell patch clamp recording to assess NMDA receptor mediated miniature 
excitatory postsynaptic currents (mEPSCs) (Fig. 3A).  Within 10 to 30 minutes after 
treatment with patient antibodies, the antibody mediated internalization of NMDA 
receptors is not yet significant (Fig. 1).  During this time window, there is no significant 
change in NMDA receptor mediated mEPSC amplitude or frequency   (Fig. 3B, C). 
These data suggest that patient antibodies don’t acutely block NMDA receptor function.   
On the other hand, NMDA receptor mediated currents are significantly reduced after 24 
hours of treatment with patient antibodies, confirming that over this time frame, there is a 
significant decrease in surface and synaptic NMDA receptor clusters (Fig. 3C).   
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We found that, while the NMDA receptor antagonist APV decreases both the 
amplitude and frequency of NMDA receptor mediated currents (Fig. 3B, C), the 
amplitude but not the frequency of NMDA receptor mediated currents was reduced after 
treatment with patient antibodies.  This is not likely to be due to a decrease in presynaptic 
release probability, since our previous studies suggested that the frequency of AMPA 
receptor mediated currents was unaffected (Hughes, et al., 2010).  These data suggest that 
the number of postsynaptic sites with functional NMDA receptors is decreased by patient 
antibodies, consistent with the observation that surface NMDA receptor cluster density is 
decreased.   
 If patient antibodies led to an acute increase or potentiation of NMDA receptor 
currents, this might be rapidly offset by NMDA receptor internalization, within 30 
minutes of treatment. To investigate this possibility, neurons were exposed to patient or 
control antibodies and NMDA receptor mediated mEPSCs were recorded over time 
before and after treatment (Fig. 3D-F).  No significant difference in NMDA receptor 
mediated mEPSC amplitude or frequency was observed before and 10 minutes after 
antibody treatment (Fig. 3D-F).  These data suggest that patient antibodies are unlikely to 
have robust, acute effects on NMDA receptor function on a time scale of minutes.
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Discussion 
 We have studied short term effects of autoantibodies from anti-NMDA receptor 
encephalitis patients on cultured hippocampal neurons. We showed that patients’ 
antibodies rapidly and significantly increased the internalization of NMDA receptor 
clusters, in just a few hours.  While the patient antibodies bind to surface NMDA 
receptors, they do not interfere with the activity of NMDA receptor currents.  Further 
more, our data suggests that the NMDA receptors activity is not interacting with required 
for patient’s antibody’s effects on decreasing antibody mediated internalization of 
synaptic NMDA receptor clusters.  Together, our data suggest cellular mechanism of 
short term effects of antibodies from anti-NMDA receptor patients which cause a rapid, 
activity independent internalization independent of NMDA receptor activity, without 
blocking NMDA receptors.  
 Surface NMDA receptors are normally internalized during synapse maturation, in 
long-term depression (LTD), and in response to ligand-binding (Roche et al., 2001; 
Vissel et al., 2001; Barria and Malinow, 2002; Montgomery and Madison, 2002; Snyder 
et al., 2005b). Internalization of NMDA receptors has been shown to be mediated by 
clathrin via endocytotic signal on C-terminal of NR2A or NR2B subunits (Roche et al., 
2001; Lavezzari et al., 2004).  NMDA receptors sort into different intracellular pathways 
after endocytosis, with NR2B containing receptors preferentially trafficking through 
recycling endosomes and NR2A through late endosomes (Lavezzari et al., 2004). We 
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showed here that the patient’s antibody associated with NMDA receptor clusters are 
internalized after a few hours of incubation, and that the net accumulation rate of 
internalized NMDA receptors are much higher than normal internalization.  Whether the 
patients’ antibodies induced internalization is mediated by the clathrin dependent 
pathway as observed in normal conditions but at a higher rate, or other pathways for 
pathologicagenicl conditions is a question to be addressed in the future.   
In addition to causing antibody mediated NMDA receptors internalization by patients’ 
antibodies capping and cross-linking NMDA receptors, as our previous studies suggested 
(Hughes et al., 2010), another mechanism to compromise NMDA receptor’s receptor 
function is that patient anti-receptor antibodies agonize or antagonize the receptor.  This 
has been suggested in other autoimmune diseases.  NR2 antibodies from patients with 
SLE cause neuronal death when injected into mouse brain; this effect is attenuated by 
treatment with the NMDA receptor blocker, MK-801, suggesting the antibodies mediate 
cell death by enhancing channel activation (DeGiorgio et al., 2001).  Conversely, 
application of nicotonic acetylcholine receptor (nAChRs) antibodies from myasthenia 
gravis patients to outside-out patches of mouse myotubes caused an acute block of AChR 
currents that became irreversible with time (Jahn et al., 2000).  However,  in our studies, 
whole cell recording experiments during acute application of antibodies in our studies 
showed that there are no significant changes of NMDA receptor mediated miniature 
amplitude and frequency, suggesting that neither agonist nor antagonist effects.  It is 
possible that the whole cell NMDA receptor mediated miniature recording is not sensitive 
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enough to detect very small changes in NMDA receptor currents, but since this technique 
can detect the changes of current resulted from internalization and reduction of synaptic 
NMDA receptors, at least our results suggest that possible agonist or antagonist effects 
are minimal, if any, compared to the later reduction of NMDA receptor currents induced 
by internalization.  Further more, if there is any direct interference of NMDA receptor 
currents by patients’ antibodies, it does not induce internalization of receptors, since in 
presence of NMDA receptor blocker APV, the patients’ antibodies’ effect in reducing 
synaptic NMDA receptor clusters are not changed.   Together, these together data suggest 
that antibody mediated cross-linking and capping is the major mechanism to that triggers 
the internalization and reduction of surface NMDA receptor clusters and thus their 
function.   
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Methods 
Preparation of patient and control CSF and IgG  
Patient or control cerebrospinal fluid (CSF) was collected and filtered using 
protein A/G sepharose columns.  CSF was diluted 1:15-100 to treat neurons in vitro.  In 
some experiments, IgG purified from serum was used to treat neurons (Fig. 1; Fig. 2A, 
E).  Briefly, 10 ml of patient or control serum were incubated with a 5 ml column of 
protein A/G Sepharose beads (50:50) for 30 min. on an orbital shaker at 4 °C.  After 
elution IgG was added to a bio-spin chromatography column (Bio-Rad) followed by 3 
washes with PBS, eluted with 100 mM glycine, pH = 2.5 and neutralized with Tris-HCl, 
pH = 8.0,  dialyzed against PBS and concentrated to stock solutions of 20 mg/ml and 
stored at -80 °C.  IgG concentration (~1mg / ml) and pH (7.4) were adjusted prior to use.  
Each CSF or IgG preparation was tested for antibody reactivity by staining mouse or rat 
brain sections or HEK cells expressing NR1/NR2 heteromers of the NMDAR as 
previously described (Dalmau et al., 2007; Dalmau et al., 2008).   
 
Cell culture and patient antibody treatment 
 Primary rat hippocampal neuron and astrocyte cultures were prepared from 
embryonic day 18-19 as previously described (Goslin et al., 1988).  Briefly, hippocampi 
were in Ca2+ free HBSS containing 1% papain for 20 min., triturated in Basal Media 
Eagle (BME; Invitrogen) supplemented with B-27 (Life Technology) and plated at 
100,000 or 400,000 (for biotinylation) cells per ml in Neural Basal (NB) supplemented 
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with 10% FBS (Hyclone), B-27, 1% Penicillin and Streptomycin (Life Technologies) and 
1% L-Glutamine (Life Technologies) on poly-L-lysine coated (Sigma) coverslips in 24-
well plates.  Culture media was changed to Neural basal (Life Technologies) 
supplemented with B27 at 4 div.  Cells were maintained at 37 °C, 5% CO2, 95% 
humidity; medium was changed weekly.  CSF was diluted 1:15-100 to treat neurons in 
vitro.  In some experiments, IgG purified from serum was used to treat neurons (10 µg to 
1 mg/ml).   
  
Immunostaining for pre- and postsynaptic components   
To label surface NMDAR clusters and measure the subsequent internalization, 
neurons were incubated with patient IgG/CSF containing anti-NR1 antibodies or Fab 
fragments for 1 to 24 hours.  Since Fab fragments can bind with NMDA receptors but not 
cross link and cause decrease in receptors clusters (Hughes et al., 2010) and do not 
induce significant reduction of surface NMDA receptors, they can serve as a control of 
static status of NMDA receptor removal and reinsertion of surface and synaptic sites.  
After treatment,  surface Fab or IgG bound NMDA receptor can be labeled by applying 
FITC conjugated secondary antibodies while the neurons are alive and without 
permeabilization.  After fixation and permeabilization, internalized Fab or IgG bound 
NMDA receptor clusters as well as remaining surface NMDA receptor clusters can be 
visualized by applying TRITC conjugated secondary antibodies  
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To stain surface NMDAR clusters, control or treated neurons were washed in NB 
plus B27 and were incubated with patient CSF containing anti-NR1 antibodies for 30 
min., washed and incubated with fluorescently conjugated anti-human secondary 
antibodies for 30 min., and washed in PBS.  Neurons were then fixed in 4% 
paraformaldehyde, 4% sucrose in PBS, pH = 7.4 for 15 min., permeabilized with cold 
0.25% Triton X-100 for 5 min., and blocked in 5% normal goat serum (Invitrogen) for 1 
hour at RT.  Additional immunostaining was performed with various combinations of 
primary antibodies:  to label glutamate receptors, anti-NR1 (1:1000; Chemicon), to label 
presynaptic terminals, mouse anti-Bassoon (1:400; Stressgen Bioreagents).  Antibodies 
were visualized after staining with the appropriate fluorescently conjugated secondary 
antibodies (1:200, Jackson ImmunoResearch). 
 
Confocal imaging, image analysis and statistical analysis   
 For all experiments, 6-12 randomly selected pyramidal neurons, identified by 
morphology (Elmariah et al., 2004; Elmariah et al., 2005) in each condition were 
confocally imaged (Leica TCS 4D system) on each of 2-3 coverslips in 3-5 independent 
experiments.  Images were thresholded automatically using an iterative thresholding 
technique (Bergsman et al., 2006), and the number and area of individual immunostained 
pre- or postsynaptic clusters were determined using interactive software (custom-written 
ImageJ macros).  Clusters with pixel overlap of pre- and postsynaptic markers were 
considered colocalized and thus synaptic.  Cluster density was compared among 
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conditions using the Kruskal-Wallis nonparametric ANOVA test followed by Dunn’s 
pairwise multiple comparison test, unless otherwise indicated.  All values are presented 
as mean ± s.e.m. 
 
Whole cell electrophysiological recordings of synaptic NMDA receptor mediated 
currents 
Whole cell voltage clamp recordings were performed as previously described 
(Hughes et al., 2010) from 14 – 21 div pyramidal neurons treated for indicated amount of 
time with patient CSF/IgG containing anti-NR1 antibodies, control CSF/IgG or left 
untreated.  Briefly, neurons were incubated in extracellular physiology solution without 
Mg2+ and with Glycine to increase detectable NMDA receptor mediated minis (in mM:  
119 NaCl, 5 KCl, 2 CaCl2, 30 Glucose, 10 HEPES, 0.001 Glycine, pH = 7.4).  Voltage-
clamp recordings were made at RT (22-25 °C) using glass microelectrodes (resistance 4-
6 MΩ) filled with a Cesium substituted intracellular solution (in mM:  100 Cesium 
gluconate, 0.2 EGTA, 5 MgCl2, 2 ATP, 0.3 GTP, 40 HEPES, pH = 7.2).  Pipette voltage 
offset was neutralized before the formation of a gigaohm seal. Membrane resistance, 
series resistance, and membrane capacitance were determined from current transients 
elicited by a 5 mV depolarizing step from a holding potential of -80 mV, using the whole 
cell application of HEKA software.  Criteria for cell inclusion in the data set included a 
series resistance ≤ 30 MΩ and stability throughout the recording period.  Currents were 
amplified, low-pass filtered at 2.5 kHz, and sampled at 5 Hz using pCLAMP.  Miniature 
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excitatory spontaneous currents (mEPSCs) were recorded at -70mV in the presence of 
TTX (1 µM), Picrotoxin (10 µM) and CNQX (10 µM).  APV (50 µM) were bath applied 
to block NMDAR mediated currents respectively.   To test whether patient antibodies 
rapidly decreased NMDAR mediated currents, consistent with a receptor blocking effect, 
neurons were recorded for 10 min. then treated with bath applied patient or control 
CSF/IgG for 10 min.  mEPSC events were detected and analyzed using MiniAnalysis 
(Synaptosoft, Leonia, NY), which employs a threshold-based event-detection algorithm.  
NMDAR and AMPAR components of mEPSCs were separated temporally by their 
distinct kinetics (Hestrin et al., 1990; Watt et al., 2000; Yang et al., 2003). All values are 
presented as mean ± s.e.m. 
 
Fab fragments preparation and treatment 
Fab fragments were prepared from serum IgG using a kit according to the 
manufacturer’s directions (Fab preparation kit, Pierce Protein Research Products, Thermo 
Scientific).  Briefly, serum IgG was digested for 2-4 hours at 37 °C with 1% (w/w) 
papain pH= 7.0 with 0.01 M cysteine, resulting in cleavage into Fab and Fc fragments.  
Fab fragments were then isolated by chromatography and concentration determined by 
absorption at 280 nm.  Fab fragments were used to treat neurons at a concentration of 4 
µg/ml.   
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Figures and Legends 
 
Figure 1.  Patient antibodies rapidly internalize surface and synaptic NMDA 
receptor clusters. 
 A.  Neurons were labeled and treated with patient or control IgG for 15 minutes – 
24 hours, or Fab fragments from patient or control IgG for 24 hours.  At the end of 
treatment,  the remaining surface NMDA receptors associated with IgG were labeled with 
FITC conjugated secondary antibodies in live, unpermeabilized neurons.  After fixation 
and permeabilization, internalized receptors were labeled with TRIC conjugated 
secondary. Over time, treatment with patient IgG decreased surface IgG-NMDA receptor 
cluster density and increased the density of internalized IgG-NMDA receptor clusters.  
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Treatment with Fab fragments from patient for 24 hours had no effect.  (N =  6 - 12 
neurons from each of 2 independent experiments for each condition.  
 B. Quantification of surface NR1 cluster density over time and type of treatment.  
Asterisk indicates significant difference compared to 15 minutes treatment (ANOVA, 
Kruskal-Wallis test, followed by Dunn’s multiple comparison test, p < 0.0001).  
 C.  Quantification of internalized NR1 clusters density over time and type of 
treatment.  Asterisk indicates significant difference compared to 15 minutes (ANOVA, 
Kruskal-Wallis test, followed by Dunn’s multiple comparison test, p < 0.0001).  
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Figure 2.  Patient antibody induced internalization of NMDA receptor clusters is 
independent of receptor activity. 
 A.  Effects of control or patient CSF with or without APV on the density of 
synaptic NMDA receptor clusters.  1:20 dilution patient CSF, but not a 1:100 dilution, 
significantly decreased the density of synaptic NMDA receptor clusters compared to 
control (Mann-Whitney U test, p = 0.002).  However, the presence of APV did not affect 
the density of synaptic NMDA receptor clusters (p = 0.08 to 0.2; N = 3-17 neurons from 
each of 2 experiments. 
  B.  Control or patient CSF with or without APV had no effect on the density of 
presynaptic Bassoon clusters (Kruskal-Wallis test, p = 0.04). 
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Figure 3.  Patient antibody mediated loss of NMDA receptor currents is due to 
internalization, not acute receptor blockade. 
 A. mEPSCs recorded in physiological saline with TTX, picrotoxin and CNQX to 
isolate synaptic NMDAR mediated currents. Under the same recording conditions, 
treatment of hippocampal neurons with patient CSF for 1 day dramatically reduced 
synaptic NMDAR mediated currents (second trace).  Treatment with patient CSF for 30 
minutes didn’t significantly change NMDAR mediated current amplitude or frequency N 
= 3 neurons treated with control IgG  for 1 day; 3 neurons treated with patient IgG for 1 
day; 2 neurons treated with control CSF for 30 minutes; 2 neurons treated with patient’s 
CSF for 30 minutes; 3 neurons recorded in presence of APV).   
 B.  Quantification of patient antibody effects on NMDA receptor mediated 
synaptic current amplitude  (control 24 h = 16.7 ± 1.3 pA;  patient’s IgG 24 h= 15.4 ± 
1.0; control 30 min = 16.1 ± 0.4; patient’s CSF 30 min = 16.1 ± 1.1; APV = 10.0 ± 0.4; 
asterisk indicates significant difference, Mann-Whitney U test,  p =  0.05).  
 C. Quantification of patient antibody effects on NMDA receptor mediated 
synaptic current frequency (control 24 h = 4.2 ± 1.5 Hz;  patient’s IgG 24 h= 1.9 ± 1.1; 
control 30 min = 3.8 ± 0.4;  patient’s CSF 30 min = 3.7 ± 0.8;  APV = 0.7 ± 0.3; asterisk 
indicates significant difference, Mann-Whitney U test, p =  0.05).  
 D.  mEPSCs recorded in physiological saline with TTX, picrotoxin and CNQX to 
isolate synaptic NMDAR mediated currents. baseline NMDA receptor mediated currents 
were recorded for 10-20 minutes, then control or patient IgG was added to the recording 
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bath and recordings continued over time (N =  5 control IgG treated neurons; 4 patient 
IgG treated neurons). 
 E. Quantification of patient antibody effects on NMDA receptor mediated 
synaptic current amplitude  (control before = 16.3 ± 1.6; control  IgG 5 min = 14.4 ± 1.1;  
patient before = 13.5 ± 0.7,  patient IgG 5 min = 13.4 ± 1.3; Wilcoxon matched-pairs test,  
p > 0.05).  
 F. Quantification of patient antibody effects on NMDA receptor mediated 
synaptic current frequency (control before = 5.1 ± 0.5; control IgG 5 min= 5.5 ± 0.3;  
patient before = 4.3 ± 0.2;  patient’s IgG 5 min = 6.2 ± 0.2; Wilcoxon matched-pairs test,  
p > 0.05). 
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Abstract 
 We recently described a severe but treatment responsive type of limbic 
encephalitis that is associated with autoantibodies to the α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor (AMPAR).  Anti-AMPAR encephalitis results in a 
severe short-term memory loss and seizures.  Here we demonstrate that in cultured 
hippocampal neurons, patients’ anti-AMPAR antibodies cause a selective decrease in the 
surface density and synaptic localization of AMPARs and their association with the 
postsynaptic protein Stargazin, by increasing the internalization of surface AMPAR 
clusters.  Patient antibodies also specifically decreased synaptic AMPAR mediated 
miniature excitatory postsynaptic currents, while NMDAR mediated currents are not 
affected. While commercially available anti-AMPAR antibodies directed against 
extracellular epitopes can compete with patient antibodies for binding to surface AMPA 
receptors, not all commercial antibodies result in loss of surface and synaptic receptor 
clusters due to internalization.  These results suggest that in anti-AMPAR encephalitis, 
patient antibodies result in a selective loss of surface and synaptic receptor clusters that is 
specific to patient antibodies. 
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Introduction 
 There are several recently identified paraneoplastic autoimmune disorders in 
which patients develop autoantibodies against cell surface and synaptic proteins including 
NMDA receptors (Dalmau et al., 2007; Dalmau et al., 2008) and AMPA receptors (Lai et 
al., 2009).  Patients with anti-AMPAR encephalitis mainly present with confusion, 
agitation, seizures, and severe short-term memory deficits, which recover with 
appropriate intervention to reduce antibody titer (Lai et al., 2009).  Patients with anti-
AMPAR encephalitis have a significant tendency to relapse, and for these patients the 
outcome depends of how well each relapse is controlled.  In contrast, patients with anti-
NMDA receptor encephalitis develop prominent psychiatric and behavioral symptoms, 
including psychosis, short term memory loss, seizures and abnormal movements 
(dyskinesias), that if untreated can progress to catatonia, hypoventilation, and autonomic 
instability (Dalmau et al., 2007; Dalmau et al., 2008).  The distinct roles of NMDA 
receptors and AMPA receptors in basic synaptic transmission, circuit function and 
activity dependent plasticity may underlie the distinct syndromes of these two 
encephalitides (Nakazawa et al., 2004; Shepherd and Huganir, 2007) .    
AMPA receptors mediate most of the fast excitatory synaptic transmission in the 
brain (Shepherd and Huganir, 2007) and the majority are heterotetramers composed of 
GluR1, 2, 3 or 4 subunits that are expressed in a region-specific manner (Palmer et al., 
2005).  GluR1/2 and GluR2/3 levels are high in hippocampus and other limbic regions 
(Sprengel, 2006), similar to the distribution of immunostaining with patients’ antibodies 
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(Lai et al., 2009). Preliminary studies suggest that the location of the epitope is the N-
terminal extracellular domain of these AMPA receptor subunits (Gleichman et al., 2009).  
 Our previous studies showed that the treatment of rat hippocampal neurons with 
patients’ antibodies resulted in a decrease in the surface and synaptic localization of 
AMPAR clusters that was reversible (Lai et al., 2009).  Thus as for anti-NMDA receptor 
encephalitis, patient antibodies likely reduce surface AMPAR receptors due to antibody 
mediated capping and internalization (Hughes et al., 2010).   
 In this study, we demonstrate that patients’ anti-AMPAR antibodies caused a 
selective decrease in the surface density and synaptic localization of AMPARs and an 
associated protein, Stargazin, due to increased internalization of AMPAR clusters.  
Patient antibodies also specifically decreased synaptic AMPAR, but not NMDAR, 
mediated miniature excitatory postsynaptic currents.  In contrast, while commercially 
available anti-AMPAR antibodies directed against extracellular epitopes can compete 
with patient antibodies for binding to surface AMPA receptors, not all commercial 
antibodies result in loss of surface and synaptic receptor clusters due to internalization.  
These results suggest that in anti-AMPAR encephalitis, patient antibodies result in a 
selective loss of surface and synaptic receptor clusters that is specific to patient 
antibodies, likely due to the specific extracellular epitope that is targeted.   
 
  
163 
Results 
Patients’ anti-GluR1 or GluR2 antibodies selectively decrease synaptic and surface 
AMPA receptor cluster density 
 Previous work showed that the antibodies from a single patient with anti-AMPAR 
encephalitis selectively and reversibly decreased synaptic AMPA receptor clusters (Lai et 
al., 2009).  To determine whether different patient antibodies had similar effects, and to 
further determine whether patient anti-GluR1 or anti-GluR2 antibodies have similar 
effects on localization of AMPA receptor subunits, hippocampal neurons were cultured 
for 1-3 days with patient anti-GluR1 or anti-GluR2 antibodies, followed by 
immunohistochemical and Western blot analyses of synaptic and surface GluR1 or 
GluR2/3 protein. Patient anti-GluR1 and anti-GluR2 antibodies significantly decreased 
both GluR1 and GluR2/3 containing AMPAR synaptic cluster density (Fig. 1A, B, C) and 
surface cluster density (Fig. 1E, F), compared to CSF from control patients.  There is no 
significant compensatory increase of GluR2/3 subunits to synapses, or compensative 
increase of surface expression of GluR2/3 subunits when treated with anti-GluR1 
patient’s CSF or vice versa, suggesting that antibodies from both type of anti-AMPAR 
encephalitis patients have similar effects on decreasing GluR1 and GluR2 containing 
AMPA receptors.  
 
Patients’ antibodies also reduce the density of synaptic Stargazin clusters but not 
other synaptic proteins 
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 We next determined whether the antibodies also affected synapse density and/or 
the density of other postsynaptic components.   Hippocampal neurons were cultured with 
CSF containing anti-GluR1/anti-GluR2 antibodies or purified IgG for 1-3 days, followed 
by immunostaining or Western blot analyses of synaptic proteins, including presynaptic 
VGlut, postsynaptic PSD-95, the AMPA receptor interacting protein Stargazin, NMDA 
receptor subunits NR1 and GluR2, and GABAb receptors.   
Patients’ antibodies did not affect the number of excitatory synapses compared to 
controls (Fig. 1D). Moreover, patients’ antibodies did not affect the density of 
presynaptic Bassoon, vGlut and postsynaptic PSD-95, NR1 clusters (Fig. 2A – E), or the 
amount of surface NR1 and GABAb receptor protein (Fig. 2 F, G).  However,  patient’s 
CSF treatment for 1 day reduced synaptic localization of Stargazin, an AMPA receptor 
interacting protein (Fig. 2E), suggesting that proteins that directly interact with AMPA 
receptor subunits may also be affected by reduction of surface and synaptic AMPA 
receptors induced by patient’s antibodies.   
These results show that patients’ antibodies reduce synaptic localization of 
AMPA receptor interacting protein Stargazin without significant effect on NMDA or 
GABAb receptors, other synaptic proteins, or the number of excitatory synapses. 
 
Patients’ antibodies decrease AMPA receptor but not NMDA receptor mediated 
synaptic transmission 
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 In order to examine the functional outcome of patients’ antibody treatment, 
AMPA receptor mediated miniature excitatory postsynaptic currents (mEPSCs) were 
measured using whole cell voltage patch recording at -70 mV from neurons treated with 
patient’s of control’s CSF for 1 day.  The recording was carried out in presence of TTX, 
picrotoxin and APV to block action potentials,  GABA receptor mediated inhibitory 
currents and NMDA receptor mediated currents, respectively.   
 In neurons treated with control CSF, there are frequent AMPA receptor mediated 
miniature current events with an average amplitude of 17.6 ± 3.7 pA and average 
frequency of 3.2 ± 0.4 Hz (Fig. 3A, upper trace,  B, left average trace, C,D).  In contrast,  
the AMPA receptor mEPSCs are significantly smaller with amplitude of  10.9 ± 0.7 pA 
(Fig. 3A, bottom trace,  3B, right average trace,  3C; Student’s t-test, p = 0.04 ).  The 
frequency of AMPA receptor mEPSCs in neurons treated with the patient’s CSF is 2.3 ± 
1.4 Hz, not significantly different from the control treated neurons.(Fig. 3D, student’s t-
test, p = 0.48).  This result suggests that patient antibodies decrease AMPA receptor 
mediated currents.   
 We also examined NMDA receptor mediated currents.  To measure NMDA 
receptor minis independently from AMPA minis,  recordings were carried out in presence 
of TTX, picrotoxin, CNQX (an AMPA receptor blocker) and Glycine to reveal all 
functional NMDA receptors (Wilcox et al., 1996).  The amplitude and frequency of 
NMDA receptor mediated currents, which can be blocked by APV (Fig. 5E, bottom 
trace), are not significantly different in neurons treated with control or patient CSF (Fig. 
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E-H).  This result suggests that the patient antibodies specifically affect the function of 
AMPA receptors. In addition, the observation that the frequency of NMDA receptor 
mediated currents was not affected also suggests that the presynaptic release probability 
is not affected by patient antibodies.   
 Together, these results show that patients’ antibodies specifically decrease 
synaptic AMPAR-mediated currents and do not affect NMDA receptor mediated 
currents, consistent with the specific loss of surface, synaptically localized AMPAR 
clusters.  
 
Patients’ antibodies increase the internalization of AMPA receptor clusters 
 Next, we asked whether the reduction of synaptic AMPA receptors is due to 
increased internalization induced by patient’s antibodies.  The surface AMPA receptors 
were labeled by a commercial anti-GluR1 antibody against extracellular epitope 
(Calbiochem) for two hours.  This commercial antibody labeled surface AMPA receptors 
without decreasing its synaptic localization (see below).  After removal of extra unbound 
commercial antibodies, neurons were treated with control or patient CSF containing anti-
GluR1 antibodies for 1 day.  Remaining surface AMPA receptor clusters were assayed by 
FITC conjugated secondary antibody, in a saturating amount, against the commercial 
GluR1 in live neurons, i.e., in the absence of fixation and permeabilization.  Internalized 
AMPA receptor clusters were revealed by TRITC conjugated secondary antibody after 
fixation and permeabilization.   
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One day of treatment with patient CSF significantly increased the density of 
internalized AMPA receptor clusters (Fig. 4A, C).  However, the density of pre-labeled 
surface AMPA receptor was not significantly decreased with patient’s CSF treatment 
(Fig. 4A, B).  This is likely due to pre-incubation of the commercial antibody that may 
have sterically hindered binding of patient antibody, thus reducing the effect of patient 
CSF.  Together, these results suggest that the patient anti-AMPAR antibodies increased 
the internalization of AMPA receptors.  
 
Commercial antibodies compete with patients’ antibodies 
 To further understand the different effects of patient’s versus commercial 
antibodies against extracellular epitopes of AMPA receptors, we examined whether pre-
incubation of patients’ CSFs can interfere with commercial antibodies staining.  After 
fixation,  neurons were pre-incubated with control, anti-GluR1 or anti-GluR2 patient’s 
CSF for 1 hour (Fig. 5A, left row of images), followed by standard immunostaining for 
commercial anti-GluR1.  Both staining intensity and the density of surface GluR1 
clusters decreased significantly (Fig. 5B).  Interestingly, both anti-GluR1 and anti-GluR2 
patient’s CSF interfered with commercial anti-GluR1 antibody binding, suggesting that 
this interference is not subunit specific.   Similar observations were obtained for a 
commercial anti-GluR2 antibody after pre-incubation of patients’ CSF (Fig. 5C).  
Furthermore, anti-NMDA receptor encephalitis patient’s CSF didn’t interfere with 
commercial anti-GluR2 antibody’s staining, suggesting that when the competing antibody 
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is physically further away from AMPA receptors, no interference occurred.  Together, 
these results suggest that patient anti-GluR1/2 antibodies compete with commercial 
antibodies for extracellular space for their own epitopes. 
 
Effects of commercial anti-AMPAR antibodies on surface AMPA receptor density 
 Next, we asked whether the commercial antibodies against extracellular AMPA 
receptor epitopes have similar effects as the patients’ antibodies in decreasing the 
synaptic localization of  AMPA receptor clusters.  After 1 day treatment with commercial 
anti-GluR1 antibody (Calbiochem; immunogen is a synthetic peptide 
(RTSDSRDHTRVDWKR) corresponding to amino acids 271-285 of rat GluR1), the 
synaptic localization of AMPA receptor clusters was unchanged across a wide range of 
antibody concentration (Fig. 6B).  When the antibody concentration was high (1:20, 1:50 
diluted),  AMPA receptor cluster staining increased, probably due to the increased 
association with commercial antibodies on the surface of neurons in the absence of 
internalization.  Interestingly, neurons treated with anti-GluR2 antibodies (Chemicon; 
immunogen is recombinant fusion protein with putative N-terminal portion of GluR2 
from AA 175-430), especially when a secondary antibody was included to cross-link the 
primary antibody, a significant decrease of synaptic AMPA receptor clusters density was 
observed (Fig 6A, 6C).  These results suggest that some, but not every, commercially 
available antibody has similar effects as patient antibodies, possibly due to binding to a 
specific extracellular epitope on AMPA receptors. 
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Discussion 
 In this study, we examined the effects of autoantibodies from anti-AMPAR 
encephalitis patients on hippocampal neurons.  Here we demonstrate that patients’ 
AMPAR antibodies cause a selective decrease in surface density and synaptic 
localization of AMPAR and its associated protein Stargazin, via increased internalization 
rate of AMPAR clusters.  Consistent with structural changes, patients’ CSF specifically 
decreased synaptic AMPAR mediated excitatory postsynaptic currents, while NMDAR 
mediated currents were not affected.  While commercial available antibodies can compete 
with patients’ antibodies to bind with AMPA receptors, they don’t necessarily have 
similar effect as patient’s antibodies in decreasing synaptic AMPA receptors.  These 
results together suggest that the in the model of anti-AMPAR encephalitis, the loss of 
AMPA receptors eliminates AMPAR-mediated synaptic function resulting in the memory 
and other behavioral deficits observed in patients with anti-AMPAR encephalitis. 
 We have previously shown that the antibodies from anti-NMDA receptor 
encephalitis selectively decrease synaptic NMDA receptor clusters by capping and cross-
linking induced internalization (Hughes et al., 2010).  In this study, our results suggest 
that the antibodies from anti-AMPA receptor encephalitis patients also have similar 
effects.  In addition our data suggest that the patients’ antibodies against GluR1 or GluR2 
epitopes have similar effects on reducing surface/synaptic GluR1 and GluR2 subunits, 
without obvious selectivity on either one subunit or compensation from the other one.  
This is probably because hippocampal AMPA receptors are mainly GluR1/GluR2 
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heteromers (Lu et al., 2009).  Once the patients’ antibodies associated with any one of the 
subunits, they could initiate capping and cross-linking resulting in endocytosis of the 
whole AMPA receptor.   
 Under physiological conditions, such as during LTD, it has been suggested that 
AMPA receptors are first moved to extrasynaptic sites followed by endocytosis through 
clathrin dependent pathways ((Ehlers, 2000; Shi et al., 2001; Park et al., 2004)).   The 
endocytosis of AMPA receptors have at least one GluR2 dependent pathway that requires 
GluR2 C-terminals interaction with clathrin (Lüthi et al., 1999; Lee et al., 2002) and 
GluR2 independent pathways (Jia et al., 1996; Meng et al., 2003), which may involve 
AMPA receptor activity-dependent ubiquitination of GluR1 and subsequent 
internalization and their trafficking to the lysosome (Ehlers, 2000; Schwarz et al., 2010). 
What pathway is used in this pathogenic condition is a future question to address.  In 
addition, whether similar endocytotic pathways are utilized in anti-NMDA receptor 
encephalitis and anti-AMPA receptor encephalitis or even more antoimmune encephalitis 
are not known.  At least, obvious loss of surface GABAb receptors was not observed in 
culture model of anti-GABAb receptor encephalitis (Lancaster et al. Neurology 2010 
abstract, in press) suggesting that different mechanisms exist.   
 Preliminary analyses suggest that the location of the epitope of patients’ 
antibodies is the N-terminal extracellular domain of these AMPA receptor subunits 
(Gleichman et al., 2009), but details are still under investigation. The commercial 
antibodies with epitope on amino acids 271-285 of rat GluR1 do not have similar effects 
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as the patient’s antibodies and conversely,  the commercial antibody against N-terminal 
portion of GluR2 from AA 175-430 has partial effects as the patients’ antibodies,  
suggesting that the epitope recognized by patients’ antibodies probably overlaps with that 
recognized by the commercial anti-GluR2 antibody.  Future studies on patients’ 
antibodies epitope will help to address this question.  However, the available commercial 
antibodies and immunized animals may provide useful animal models to study anti-
AMPAR antibody effects on circuits, learning, memory and behavior.   
 The consequences of loss of AMPA receptor expression have been studied in 
mouse models.  Spatial learning and memory are largely unaffected in GluR1 knockout 
mice despite the fact that LTP is reduced in CA1 and CA3 (Zamanillo et al., 1999) and 
working memory is diminished (Reisel et al., 2002; Sanderson et al., 2007).  GluR2 
knockout mice show reduced exploration and impaired motor coordination.  In these 
animals, AMPA receptor mediated synaptic transmission is reduced, but LTP is enhanced 
(Jia et al., 1996; Gerlai et al., 1998).  GluR2 knockout mice also have increased cell 
death (Feldmeyer et al., 1999; Oguro et al., 1999), possibly due to excitotoxicity related 
to increased, compensatory insertion of GluR1 homomeric AMPA receptors (Mainen et 
al., 1998).  While AMPA receptor subunit knockout mice have not provided a satisfying 
explanation for the role of AMPA receptors in synaptic plasticity related to learning and 
memory, the fact that patients with AMPA receptor antibodies have short-term learning 
and memory deficits argues that further studies at the circuit and behavioral levels are 
warranted.  
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Methods 
Preparation of patient and control CSF and IgG  
Patient or control cerebrospinal fluid (CSF) was collected and filtered using 
protein A/G sepharose columns.  CSF was diluted 1:15-100 to treat neurons in vitro.  In 
some experiments, Patients’ serum was used to treat neurons (Fig. 1D; Fig.2G).  Each 
CSF was tested for antibody reactivity by staining mouse or rat brain sections or HEK 
cells expressing GluR1/GluR2 heteromers of the AMPAR as previously described (Lai et 
al., 2009).   
 
Cell culture and patient antibody treatment 
 Primary rat hippocampal neuron and astrocyte cultures were prepared from 
embryonic day 18-19 as previously described (Goslin et al., 1988).  Briefly, hippocampi 
were in Ca2+ free HBSS containing 1% papain for 20 min., triturated in Basal Media 
Eagle (BME; Invitrogen) supplemented with B-27 (Life Technology) and plated at 
100,000 or 400,000 (for biotinylation) cells per ml in Neural Basal (NB) supplemented 
with 10% FBS (Hyclone), B-27, 1% Penicillin and Streptomycin (Life Technologies) and 
1% L-Glutamine (Life Technologies) on poly-L-lysine coated (Sigma) coverslips in 24-
well plates.  Culture media was changed to Neural basal (Life Technologies) 
supplemented with B27 at 4 div.  Cells were maintained at 37 °C, 5% CO2, 95% 
humidity; medium was changed weekly.  Control or patient CSF was used at 1:15 – 1:100 
dilutions to treat neurons.  Serums were used at 1:200 dilutions.   
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Immunostaining for pre- and postsynaptic components   
To label surface AMPAR clusters and measure the subsequent internalization,  
neurons were incubated with commercial anti-GluR1 (Calbiochem) antibodies for 2 
hours.  This commercial antibody can associate with AMPA receptors but not cross link 
and do not induce significant reduction of surface AMPA receptors.  After 2 hours, 
unbound antibodies were washed off and neurons where treated with control or patient’s 
CSF containing anti-GluR1 antibodies for 24 hours.  After treatment,  remaining surface 
AMPA receptor can be labeled by applying FITC conjugated secondary antibodies 
against commercial anti-GluR1 (Calbiochem) while the neurons are alive and without 
permeabilization.  After fixation and permeabilization, internalized AMPA receptor 
clusters can be visualized by applying TRITC conjugated secondary antibodies.  
To stain surface AMPAR clusters, control or treated neurons were washed in NB 
plus B27 and were incubated with commercial extracellular anti-GluR1 or anti-GluR2 
antibodies for 30 min., washed and incubated with appropriate fluorescently conjugated 
secondary antibodies for 30 min., and washed in PBS.  Neurons were then fixed in 4% 
paraformaldehyde, 4% sucrose in PBS, pH = 7.4 for 15 min., permeabilized with cold 
0.25% Triton X-100 for 5 min., and blocked in 5% normal goat serum (Invitrogen) for 1 
hour at RT.  Additional immunostaining was performed with various combinations of 
primary antibodies:  to label glutamate receptors and other postsynaptic proteins, anti-
NR1  (1:1000; Chemicon),  anti-GluR1 against intracellular epitope (1:10; CalBioChem) 
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or anti-GluR2/3 with against epitope (1:100; Chemicon), anti-GluR1 against extracellular 
epitope(1:10; Calbiochem), anti-GluR2 against extracellular epitope (1:500; Millipore), 
anti-PSD-95 (1:500; Affinity BioReagents), anti-Stargazin (1: 500;  Chemicon);  to label 
presynaptic terminals, mouse anti-SV2 (1:200; DHSB); guinea pig anti-VGLUT 1 
(1:5000; Chemicon), or mouse anti-Bassoon (1:400;  Stressgen Bioreagents).  Antibodies 
were visualized after staining with the appropriate fluorescently conjugated secondary 
antibodies (1:200, Jackson ImmunoResearch). 
 
Confocal imaging, image analysis and statistical analysis   
 For all experiments, 6-12 randomly selected pyramidal neurons, identified by 
morphology (Elmariah et al., 2004; Elmariah et al., 2005) in each condition were 
confocally imaged (Leica TCS 4D system) on each of 2-3 coverslips in 3-5 independent 
experiments.  Images were thresholded automatically using an iterative thresholding 
technique (Bergsman et al., 2006), and the number and area of individual immunostained 
pre- or postsynaptic clusters were determined using interactive software (custom-written 
ImageJ macros).  Clusters with pixel overlap of pre- and postsynaptic markers were 
considered colocalized and thus synaptic.  Cluster density was compared among 
conditions using the Kruskal-Wallis nonparametric ANOVA test followed by Dunn’s 
pairwise multiple comparison test, unless otherwise indicated.  All values are presented 
as mean ± s.e.m. 
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Biotinylation of surface proteins and analysis by Western blot   
Neurons were treated with 1:200 diluted patient serum with anti-GluR1 or anti-
GluR2 antibodies for 1 day, washed with PBS supplemented with 0.1 mM CaCl2 and 1 
mM MgCl2 (rinsing buffer) and incubated for 30 min. at 4 °C with 1 mg/ml Sulfo-NHS-
Biotin (Thermo Scientific) in rinsing buffer.  Neurons were then washed with rinsing 
buffer + 100 mM glycine (quenching buffer), incubated in quenching buffer for 30 
minutes at 4°C to quench excess biotin, then lysed in RIPA buffer (150 mM NaCl, 1 mM 
EDTA, 100 mM Tris HCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, pH 
7.4, supplemented with 1:500 protease inhibitor cocktail III, Calbiochem) at 4 °C for 1 
hour.  Lysates were cleared of debris by centrifugation at 12400 x g for 20 min. An 
aliquot of the remaining supernatant was taken for the lysate fraction, and a second 
aliquot was incubated with avidin-linked agarose beads (Immobilized Monomeric 
Avidin, Thermo Scientific) overnight at 4 °C.  After centrifugation, the supernatant was 
removed and the beads (surface fraction) were washed 1X RIPA buffer, 2X high-salt 
wash buffer (500 mM NaCl, 5 mM EDTA, 50 mM Tris, 0.1% Triton X-100, pH 7.5), and 
1X no-salt wash buffer (50 mM Tris, pH 7.5). The surface fraction was eluted from the 
beads with 2X sample buffer and proteins separated on an 8% gel using SDS-PAGE.  
Samples were transferred to nitrocellulose membranes and probed for antibodies against 
NR1 (1:1000, chemicon), GluR1 (1:200, Calbiochem) , GluR 2/3 (1:200, 07-598, 
Upstate),  Stargazin(1:500, Chemicon),  GABAbRs ( 1:1000, chemicon) and actin 
(1:2000, Sigma). Actin and GABAbRs were used as loading controls for total and surface 
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fractions, respectively. Blots were incubated with HRP-conjugated goat anti-mouse or 
goat anti-rabbit secondary antibodies (1:3000, Cell Signaling), and signals were 
visualized using chemiluminescence (SuperSignal Chemiluminescent Substrate, Thermo 
Scientific).  All quantified films were in the linear range of exposure, were digitally 
scanned and signals quantified using NIH ImageJ. 
 
Whole cell electrophysiological recordings of synaptic NMDA and AMPA receptor 
mediated currents 
Whole cell voltage clamp recordings were performed from 14 – 21 div pyramidal 
neurons treated for 24-48 hours with patient CSF containing anti-NR1 antibodies, control 
CSF or left untreated.  Briefly, neurons were incubated in extracellular physiology 
solution (in mM:  119 NaCl, 5 KCl, 2 CaCl2, 2MgCl2, 30 Glucose, 10 HEPES, pH = 7.4) 
for AMAPR minis.  For NMDAR minis, no MgCl2 is included and Glycine (1 µM) is 
added to reveal all NMDA receptor currents.  Voltage-clamp recordings were made at RT 
(22-25 °C) using glass microelectrodes (resistance 4-6 MΩ) filled with a Cesium 
substituted intracellular solution (in mM:  100 Cesium gluconate, 0.2 EGTA, 5 MgCl2, 2 
ATP, 0.3 GTP, 40 HEPES, pH = 7.2).  Pipette voltage offset was neutralized before the 
formation of a gigaohm seal. Membrane resistance, series resistance, and membrane 
capacitance were determined from current transients elicited by a 5 mV depolarizing step 
from a holding potential of -80 mV, using the whole cell application of HEKA software.  
Criteria for cell inclusion in the data set included a series resistance ≤ 30 MΩ and 
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stability throughout the recording period.  Currents were amplified, low-pass filtered at 
2.5 kHz, and sampled at 5 Hz using pCLAMP.  Miniature excitatory spontaneous 
currents (mEPSCs) were recorded at -70mV in the presence of TTX (1 µM), Picrotoxin 
(10 µM), APV (50 µM) and CNQX (10 µM) were bath applied to block NMDAR and 
AMPAR mediated currents respectively.  mEPSC events were detected and analyzed 
using MiniAnalysis (Synaptosoft, Leonia, NY), which employs a threshold-based event-
detection algorithm.  NMDAR and AMPAR components of mEPSCs were separated 
temporally by their distinct kinetics (Hestrin et al., 1990; Watt et al., 2000; Yang et al., 
2003). All values are presented as mean ± s.e.m. 
 
 
  
178 
Figure and Legends 
 
Figure 1: Patients’ anti-GluR1 or anti-GluR2 antibodies selectively decrease 
synaptic and surface AMPA receptor clusters 
 A. Hippocampal neurons immunostained for GluR1 or GluR2 containing 
AMPAR clusters and postsynaptic PSD-95.  Synaptic AMPARs are defined as the 
colocalization between GluR1 or GluR2/3 staining and PSD-95 staining.  Anti-GluR2 
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(middle panel) or anti-GluR1 (right panel) patient CSF treatment for 24 hours reduced 
synaptic GluR2 as well as GluR1 clusters density without affecting PSD-95 density (N = 
6-18 neurons from 1-3 independent experiments for each condition).  Scale bar = 10 µm.  
 B, Quantification of density of synaptic GluR1 clusters defined as colocalization 
between GluR1 and PSD-95 clusters per 20 µm dendrite from neurons treated with 
control, anti-GluR1 or anti-GluR2 patient’s CSF (compared with control,  anti-GluR2 
patient’s CSF treatment = 0.74 ± 0.08, Mann-Whitney test , p = 0.08;  anti-GluR1 
patient’s CSF treatment = 0.64 ± 0.05,  p =0.04).  
 C, Quantification of density of synaptic GluR2/3 clusters defined as the 
colocalization between GluR2/3 and PSD-95 clusters per 20 µm dendrite from neurons 
treated with control, anti-GluR1 or anti-GluR2 patient’s CSF (GluR2 patient’s CSF 
treatment = 0.54 ± 0.06, p < 0.0001 ; GluR1 patient’s CSF treatment = 0.39 ± 0.03,  p = 
0.0002).   
 D. Western blot analyses of surface biotinylated and total lysate AMPAR protein. 
Patient serum treatment for 1 day reduces surface AMPAR protein.  Actin was used as 
the loading control.  
 E. Surface NMDAR protein after treatment with serum from anti-GluR1 or anti-
GluR2 patients, showing a decrease in AMPAR protein (1 anti-GluR1 patient,   anti-
GluR2 patient, 1 control, 1 experiment).  
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Figure 2: Patients’ anti-GluR1 or anti-GluR2 antibodies decrease the clusters 
density of Stargazin but not other synaptic proteins. 
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 A. Hippocampal neurons immunostained for the presynaptic marker vGlut or the 
postsynaptic markers PSD-95,  NR1 or Stargazin.  Synaptic Stargazin is defined as the 
colocalization between Stargazin staining and PSD-95 staining.  Anti-GluR2 patient CSF 
treatment for 24 hours reduces synaptic Stargazin cluster density without affecting PSD-
95 and NR1 density (12-36 neurons from 2-3 independent trials for each condition).  
Scale bar = 10 µm.  
 B, Quantification of density of excitatory synapses defined as colocalization 
between postsynaptic PSD-95 and presynaptic vGlut per 20 µm dendrite from neurons 
treated with control or patient’s CSF (patient’s CSF treatment = 93 % ± 10 % of control 
CSF treatment,  p = 0.3 ). 
 C. Quantification of density of PSD-95 clusters per 20 µm dendrite from neurons 
treated with control or patient’s CSF (control = 16.7 ± 0.93 ,  patient = 15.2 ± 0.7 ,  
Mann-Whitney U test,  p = 0.16).  
 D. Quantification of density of vGlut clusters per 20 µm dendrite from neurons 
treated with control or patient’s CSF (control = 10.2 ± 0.7 ,  patient = 9.1 ± 0.7,  Mann-
Whitney U test,  p = 0.16).  
 E. Quantification of density of NR1 clusters per 20 µm dendrite from neurons 
treated with control or patient’s CSF (control = 17.0 ± 1.1,  patient = 16.1 ± 1.2,  Mann-
Whitney U test,  p = 0.57).  
 F. Quantification of synaptic Stargazin defined as the colocalization between 
Stargazin staining and PSD-95 staining per 20 µm dendrite from neurons treated with 
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control or patient’s CSF (control = 14.2 ± 3.1,  patient = 6.3 ± 1.5,  Mann-Whitney U test,  
p = 0.02).  
 G. Western blot analyses of surface biotinylated Stargazin,  NMDAR and 
GABAb receptor protein. Patient serum treatment for 1 day reduced surface Stargazin 
protein. 
 H. Quantification of surface Stargazin,  NMDAR and GABAb receptor protein 
after treatment with serum from anti-GluR1 or anti-GluR2 patients, showing a decrease 
in Stargazin protein (1 anti-GluR1 patient,  1 anti-GluR2 patient, 1 control,  1 
experiment; no statistics were performed).  
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Figure 3: Patients’ antibodies decrease AMPA receptor but not NMDA receptor 
mediated synaptic transmission 
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 A. mEPSCs recorded in physiological saline with TTX, picrotoxin, APV,  an 
NMDAR antagonist to isolate synaptic AMPAR mediated currents (upper trace). Under 
the same recording conditions, treatment of hippocampal neurons with patient CSF for 1 
day dramatically reduces synaptic NMDAR mediated currents (bottom traces).  N = 4 
neurons treated with control CSF, 4 neurons treated with patient CSF, 1 patient and 1 
control sample.  
 B. Representative average mEPSCs from neurons treated for 1 day with control 
CSF (left) or patient CSF (right).  Neurons treated for 1 day with patient CSF have less 
AMPAR-mediated synaptic current than neurons treated with control CSF.  
 C. Effect of patient antibodies AMPA receptor mediated synaptic currents 
amplitudes (control = 17.6 ± 3.7 ,  patient’s CSF treated = 10.9 ± 0.7;  asterisk indicates 
significant difference, Student’s t-test,  p =  0.04).  
 D. Effect of patient antibodies AMPA receptor mediated synaptic currents 
frequency (control = 3.2 ± 0.4 ,  patient’s CSF treated = 2.3 ± 1.4; Student’s t-test,  p =  
0.48).  
 E. mEPSCs recorded in physiological saline with TTX, picrotoxin, CNQX,  an 
AMPAR antagonist to isolate synaptic NMDAR mediated currents. Treatment of 
hippocampal neurons with control (upper trace) and patient CSF (bottom traces) for 1 day 
have similar synaptic NMDAR mediated currents.  N = 4 control CSF treated neurons, 5 
patient CSF treated neurons, 1 patient, 1 control sample.  
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 F. Representative average mEPSCs from neurons treated for 1 day with control 
CSF (left) or patient CSF (right). Treatment of hippocampal neurons with control (left 
trace) and patient CSF (right traces) for 1 day have similar synaptic NMDAR mediated 
currents.  
 G. Effect of patient antibodies on NMDA receptor mediated synaptic currents 
amplitudes (control = 12.8 ± 1.2,  patient’s CSF treated = 12.1 ± 1.7;  Student’s t-test,  p 
=  0.56).  
 H. Effect of patient antibodies AMPA receptor mediated synaptic currents 
frequency (control = 6.1 ± 0.7 ,  patient’s CSF treated = 6.1 ± 0.3; Student’s t-test,  p =  
0.94).  
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Figure 4: Patients’ antibodies increase the internalization of AMPA receptor 
clusters 
 A. Hippocampal neurons live labeled for surface GluR1 for 2 hours,  then treated 
with control or patient CSF for 24 hours, followed by  immunostaining for the remaining 
surface GluR1 in live neurons,  then fixed, permeabilized and immunostained for internal 
GluR1 and postsynaptic marker PSD-95.  Patient CSF treatment for 24 hours increases 
internal GluR1 cluster density.  N = 9 neurons from 1 trial for each condition,  Scale bar 
= 10 µm.  
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 B. Quantification of density of surface GluR1 clusters per 20 µm dendrite from 
neurons treated with control or patient’s CSF (control treated = 15.9 ± 1.1 ,  patient’s 
CSF treated = 19.4 ± 1.3, Mann-Whitney U test,  p = 0.06).  
 C. Quantification of density of internal GluR1 clusters per 20 µm dendrite from 
neurons treated with control or patient’s CSF (control treated = 3.2 ± 0.4 ,  patient’s CSF 
treated = 6.7 ± 1.3, Mann-Whitney U test,  p = 0.01,  asterisk indicates significant 
difference compared to control CSF treated neurons). 
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Figure 5: Commercial antibodies pre-block patients’ antibodies 
 A. Neurons were fixed but non-permeabilized,  pre-incubated for control, anti-
GluR1 or anti-GluR2 patient’s CSF,  then immunostained for surface GluR1.  Both 
AMPAR Patient CSF preincubation for one hours decrease surface GluR1 clusters 
density staining.  Scale bar = 10 µm.  6 neurons from 1 trial of treatment for each 
condition. 
 B. Quantification of density of surface GluR1 clusters per 20 µm dendrite from 
neurons pre-incubated with control or patient’s CSF. (Control CSF pre-incubated = 40.4 
± 4.4,  GluR1 patient’s CSF pre-incubated = 27.7 ± 3.0,  compare to control,  Mann-
Whitney test, p = 0.03;  GluR2 patient’s CSF pre-incubated =  29.4 ± 1.8,  p = 0.04) 
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Figure 6: Commercial antibodies do not have similar effects as patients’ antibodies 
 A. Neurons were treated with PBS, commercial anti-GluR2 or anti-GluR1 
antibodies with and without secondary antibodies to crosslink the primary antibodies,  or 
secondary antibodies alone for 24 hours. Neurons were immunostained with C-term anti-
GluR1 antibodies and presynaptic marker Synapsin.  Commercial anti-GluR2 antibodies 
+ secondary treatment for 24 hours decrease synaptic GluR1 clusters density staining.  
Scale bar = 10 µm. 5-6 neurons from one trial of experiment for each condition.  
 B. Quantification of density of synaptic GluR1 clusters per 20 µm dendrite from 
neurons treated with commercial GluR2 antibody (ANOVA followed by Dunn’s multiple 
comparison test,  p < 0.0001,  asterisk indicates significant difference) 
  
190 
 C. Quantification of density of synaptic GluR1 clusters per 20 µm dendrite from 
neurons treated with commercial GluR1 antibodies (ANOVA followed by Dunn’s 
multiple comparison test,  p < 0.0001,  asterisk indicates significant difference). 
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Conclusions and future directions 
 
 The work discussed in the previous chapters extended our understanding of how 
functional neural circuits are established and maintained. In particular, I have 
investigated the spatial distribution of functional properties of presynaptic terminals 
along axon arbors and suggest that the mechanisms that determine synaptic strength 
differ spatially.  I have also examined the structural and functional consequences of the 
loss of postsynaptic glutamate receptors that occurs in two forms of human autoimmune 
encephalitis.  My results suggest that patient antibodies selectively cause reduction of 
surface receptor clusters, their synaptic localization, and the synaptic currents mediated 
by these receptors.  My work extends our understanding of the repertoire of pre- and 
postsynaptic mechanisms that are required to establish and maintain functional neural 
circuits during development and in diseases that compromise nervous system function.  
 The work investigating the spatial distribution of presynaptic function raises 
important questions for future research into the formation and maintenance of functional 
neural circuits (Chapter 2).  One of them, raised from the observation of a proximal–
distal difference in presynaptic strength, leads to the question of what is the physiological 
implication of this difference.  One hypothesis is that the loss of action potentials due to 
branch point failures along axon arbors results in a compensatory increase in distal 
presynaptic strengths.  Previous work using simulations suggested that action potentials 
can be lost due to branch point failures and en passant terminals (Lüscher and Shiner, 
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1990).  Though there was the observation that action potentials invaded proximal axon 
arbors and all their branches efficiently within 100 µm from the cell body (Cox et al., 
2000), direct examination of action potential activities over longer distances along the 
axon arbors >1000 µm is still missing. These together give rise to the hypothesis that the 
possibility that distal segments of axons see fewer action potentials from the soma 
underlies the higher presynaptic strengths in distal terminals. Measuring action potentials 
in small axons of central neurons is difficult to carry out; however, the following 
experiments can address the previous question without directly measuring action 
potentials in axon arbors. First, further detailed investigation of the relationship between 
presynaptic strengths and spatial distribution is needed.  My research examined the most 
proximal and the most distal terminals and their presynaptic strengths.  Future works 
should examine the relationship between the presynaptic strengths and the terminals’ 
distance to the cell body, the number of branch points between the terminals and the 
soma, and the number and density of en passant terminals along the axon arbors.  A 
second set of experiments could investigate the changes in presynaptic strengths during 
activity manipulations.  Activity blockade using TTX, to completely eliminate action 
potentials in cultures, can be used to see whether the proximal-distal difference of 
presynaptic strengths can be eliminated. A third set of experiments could examine 
changes in presynaptic strengths in response to spatially distinct stimulation, for example 
comparing the presynaptic response when the action potential is triggered locally in axon 
arbors and when it is triggered from the cell body. The differences in presynaptic 
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strengths measured when the stimulation locations are different would indicate loss of 
action potentials along axon arbors in between the soma and the terminal of interest.   
Together, these results could help to address the possible causes of differences in 
proximal and distal presynaptic strengths that I observed in my research.  
 Other interesting future research includes the following.  It will be of interest to 
examine how the proximal-distal difference is established during development and 
maturation of neural circuits.  Also, it will be important to examine pre- and postsynaptic 
mechanisms in a spatially specified manner in vivo to address how synaptic properties at 
different spatial locations along axons and dendrites are specified and how different 
mechanisms are orchestrated to achieve this spatial heterogeneity. Techniques to 
specifically label a small number of neurons and their synapses (Li et al., 2010; Marshel 
et al., 2010) and to precisely activate individual neurons and/or synapses (Knöpfel et al., 
2010) have already set the stage for this type of study.    
 The identification of cellular and synaptic mechanisms underlying anti-NMDAR 
encephalitis (Chapter 3 and Chapter 4) and anti-AMPAR encephalitis (Chapter 5) raises 
many important questions for future research.  One interesting question is through what 
pathways these receptors are internalized, and are they degraded or recycled.  NMDA 
receptors and AMPA receptors are trafficked into and out of postsynaptic sites during 
physiological processes.  Internalization of NMDA receptors has been shown to be 
mediated by clathrin via endocytotic signal on C-terminal of NR2A or NR2B subunits 
(Roche et al., 2001; Lavezzari et al., 2004).  NMDA receptors then sort into different 
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intracellular pathways after endocytosis (Lavezzari et al., 2004).  Under physiological 
conditions, such as during LTD, it has been suggested that AMPA receptors are first 
moved to extrasynaptic sites followed by endocytosis through clathrin dependent 
pathways (Ehlers, 2000; Shi et al., 2001; Park et al., 2004).   The endocytosis of AMPA 
receptors can follow a GluR2-dependent pathway (Lüthi et al., 1999; Lee et al., 2002) or 
a GluR2-independent pathway (Jia et al., 1996; Ehlers, 2000; Meng et al., 2003; Schwarz 
et al., 2010). Whether the internalization of the patients’ antibodies in encephalitis is 
mediated by a pathway that was already identified in physiological conditions, or by a 
pathway specific for pathological conditions, is a question to be addressed. One set of 
experiments could investigate whether known endocytic machinery is involved in 
internalization of these receptors.  Pharmacological blockade or RNAi could be used to 
interfere with the function or expression of clathrin to allow for investigation into 
whether the internalization is dependent on clathrin.  In addition, experiments could be 
performed using known NMDAR or AMAPR mutants that can block specific 
internalization pathways of these receptors (Lavezzari et al., 2004).  These experiments 
will help to address whether the same endocytotic signals on these receptors are needed 
in pathological situations. A second set of experiments can examine where the 
internalized receptors are localized, and whether they are degraded or recycled.  
Receptors on the neuronal surface can be labeled and treated with patients’ antibodies to 
induce internalization, followed by labeling of internalized receptors and 
immunocytochemistry for markers of other subcellular structures,  such as Rab-5 
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(recycling endosome) , Rab-9 (late endosomes), Lamp1 (lysosomes), P4D1 (ubiquitin) 
and proteosome subunits.  Together, these results can illuminate the mechanisms and 
pathways by which NMDAR or AMPAR are internalized, degraded or recycled during 
autoimmune encephalitis.   
 Other important directions include the following. One is the generation of in vivo 
animal models to examine how the autoantibodies cause the cellular and physiological 
defects in neural circuits and how these give rise to the repertoire of behavioral and 
cognitive deficits in the patients.  Generation of the animal models can help to address 
several important questions.  One interesting question is to examine the alterations of 
synaptic transmission and functional plasticity that are caused by these autoantibodies 
and that give rise to behavioral deficits.  This animal model is more relevant to 
understanding human behavior, cognition, and disease than knockout animal models.   
Further interesting questions concern the examination of the cascade of events leading to 
peripheral autoantibody production, the penetration of autoantibodies through the blood-
brain-barrier (BBB), and potential intrathecal synthesis of antoantibodies.   A third 
important direction is to study the process of recovery and relapse, and to examine which 
neural effects are reversible, and which tend to be refractory to treatment.  Since many 
other severe neurological diseases such as schizophrenia and autism are not reversible, in 
contrast to autoimmune mediated encephalitis, studying the recovery and relapse of 
autoimmune mediated encephalitis may be helpful for treatment of other neurological 
diseases.  Ultimately, knowledge obtained by studying the mechanisms underlying these 
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autoimmune mediated encephalitides will help to further understanding and improve 
treatment of other neurological diseases such as schizophrenia and autism.   
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